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ABSTRACT 
The expression of the ovine milk protein frlactoglobulin (BLG) in transgenic 
mice is both mammary specific and hormonally regulated only being produced in 
mammary epithelial cells during lactation and gestation. Since BLG is a protein 
not encoded in the rodent genome this transgenic system presents a unique 
opportunity to investigate systemic tolerance to a 'foreign' transgenic protein and 
neonatal tolerance to a milk protein encountered in the gut. 
Systemic tolerance to BLG was studied in a) male and female mice heterozygous 
for the BLG transgene derived from crossing homozygous BLG transgenic males 
and wild-type females, b) BLG-transgenic and non-transgenic offspring derived 
from mating male and female heterozygous for BLG transgene with wild-type 
partners and c) BLG-transgenic and non-transgenic mice derived from back 
crossing onto a CBA/Ca MHC background. Using either a BLG-specific ELISA (for 
antibody responses) or footpad thickening assay (for T cell responses) the 
immune response to the BLG antigen was assessed. Hyporesponsiveness to both 
ovine and bovine BLG was observed at the antibody level but not at the T cell level 
for mice transgenic for BLG as compared to wild-type and non-transgenic 
littermates. Antibody tolerance could not be attributed to expression of the gene 
during pregnancy and lactation since all mice tested were virgin mice. These 
experiments also confirm that suckling on BLG-containing milk was not 
responsible for the antibody hyporesponsiveness seen in BLG-transgenic mice. 
Male and female mice heterozygous for the BLG transgene were mated to wild-
type partners such that the offspring fell into eight classes: male and female, 
suckled or non-suckled on 'transgenic' milk and heterozygous or wild-type for 
the transgene. Antibody and T cell data indicated that suckling "transgenic' milk 
did not induce oral tolerance to ovine BLG in either transgenic or non-transgenic 
offspring. In contrast, voluntary ingestion of bovine BLG by wild-type mice for 
24 hour or 21 days resulted in both antibody and T cell tolerance. 
Hyporesponsiveness could not be induced by transferring transgenic marrow into 
lethal irradiated normal recipients, but similarly irradiated transgenic 
recipients were still hyporesponsive after reconstitution with normal bone 
marrow. 
These data demonstrate that in the absence of detectable expresssion of transgenic 
BLG protein mice are tolerant to this transgenic product at the antibody level but 
probably not at the T cell level. Bone marrow transplantation experiments have 
demonstrated that transgenic B cells can mount normal antibody responses to BLG 
in a wild type recipient environment, but wild type B cells tend to be tolerant to 
BLG immunisation in a transgenic environment. Although BLG can be 
demonstrated to be an oral tolerogen, wild type mice suckling on BLG-containing 
milk from birth are not tolerant to this antigen in adulthood. 
In summary, some yet undetectable low level expression of a transgene, probably 
in a lymphoid differentiation environment, can render animals tolerant to the 
transgene antigen. Exposure to such antigens perinatally, through suckling, does 
not necessarily render offspring unresponsive to that antigen over the long term. 
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1.1) B cell differentiation 
B cell differentiation has been reviewed extensively 
elsewhere see [1-18] and will be summarised here. B cells 
provide the humoral arm of the immune system through the 
expression of surface immunoglobulin (Ig) which acts as a 
specific antigen receptor. This receptor consists of two light 
and two heavy chains which are non-covalently linked to the 
products of the mb-i and B29 genes, Iga (CD79a) and lg3 
(CD74b) respectively. Iga and lg3 are glycoslyated and 
phosphorylated transmembrane proteins with extracellular Ig 
like domains and cytoplasmic tails and they are involved in 
transporting Ig to the cell surface. The Iga and lgf3 heterodimer 
is found associated in the mouse with 1gM, lgD, lg2b, lgG and 
IgE constant regions. 
Signalling through this Ig receptor occurs following cross 
linking with a specific antigen. In mature B cells this results 
in proliferation and immunoglobulin secretion. In immature B 
cells this event may induce cell death. 
Genes encoding the Ig light and heavy chains are present in the 
germline of lymphoid progenitors. There are two possible light 
chains, K and ?, K is the most common. In K negative transgenic 
mice k light chains are utilised instead; thus rearrangement of 
K is not a prerequiste for the initition of ?. rearrangements. 
Light chain genes are encoded by variable (V) and joining (J) 
genes, whilst heavy chains (H) are encoded by V, diversity (D), 
J and constant (C) genes. The C genes encoding the heavy 
chain/the isotype of the immunoglobulin, are 	(1gM) o (lgD) y 
(IgG) or a (IgA). Gene recombinase systems (terminal 
deoxynucleotidyl transferase (Tdt) and recombinase activation 
genes (RAG) 1 and 2) facilitate gene rearrangement leading to 
a functional gene product. Heavy chain rearrangement occurs 
first. One of many D segments is combined with a J segment 
W. 
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and this DJ combines with a V region. This VDJ then combines 
with the 1gM heavy chain constant region. Following each of 
these combinations other V, D, and J regions are removed. 
Light chain rearrangement involves a V and J combination but 
unlike the heavy chain this does not alway result in the loss of 
the unused V and J regions. A large amount of diversity is 
possible due to the number of V, D and J region combinations. 
Diversity is also increased by the Tdt recombination system 
which adds N-sequences at the junction of these segment 
combinations. 
B cells are derived from B cell committed lymphoid progenitor 
(stem cells) and the site for B cell differentiation is the bone 
marrow. This stage of development is independent of antigen, 
in other words antigen does not affect maturation of B cells 
within this primary lymphoid tissue. 
The first stage in B cell development is characterised by the 
upregulation of "early" B cell lineage surface antigens, B220 in 
mice, and the machinery for immunoglobulin rearrangement. 
Each stage of the antigen independent phase of B cell 
differentiation has been named; the pro-B cell stages (early 
and late), pre-B cell stage (large pre-B cell I and and small 
pre-B cell II) and the immature B cell stage (see Figs 1.1 and 
1.2). 
Early pro-B cells express cell surface markers B220+, CD34+ 
and CD19+ whilst late pro-B cells express B220+, CD19+ and 
CD43+. These cells have immunoglobulin genes in germline 
configuration and they are further identified as belonging to 
the early B cell lineage due to expression of other B cell 
specific genes including mb-1, B29, ?5 and Vpre-B (surrogate 
light chains) in germline configuration. It has been shown in 
RAG -deficient mice that pro- B cells can express surrogate 
light chains without the 1gM heavy chain [6].  At this stage of 
development pro-B cells express the immunoglobulin 
recombination genes Tdt and RAG 1 and 2. 
The pre-B cell stage is split into 2 stages: pre-B cell I and 
pre-B cell II. At the pre-B cell I stage DH and JH  recombination 
has occurred as well as recombination with the Cj. heavy chain. 
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This DHJHCt complex is found on the cell surface in 
association with the non-covalently linked A5 and Vpre-B gene 
encoded surrogate light chains. At the pre-B cell I stage Iga is 
expressed associated with lg3. The DHJHCiJX5/Vpre-B/lga and 
Igp complex is known as the pre-B cell receptor [2] This pre-B 
cell receptor is also expressed on pre-B cell II cells. However 
the DHJHCt is replaced by a functional VHDHJHCI. These cells 
do not undergo conventional light chain VJ rearrangements. 
The importance of the C.t chain has been shown in transgenic 
homozygous mice carrying an inactivated exon of the It (1gM) 
heavy chain resulting in mice lacking membrane [t heavy chain 
(Kitamura et al (1 991) cited in [17]). These mice are devoid of 
mature B cells and they are arrested at the pre-B cell stage. 
Further evidence that a successful rearrangement of the 1gM 
heavy chain is important for further B cell differentiation was 
shown using RAG deficient mice [6].  In these mice inactivation 
of the RAG 1 and 2 genes resulted in the complete absence of 
both mature B and T cells due to no initiation of the 1gM heavy 
chain VDJ rearrangements in the case of B cells. B cell 
development was arrested at the pro-B cell stage. The 
appearance of pre-B cells in the bone marrow only occurred if 
a functionally assembled human t or murine lgM+D+ transgenes 
were introduced into the RAG-1 or a RAG-2 deficient 
background respectively. No differentiation occurred if 
functionally assembled K or ? light chain genes were 
introduced [6]. 
In these mice it was also shown that 1gM heavy chain 
expression appeared to induce heavy chain allelic exclusion 
and conventional light chain gene rearrangement. 
Evidence for the importance of the pre-B cell receptor was 
shown in transgenic mice in which the ?5 and JH  genes were 
disrupted [17]. In these mice B cell development was also 
diminished. It was concluded that only pre-B cells expressing 
a Ct chain would express a pre-B cell receptor and this 
permits further differentiation. 
As with pro-B cells, pre-B cells can express VpreB and ?5 
surrogate light chains in the absence of the CR chain. However 
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expression of these chains requires association with a 
complex of proteins. 
Pre-B cells also express various cell surface markers as 
shown in Fig. 1.2. 
Immature B cells rearrange light chain genes and the 1gM heavy 
chain is found associated with either K or X light chains. 
Surrogate light chains are still present on immature B cells. 
Iga and Igf3 are also found associated with the 1gM receptor. At 
this stage RAG and Tdt gene expression is turned off. 
Immature B cells become virgin B cells which express 1gM and 
IgD and these mature B cells no longer express surrogate light 
chains. B cell development at this stage is antigen dependent. 
During an immune response mature B cells are recruited into 
germinal centers (GC). In the presence of antigen on the 
surface of GC follicular dendritic cells (FDC) and with T cell 
help B cells proliferate and further differentiate into plasma 
cell/antibody forming cells. During this T cell dependent 
response virgin B cells undergo a process known as somatic 
mutation. Somatic mutation affects the V regions of the Ig 
receptor resulting in receptors with different specificities 
and affinity. Those B cells with high affinity receptors are 
selected for and rescued from apoptotic cell death. This 
process appears to involve the expression of bcl-2 which has 
been shown to prolong B cell life span. Transgenic mice 
expressing the bcl-2 gene under the control of the Ig heavy 
chain enhancer have more B cells than normal mice but these 
cells are non-dividing. Thus bcl-2 prevents cell death but does 
not promote B cell proliferation. Antibody production in these 
mice is greatly prolonged and mice eventually develop an 
systemic lupus erythematosus (SLE)-like autoimmune disease 
(Strasser et al (1991) cited in [17]). 
These high affinity B cells differentiate into either plasma 
cells, the terminal differentiation point or into memory B 
cells which respond quicker and produce high affinity 
antibodies of different isotype following a secondary 
challenge with antigen. It is thought that the prolonged 
presence of antigen on the surface of FDC is important for the 
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maintainence of memory. It is also suggested that memory 
cells may require bc1-2 expression to be safe from apoptosis. 
Various external factors have been implicated in B cell 
differentiation at both the antigen independent and dependent 
stages. Maturation is dependent on the interaction between the 
developing cell and bone marrow and peripheral lymph node 
stroma as well as with soluble factors. Developing B cells 
themselves and stromal cells express surface molecules which 
have been shown to influence maturation, for example, pro and 
pre-B cells express VLA-4 the ligand for which is VCAM-1 
present on bone marrow stromal cells. Monoclonal antibodies 
to both inhibits binding of murine B cells to stromal cells and 
addition of anti-VLA-4 antibodies to long term bone marrow 
cultures prevented B cell lymphopoiesis (Miyakeit et al and 
Nuccie, Ryan and Abbound cited in [16]). 
In mature B cells CD40 binds to its ligand on T cells and this 
is important for the generation of T cell dependent humoral 
immune responses. Treatment with anti-CD40 monoclonal 
antibodies prevent primary and secondary T dependent 
responses (Foy et al cited in [1 6]). 
Mature B cells also express CD80 (137I13131) which is the ligand 
for CD28 present on T cells. In CD28 deficient mice 1gM (T 
independent) responses are normal but IgG (T dependent) 
responses are deficient. Thus signalling via the CD28/CD80 is 
important for class switching. It has also been shown that the 
B7 molecule is not important for early B cell development 
since B7 deficient mice have apparently normal B cell 
populations (Freedman et al (1 993) cited in [34]). 
Mature B cells also express CD23 and CD21. CD23 is the ligand 
for CD21 which is present on the FDC. 
Cytokines have also been shown to be important in B cell 
development. 11-7 plus stromal cells promote the preferential 
expansion of pre-B cells from suspensions of murine bone 
marrow and fetal liver cells [18]. Stromal cell derived 
cytokines have also been implicated in B cell maturation. Two 
cytokines IL-1 1 and mast cell growth factor (MGF) have been 
defined although, they cannot overcome the requirement for 
stromal cells. 
1.2) B cell tolerance 
Possibily the easiest explanation for B cell tolerance is that it 
is a consequence of T cell tolerance. Due to the lack of T cell 
help and appropriate T cell signals, the B cell compartment is 
unable to produce auto-antibodies [19]. However the story is 
not as simple as this since self reactive T cells have been 
shown to escape from the thymus [20] and these cells have the 
potential to stimulate autoreactive B cells. Why is there a 
need for B cell tolerance? Unlike T cells, mature B cells with 
low affinity receptors on encountering both antigen and T cell 
help undergo a process called somatic mutation [21]. This 
process results in mature B cells secreting high affinity 
antibody and it may also result in self-reactive B cells [22]. 
Low affinity B cells expressing 1gM receptors for self antigens 
have been found in normal mice at high frequency and these are 
non-tolerised (Primi et al (1987), Nakamura et al (1981), 
Holmberg et al (1986), Ternynck et al (1 986) cited in [23]). 
Through the use of transgenic (tg) mice B cell tolerance has 
been shown to occur for both immature and mature B cells. 
Tolerance appears to be operating through various routes 
either by deletion, silencing or functional arrest of self-
reacting B cell clones according to the particular mouse model 
studied. 
i) Deletion 
a) Anti-H-2 Kk transgenic mice 
Nemazee and Burki (1989) [24, 25] have created transgenic 
mice expressing an 1gM antibody (3-83) which has an lgG 
idiotype specific for MHC Class 1 Kk  and the heavy chain of an 
1gM molecule. This antibody recognises MHC Class 1 Kk  with 
high affinity and also recognises with low affinity (100-fold 
lower), MHC Class 1 Kb.  
In transgenic mice with an H2d background, the 3-83 1gM 
antibody makes up 61.6% of the total 1gM. In transgenic mice 
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on an H-2d x H-2 1< (H-2d/k) background the 3-38 1gM levels in 
the sera are reduced to approximately 15% of total 1gM. In the 
spleens of the H2d/k transgenic mice neither resting B cells 
nor plasma cells were present whereas on a non-selecting 
background 3-38 antibody producing cells were in the 
majority. Tolerance was also observed in the presence of the 
lower affinity Kb  antigens. 
This tolerance was not due to the expression of H21(k by the 
antiH21(k B cells themselves as shown by transferring H-2d 
bone marrow to irradiated H-2d X H2k, or H-2d recipients. 3-
83 1gM antibodies were found in mice expressing the H-2d but 
not the H-2d X H2k mice. 
These experiments suggested that the site of tolerance in 
these mice was the bone marrow [24]. Further experiments 
supported these conclusions. Bone marrow depleted of T cells 
from an anti-H-21(k transgenic mouse was transplanted into 
both H-2d X H-2k or H-2d mice. Only in the presence of H-2k 
were the 3-83 1gM antibodies deleted from the spleen. 
However some antiH-21(k idiotypic bearing pre-B cells, 
expressing B220 and membrane (m)IgM were found in the bone 
marrow of H-2d X H2k transgenic mice, but in reduced 
numbers. The presence of self-reactive B cells which appear to 
escape tolerance is due to receptor editing [26-35]. 
These data led to the hypothesis that tolerance is affecting 
the pre-B cell stage of B cell ontogeny and that the mechanism 
is one of a deletion rather than a down regulation of Ig 
receptors. 
These transgenic mice have been further used to investigate 
autoimmunity in MRL-lpr/lpr mice [36], which contain B cells 
with specificities for DNA. Crossing antiH21(k 3-831gM 
transgenic mice with either a H-21( or H-2d MHC background 
with MRL-Ipr/Ipr mice (H21(k) resulted in transgenic mice 
expressing both the 3-83 transgene on a background of either 
H2k or H-2d X H2k. These mice had significant numbers of 3-
83 1gM positive B cell and low levels of 3-83 in the sera. 
These B cells were not anergic and secreted the transgene 
encoded 1gM antibody. Control, non MRL-lpr/lpr mice, on these 
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backgrounds gave results similar to the data above, suggesting 
that the autoimmune disease of the MRL-lpr/lpr mouse is due 
to a failure in deletion of self-reactive B cells. 
b) Hen egg lysozyme (HEL) - transgenic mice 
Deletion was also shown to be responsible for tolerance in 
double transgenic (Dbl-tg) mice expressing both the HEL 
transgene (under the control of the H2Kb promoter) and either 
lgM+D+ or lgM+ transgenes with anti-HEL specificity [37]. In 
the HEL-only transgenic mice HEL is expressed as a membrane 
bound protein on the surface of B cells found in the spleen, 
bone marrow, lymph node and thymus. 
Dbl-tg mice do not make anti-HEL specific antibody. This 
appears to be due to the deletion of lysozyme binding B cells, 
since FACS analysis of both spleen and lymph node indicated 
the absence of mature anti-HEL Ig binding cells in these mice. 
This observation was not affected by the absence or presence 
of IgD. 
Deletion of mature B cells in these mice was also shown via 
bone marrow chimaeras: irradiated HEL expressing transgenic 
mice were recontituted with anti-HEL Ig (lgM+D+) bone 
marrow. The recipient mice were devoid of 13220h 1 B cells 
bearing the HEL specificity. However there was no reduction in 
the number of B22010 mlg+ve cells in the bone marrow. This 
agreed with the antiH21(k transgenic mice and further 
suggested that deletion of these cells occurs at the pre-B cell 
to immature B cell stage of development. The reduced levels of 
mlgM on these cells suggested that they had encountered 
antigen although this exposure had not induced cell death since 
no sign of apoptosis was found. This led the authors to suggest 
that deletion occured in two steps. The first step, functional 
arrest is caused by the interaction of immature cells and 
membrane bound antigen and the second, and later step, cell 
death [38]. 
Arrested development results in immature B cells which 
express low levels of membrane 1gM and which do not acquire 
adhesion, activation and migration receptors. This step is 
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reversible since exposure to membrane bound HEL antigen did 
not result in a cell incapable of response. Sorted B22010 lgD-
ye bone marrow B cells from the Dbl-tg mice, when cultured 
with thymocytes not expressing the HEL protein, expressed a 
twenty fold increase in mlgM+ levels and an increase in B220 
and lgD expression: ie; in other words a more mature B cell 
phenotype. This did not occur when they were cultured with 
thymocytes from an HEL tg mouse. 
Cell death, which was shown to occur after 1-3 days when 
Dbl-tg cells were constantly exposed to HEL, could be 
prevented by the introduction of the bcl-2 transgene. This 
protein has been shown to greatly increase the life span of 
both immature and mature B cells in transgenic mice 
expressing bcl-2 under the control of an Ig heavy chain 
promoter. Bcl-2 transgenic mice were mated with anti-HEL Ig 
transgenic mice. Bone marrow from these (bcl-2 x anti-HEL) 
transgenic mice was transferred into irradiated HEL 
transgenic and non-transgenic mice. Control mice were given 
anti-HEL Ig bone marrow. Non-transgenic mice that received 
anti-HEL bone marrow had mature B cells expressing high 
levels of B220 as well as homing and adhesion molecules 
whilst HEL transgenic mice receiving this bone marrow did not 
express mature B cells in the spleen, lymph node or peripheral 
blood. However when HEL transgenic mice were given (bcl-2 x 
anti-HEL Ig) bone marrow a large number of B22010 CD23-ve, 
CR1 and 2-ye, lgD-ve, CD22-ve and L-selectin -ye immature B 
cells were present in peripheral blood and spleen. These B 
cells also expressed large amounts of anti-HEL 1gM and were 
found to be self-reactive in that they bound HEL. An immature 
to mature B cell phenotype transition was achieved when the 
HEL antigen was removed. Mature HEL binding cells also 
occurred in non-transgenic mice reconstituted with this (bcl-
2 x anti-HEL Ig) bone marrow combination. 
From these data it was concluded that the deletion process 
occurred in two independent steps within the bone marrow. 
Expression of the bcl-2 gene stops cell death but does not 
interfere with the arrested development such that immature B 
22 
cells are present in these mice. The persistent expression of 
HEL antigen however does not allow phenotypic maturation of 
these cells, and in the absence of the bcl-2 gene would result 
in cell death. Removal of the antigen allows mature cells to 
develop. These data were supported by the use of the immature 
B cell lines CH31 and WEHI1 23. It was also found that IL-5, as 
well as bcl-2, could inhibit anti-lgM induced apoptotic 
deletion while not affecting the arrested development stage 
[39]. 
Autoimmune Haemolytic Anaemia (AHA) transgenic mice 
Two transgenic mouse lines were created, one expressing 1gM 
light chain genes, the other 1gM heavy chain genes from an 
anti-murine erythrocyte autoantibody derived from hybridoma 
4C8. Both transgenes in these mice were expressed in the 
spleen, lymph node, bone marrow and thymus [40]. 
Mating the above mice produced double transgenic mice with 
antibody specific for murine red blood cells (RBC's). These 
mice had three different phenotypes: 51% of the mice were 
tolerant, 41% were intermediate whilst others, around 5%, 
were anaemic. It was also found that tolerant mice can become 
anaemic and vice versa. 
Further investigation showed that lymph node and splenic 
expression of the anti-RBC B cells in tolerant mice was 
greatly reduced. This was not seen in the bone marrow, 
suggesting deletion of auto-reactive B cell clones, probably at 
the pre-B cell to B cell transition on encountering antigen 
within the bone marrow. Serum auto-antibody was also 
reduced in tolerant mice [41] [42]. 
Anti-CD8 immunoglobulin transgenic mice 
The CD8 a chain gene in mice has two alleles, CD8.1 and CD8.2. 
The CD8.2 allele is recognised by a monoclonal antibody, the V 
region genes of which, plus either the Cji. membrane (m) and 
secretory (s) or Cp membrane only, were cloned into the 
germline of mice producing two transgenic lines [43]: the anti-
CD8.2p(m+s) and the anti-CD8.2p(s) respectively. 
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Backcrossing the former transgenic mice onto a mouse 
background positive for the CD8.2 antigen resulted in tolerance 
as seen by the lack of detectable anti-CD8.2 antibody. In 
contrast, crossing the anti-CD8.2p(s) transgenic mice onto 
this background did not result in tolerance and anti-CD8.2 
antibodies could be detected. 
After lipopolysaccharide (LPS) stimulation in vivo spleen cells 
from anti-CD8.2p(s) but not anti-CD8.2p(m+s) transgenic mice 
resulted in production of anti-CD8.2 antibodies. 
On a CD8.1 background both sets of transgenic mice made anti-
CD8.2 antibodies and the mice were not tolerant. The authors 
of this work suggested that in these mice tolerance was due to 
deletion of self-reactive cells since previous experiments had 
suggested that a) anergic B cells can be rescued in hybridomas 
and b) that deletion occurred for multivalent membrane 
antigens. 
e) lgD transgenic mice 
The role of lgD in tolerance was investigated in mice that 
lacked lgD [44].  These mice had 30-50% fewer B cells in the 
spleen and lymph nodes however there was a normal number of 
pre-B cells which expressed 2-3 times as much 1gM as control 
mice. These mice were capable of T independent as well as T 
dependent responses. 
Mice were created with transgenic mlgM or transgenic mIgM 
and mIgD specific for the hapten trinitrophenyl (TNP). When 
lgD-ve anti-TNP transgenic lg+ve mice were given high doses 
of TNP coupled to Bovine serum albumin (BSA) deletion of 
mature bone marrow B cells occurred at a high frequency. 
However for those mice expressing both 1gM and lgD, tolerance 
was abrograted: thus the presence of lgD may have protected 
mature B cells from deletion such that they could generate 
immune responses. 
These mice show that a negative signal via the mlgM receptor 
on B cells results in deletion of autoreactive B cells when in 
contact with the auto-antigen and that mlgD does not induce 
additional negative signals but may modulate this signal [45]. 
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f) Anti double stranded (ds) DNA transgenic mice. 
Deletion of B cells with specificity for dsDNA has also been 
shown [26]. In transgenic mice expressing light and heavy 
chains which encode an antibody (VH3H9/VK4) [46] with an 
idiotype specific for single stranded (ss) and dsDNA, B cells 
with dsDNA specificity were undetectable. In another 
transgenic mouse expressing anti-ssDNA idiotypic antibody 
(VH3H9/VK8) no deletion of these B cells occurred. By 
mutating the CDR2 region of the VH3H9 transgene, the 
resulting transgenic heavy chain, VH56R, when combined with 
endogenous light chains VK4, VK8 or ?1, has high affinity for 
both ss and dsDNA. 
Analysis of the VH56R/VK8 transgenic mice showed that 
unlike the V3H9/VK8 tg mice the frequency of B cells, as 
shown via FACS analysis, was about 40% of that of the non- 
transgenic littermates. These mice were not immunodeficient 
since they had normal frequencies of T cells. VH56R only tg 
mice, which bound to an endogenous light chain which 
conferred dsDNA specificity, also had 40-50% fewer B cells 
than VH3H9 only tg and non-transgenic mice. 
Antibody production in these mice was analysed using 
hybridomas created from LIDS stimulated tg splenic cells. 
Testing the hybridomas for anti-dsDNA antibodies revealed 
that autoantibody production was severely reduced, 1/63 
clones (both tg mice) produced dsDNA which might have been 
the result of this hybridoma expressing both endogenous and 
transgenic H chains. In conclusion deletion of B cells specific 
for membrane bound dsDNA can occur. 
ii) Silencing/functional arrest 
a) HEL and anti-HEL single transgenic mice 
Transgenic mice expressing HEL under the control of the zinc 
inducible metallothionein promoter [47] were created. Unlike 
the previously mentioned HEL-transgenic (HEL-tg) mice these 
mice expressed the HEL protein as a soluble protein and lines 
of mice expressed either high or low levels of this protein. 
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When one of the high HEL expressing lines, line MI-5 (1 3-
2Ong/ml-1), was immunised with HEL plus complete freunds 
adjuvant (CFA) no anti-HEL antibodies and no 1gM nor lgG 
plaque forming cell (PFC) were detected. Non-transgenic mice 
made high antibody titres to this protein and lgG PFC were 
present. 
In these transgenic mice it was shown that although T cells 
were also tolerant in vitro and in vivo the inability to respond 
at the antibody level was due to B cell tolerance. When the MI-5 
tg line were injected with HEL coupled to SRBC, which 
provides an alternative T cell help, these mice produced an 
anti-SRBC response although the anti-HEL response was 
decreased by 50 fold. 
Anti-HEL tg mice were created expressing high affinity heavy 
(H) and light chain V regions with an IgM+D+ constant region 
[47]. The heavy chain of this antibody expressed a BALB/c lgHa 
allotype marker which allowed the distinction between 
endogenous H chains, lgHb allotype, and the transgenic chain. In 
these mice 90% of the splenic B cell expressed the tg 1gM. 
Whilst only 1-6% of these cells possessed endogenous antibody 
a large number of plasma cells from these mice were found to 
express endogenous 1gM [48]. B cell differentiation in these 
mice was found to be the same as non-transgenic mice, with 
development occurring normally at the bone marrow pre-B to 
immature B cell stage, although the number of pre-B cells was 
reduced. B cells also located to the correct microenvironments 
giving rise to well developed follicular mantle zone as well as 
splenic marginal zones [48]. 
Immunisation of these mice with HEL plus CFA resulted in the 
production of high anti-HEL 1gM titres. 
b) HEL X anti-HEL mice, the double transgenics. 
These Dbl-tg were progeny of a cross between mice transgenic 
for the soluble HEL gene (line MI-5 high lysozyme expressing 
cells) and mice transgenic for the heavy and light chain genes 
encoding a high affinity anti-HEL antibody [49]. 
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Testing for HEL tolerance in 6 week old Dbl-tg revealed that 
these mice were tolerant to HEL at both the antibody and PFC 
levels. This was also shown when anti-HEL tg bone marrow 
was transferred into ML5 HEL tg mice and following 
immunisation of iradiated C57BL/6 mice reconstituted with 
Dbl-tg spleen cells and C57BL/6 T cells primed with HEL-HRBC 
(horse red blood cells). Thus Dbl-tg mice are tolerant to HEL 
even in the presence of T cell help. 
These Dbl-tg mice were tolerant inspite of the presence of 
anti-HEL+ve B cells. This suggested that deletion of 
autoreactive B cells in these mice was not the mechanism of 
tolerance induction (cf membrane bound HEL above) but the 
result of functional silencing (anergy) of autoreactive B cells. 
These anergic B cells had down regulated membrane 1gM levels 
but the expression of IgD, B220, Ji 1 D, la, Ly-i and Mac-1 
remained unaffected. The down regulation of 1gM on tolerant B 
cells was not due to non-association of 1gM heavy chains with 
mb-i and B29, which form the heterodimer associated with 
membrane expression of immunoglobulins. lgD on tolerant B 
cells was also associated with these molecules. It was shown 
that 1gM heavy chains were associated with mb-i and B29 but 
this complex appeared not to exit from the endoplasmic 
reticulum, and no Golgi processing was evident [50]. 
8 week old Dbl-tg mice also displayed these characteristics 
with bone marrow and lymph node cells of these mice having 
similar changes. It was however noticed that in these mice 
there was a decline in the number and frequency of B cells, 
which may have been due to deletion of these cells. 
The development of the B cells in these mice was normal until 
they reached the follicular mantle zone stage. Splenic 
marginal zone and red pulp were both devoid of transgenic B 
cells [48]. It has recently been shown that the life span of 
these anergic B cells, once they reach the periphery, is greatly 
reduced and unaffected by the expression of HEL [51]. 
Double transgenic mice expressing low level of lysozyme (line 
ML3) were also created. These mice had no reduction in the 
serum levels of anti-HEL 1gM antibody as well as no reduction 
in B cell numbers as compared to non-transgenic mice. In these 
Dbl-tg mice self-reactive T cells were absent [52]. 
Expression of the HEL-transgene was induced in these 
transgenic mice following zinc feeding (in drinking water) for 
1-4 days. Increased HEL secretion corresponded with a 
decrease in 1gM levels on the B cells although there was no 
reduction in the number of B cells in these mice [49]. Adelstein 
et al (1991)[52]  also showed that giving zinc to another low 
expressing HEL-transgenic mouse line, ML4, resulted in 
increased serum HEL levels and a marked decrease in both the 
number and affinity of responding lysozyme specific B cells, 
as compared to non-transgenic mice. 
In these HEL induced transgenic mice it was shown that both 
immature B cell and mature B cells were tolerised. Immature B 
cells could have been tolerised at the level of the bone marrow 
since staining with anti-HEL antibody revealed that immature 
B22010 B cells had bound HEL and around 50% of receptors 
were occupied. These immature B cells also had down 
regulated mlgM levels [48]. Tolerance to HEL was induced in 
non-transgenic mice when bone marrow from Dbl-tg mice was 
transferred with T cell help and antigen. 
Tolerance of B cells also needs to occur in the mature B cell 
population since, unlike the T cell receptor, mature B cell 
receptors undergo further diversification through somatic 
hypermutation. The resulting cells may express high affinity 
self receptors. 
Experiments to test that mature self-reactive B cells can be 
effectively tolerised involved the investigation of low-
lysozyme expressing (ML3) Dbl-tg mice [49]. Irradiated non-
transgenic mice were primed with HRBCs before being given 
anti-HEL Ig (Ig-T), zinc uninduced or zinc induced HEL low 
expressing Dbl-tg splenic B cells. Following immunisation 
with HEL-HRBC, recipient mice given Ig-T and the zinc 
uninduced DbI-tg spleen cells respond to HEL in contrast to 
those receiving zinc induced Dbl-tg B cells which responded 
poorly. Thus increasing the levels of HEL resulted in tolerance 
of the mature B cell population. If primed T cells were also 
transferred, the mice remained unresponsive. 
Unresponsiveness was not due to receptor blocking by HEL 
since transferring lg-T only B cells which had half of their 
receptors blocked in vitro did not result in tolerance. 
Mature B cell tolerance was also shown by transferring lg-T 
only or non-transgenic splenic B cells to irradiated HEL-
transgenic mice expressing high levels of HEL or to irradiated 
non-transgenic controls. HEL expressing transgenic mice 
remained tolerant and the level of mlgM on transferred cells 
decrease by ten fold. Thus mature lg-T B cells could be 
tolerised to soluble HEL. This unresponsiveness was not 
reversed by the addition of helper T cells. 
Having established that tolerance to HEL occurs in both the 
immature and mature B cell populations of mice expressing 
sufficient levels of HEL, the question arose as to whether this 
was an intrinsic property of the B cells themselves. Through 
the use of irradiation chimaeras it was shown that tolerance 
was due to an intrinsic functional change in the anergic B cells 
themselves; transferring Dbl-tg but not lg-T spleen cells into 
non-trangenic mice resulted in an animal unresponsive to HEL. 
This was not attributable to the presence of suppressor cells 
transferred in the spleen mixtures [53]. B cells from Dbl-tg 
mice also responded poorly to HEL as well as to non-specific 
stimuli (LPS) in vitro as compared to lg-T only mice. However 
after stimulation with LPS for 7 days they responded to the 
same extent as control cells. This suggested that a reversal in 
tolerance could occur in these anergic B cells. This was 
further shown by Goodnow et al (1991) [54]. Transferring B 
cells from the HEL-tolerant Dbl-tg mice plus helper T cells 
primed to RBC into non-transgenic or HEL (expressing 
tolerogenic levels of HEL) transgenic mice, resulted in non-
transgenic mice capable of responding to HEL-RBC whilst HEL-
only recipients remained unresponsive. Although the reversal 
of tolerance occurred once B cells were removed from an HEL 
environment, the level of antibody responses to HEL was never 
equivalent to that of lg-T mice. "Parking" Dbl-tg cells within a 
non-transgenic mouse for a period of 10 days resulted in 
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spontaneous mIgM recovery on tolerant cells, but not 
spontaneous anti-HEL antibody production. This was not due to 
expansion of new pre-B cells. An anti-HEL response only 
occurred following a secondary boost of HEL antigen 
suggesting that antibody production reversiblity may require 
many rounds of mitogenic stimulation either with TH or LIPS in 
the absence of HEL antigen. 
These anergic B cells have been shown to constitutively 
express HEL. However this has not yet been found in HEL 
expressing transgenic mice [55, 56].  Dbl-tg anergic B cells 
have been shown to constantly stimulate HEL-specific I cell 
hybridomas and they can present a specific HEL peptide, 
HEL46-61. This expression of HEL is not due to synthesis of 
the protein by B cells themselves but through the binding of 
HEL present in the Dbl-tg mice. Reconstituting an irradiated 
HEL expressing Dbl-tg mouse with lg-T bone marrow (B cell 
are not capable of producing HEL) resulted in B cells which 
could stimulate T cell hybridomas. These cells could also 
stimulate HEL-specific T cells from immunised mice. 
Although B cells from Dbl-tg mice were capable of stimulating 
I cells this was not as effective as lg-T B cells plus 
exogenous HEL. Addition of HEL to Dbl-tg B cell did not 
increase their ability to stimulate T cell hybridomas 
suggesting that the Ig-receptor dependent uptake of antigen 
and antigen presentation is impaired. This maybe due to the 
reduced level of mlgM on anergic cells since mlgD can process 
and present HEL. Tolerant B cells from the Dbl-tg mice were 
unable to trigger an increase in intracellular tyrosine 
phosphorylation, Ca2+ release or subsequent B cell activation 
following binding of HEL to membrane 1g. 
It was also noticed that anergic Dbl-tg B cells had no defect 
on their ability to process and present nominal antigens such 
as keyhole limpet haemocyanin (KLH). 
Anergic B cells however respond to other signals which 
mediate later B cell activation responses. Stimulating Dbl-tg 
cells in vitro with IL-4 and anti-CD40 resulted in cells with 
the capacity to respond to T cell help. Signalling occurred in 
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Dbl-tg mice using the membrane form of HEL mig and this also 
restored their B cells' ability to collaborate with TH cells and 
resulted in antibody production [57]. The role of CD40 was also 
investigated by Ens et al (1 994) [55]. TH cell membranes 
expressing the CD40 ligand stimulated B cells from Dbl-tg 
mice resulting in the upregulation of mlgM. In the presence of 
both activated TH membranes and cytokines, anergic B cells 
produced anti-HEL antibodies. This was inhibited if a soluble 
CD40-lg fusion protein was added to the cultures. Anergic B 
cells from Dbl-tg mice plus HEL-primed T cells plus HEL in 
CFA injected into an irradiated Dbl-tg mouse resulted in mice 
which, when stimulated with HEL made an anti-HEL response 
equivalent to lg-T mice. This may have been due to CFA 
increasing receptors such as the CD28 ligands on B cells 
(these are expressed at reduced levels in anergic B cells), thus 
increasing T cell help to B cells. 
c) Anti-DNA immunoglobulin transgenic mice 
As described above, anti-DNA tg mice were created expressing 
anti-DNA specific V region genes from a hybridoma derived 
from a MRL-lpr/Ipr mouse, joined to an 1gM constant region but 
not the lgD region. The VH3H9 gene can combine to any 
endogenous light chain to give anti-ds or ssDNA specific 
antibodies. Mating VH3H9 tg mice with a VK8 transgenic 
resulted in mice specific for ssDNA. These tg mice had a high 
frequency of anti-DNA B cells which bound DNA and anti-DNA 
serum titres were not greater than normal mice, which have 
low serum anti-DNA 1gM levels. 
The VH3H9 only transgenic also confirmed these data. 38-86% 
of these tg mice splenic B cells were lgM+ve and bound ssDNA; 
the rest did not bind DNA. Looking at hybridomas created from 
splenic B cells it was found that although 52% of hybrids 
secreted ssDNA antibodies the levels of serum anti-ssDNA 
never exceeded that found in normal mice. Therefore it appears 
that tolerance to ssDNA occurs through functional silencing, 
i.e. although these cells are present they do not differentiate 
into antibody forming cells. This functional 
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silencing appears to be due to a signalling defect in the B cell 
since expression of high levels of mlgM did not inhibit anergy 
[46]. 
Tolerance to DNA was also studied by Tsao et al (1993) [58]. 
They created an 1gM transgenic mouse expressing the VicJi 
regions of an lgG2a monoclonal antibody. It had been shown 
previously that tg mice encoding the lgG2a monoclonal 
antibody were not tolerant and this resulted in mice 
developing a non-fatal autoimmune condition. These 1gM tg 
mice expressed the transgene at high levels on the surface of 
most splenic B cells. As compared to non-transgenic mice 
there appeared to be no reduction in the number of B cells in 
the tg mice and they did not secrete transgenic 1gM antibodies. 
These mice appeared to be tolerant through functional 
silencing since this tolerant state could be over come by in 
vitro incubation of tg 1gM spleen cells plus LIPS, which 
resulted in an increase in secreted 1gM anti-DNA antibody. 
Anergy to dsDNA has also been shown [59].  Non-autoimmune tg 
mice expressing anti dsDNA antibody had reduced spleens (14-
39% of the non-transgenic mice) and they also had 50-70% 
fewer B cells. This was due to the loss of B cells, suggesting a 
deletional tolerance to dsDNA. However the remaining B cells 
had an immature phenotype and were shown to be anergic 
dsDNA specific B cells. These cells however could be 
stimulated to produce antibody specific for dsDNA with LIPS 
over a period of a few days in culture. In vivo these tolerant 
cells produced little or no dsDNA antibody. The antibody 
produced was non-pathogenic. 
d) VSV-GP transgenic mice. 
Steinhorff et at (1 993) [60] created two transgenic lines 
expressing the membrane glycoprotein (GP) of vesicular 
stomatitis virus (VSV) under the control of two promoters: 
SV40 (line 207) and myelin basic protein (MBP) (line 163). 
Transgene expression was found in the kidney, heart, thymus, 
lung, brain, liver, and central nervous system. 
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Immunisation of these transgenic lines with recombinant 
vaccinia virus expressing VSV-GP resulted in no measurable 
lgG immune response. However if these mice were immunised 
with either wild type VSV or VSV-GP covalently coupled to 
sperm whale myoglobulin, a strong immune response resulted 
with the production of high titres of high affinity neutralising 
lgG antibodies. These data suggested that although the tg mice 
were tolerant to VSV-GP, probably through anergy, the 
tolerance could be broken by different forms of the antigen. 
This ablation of tolerance was T cell dependent: removal of 
CD4+ve T cells resulted in no VSV-GP auto-antibodies. 
The influence of antigen organisation on B cell tolerance was 
also shown by Bachmann et al (1993) [61]. Transgenic mice 
were created that expressed VSV-GP (serotype Indiana (IND)) 
under the control of the H21(b promoter. When these mice 
were immunised with"poorly" organised antigen, soluble VSV-
GP (IND) or 2x`106  PFU recombinant virus expressing VSV-GP 
(IND) cells no measurable 1gM or IgG response was evident. 
Control mice responded well to these antigens. Thus these 
transgenic mice were tolerant to the product of their 
transgene. The tolerance was transferable to non-transgenic 
mice, but tolerance was broken when these mice were 
immunised with a "highly" organised form of the antigen which 
results in high titres of neutralising antibody. Thus it appears 
that although tolerance had occurred cells remained which had 
the potential to respond to other forms of the antigen, in 
particular repetitive arrangements of the antigen. It should 
also be noted that in these VSV-GP tg mice the antigen is 
membrane bound, thus anergy can perhaps occur to membrane 
proteins which are at a low density. 
iii) B cell tolerance summary 
The presence of a self protein either membrane bound or in a 
soluble form can induce B cell tolerance, in the presence or 
absence of T cell tolerance. Two mechanisms of B cell 
tolerance have been described; 1) deletion and 2) anergy. 
Deletion of self-reactive B cells occurs in the bone marrow at 
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the pre-B cell to immature B cell transitional stage following 
mlgM interaction with a membrane bound protein. This process 
occurs in two stages, firstly arrested development and 
secondly cell death. 
Anergy occurs following mlgM interaction with soluble antigen 
(although anergy has been shown to occur upon contact with 
membrane bound antigens) and both immature and mature B 
cells can be tolerised in this way. This process is thought to 
be the result of biochemical changes affecting the B cell 
receptor complex and not signals that mediate later B cell 
activation processes. 
1.3) Thymic architecture and T cell differentiation 
i) The thymus 
a) Introduction 
The organ in which I cell differentiation occurs is the thymus. 
Within the thymus T cells mature and proliferate, they 
rearrange and express the T cell receptor (TCR), and they 
undergo two selection procedures; positive and negative 
selection. I cells emerging from the thymus express a TCR 
capable of recognising foreign antigen in the context of self 
MHC. Apart from TCR expression T cells express different 
surface molecules throughout development. Two of these, CD4 
and CD8, have been implicated in influencing the specificity of 
the maturing T cell. 
Many reviews have described the structure of the thymus, see 
[62-68]. The following section presents a brief summary of 
work described in these reviews. 
The thymus is a bibbed structure that lies just above the 
heart in adult mammals. Surrounding each lobe is a capsule of 
connective tissue that indents periodically to create septa 
which further divide the lobe into lobules. Within these septa 
are the vascular and neural supplies to and from the thymus 
and the wide blunt ends of the septae form the perivascular 
space. In this area exchange of both cells and solutes between 
the perithymic stroma and the periphery occurs. It is also rich 
















Schematic representation of the stromal cell population 
within an individual thymic lobule. All intervening spaces 
are filled with thymocytes (not shown). 
Diagram modified from [65]. 
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in various cells including plasma cells, mast cells, myeloid 
cells and thymic B cells, either scattered individually or in 
lymphoid follicle or germinal centres. A basement membrane 
is found below the capsular region and this is also found 
around thymic blood vessels. 
Each lobule is made up of various regions, starting from the 
outside and moving inward, the subcapsular, the cortex, the 
cortico/medullary (CM) junction and medulla regions (see Fig. 
1.3). Each of these areas are composed of histologically 
distinct epithelial cells. 
Within the murine thymus, epithelial cells within these 
regions do not represent a homogenous population, 
(heterogenity being indicated by keratin staining, light and 
electron microscopy (EM) (Type 1-6) and monoclonal antibodies 
(CTES 1-5)). Heterogenity was also found at the MHC level for 
both Class 1 and Class 2. Although all thymic epithelia express 
MHC Classl at high levels MHC Class 2 expression is not as 
simple. MHC Class 2 is present at high levels on all cortical 
epithelia whilst medullary cells also possess Class 2, but the 
level of expression differs between species. For example, in 
mice a large proportion of these cells are Class 2 positive. 
Subcapsular epithelial cells are negative for Class 2. 
Bone marrow derived cells are also found throughout the 
thymus. Monocyte and dendritic cell precursors enter the 
thymus where they differentiate into macrophages and 
interdigitating cells respectively. Macrophages are present in 
the cortex and CM junction. It is thought that these 
macrophages are involved in the removal of dead cells as well 
as produce cytokines which are important in T cell 
differentiation. Since these cells also express MHC Class 2 
they may act as antigen presenting cells. Interdigitating cells 
are found in the medulla and CM junction. These cells express 
large amounts of MHC Class 2 and may therefore act as antigen 
presenting cells. Mature T lymphocytes are also present in the 
medulla. Bone marrow derived cells have been implicated in 
both positive and negative selection events (see later 
sections). 
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b) Thymic epithelia and T cell differentiation 
The importance of the thymic environment is evident when the 
thymus is observed following sublethal irradiation [69, 70].  A 
close relationship exists between the stromal cell 
architecture of the thymus after irradiation and reappearance 
of lymphoid cells that repopulate the thymus during the first 
phase of regeneration. Following whole body irradiation the 
cortex is reduced in size and is largely depleted of lymphoid 
cells as well as MHC Class 2 expression. In contrast the 
medulla is less affected. After 5 days the thymic cortex 
stroma is restored and at this time MHC expression reappears, 
coinciding with the vascularisation and repopulation of the 
cortex by T cell progenitors. 
It has been suggested that haematopoietic precursors cells 
migrate to the thymus by chemotaxis, the directional 
migration of cells along soluble gradients of chemical 
substances called chemoattractants. Chemotactic factors are 
thought to be produced by the thymus itself. Rat subcapsular 
and perivascular epithelia (Type 1) cells produce and secrete 
an 11 kDa protein that selectively attracts immature lymphoid 
cells in vitro. This protein was named Thymotaxin [71, 72]. 
However recent experiments have shown that this molecule is 
132rn [73], which is associated with the a3 domain of MHC Class 
1 as well as the non-classical MHC molecule CD1, both of 
which are found on thymic epithelia (CD1 found on cortical 
cells only). pzm from mouse and human epithelial cells has 
also been shown to be a chemoattractant. 
Although pzm appears to be important for thymic homing it is 
not the sole chemotactic factor since T cell migration occurs 
in mice lacking the 13m gene. Subcapsular and medullary 
epithelial cells produce polypeptides factors termed thymic 
"hormones". These hormones were indentified from crude 
thymic extracts and have been shown to be biologically active 
pre-thymically and in the periphery. Two main properties have 
been described. Firstly they are involved in the phenotypic 
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maturation of bone marrow progenitors and secondly in the 
modulation of mature T cell functions. 
If murine bone marrow progenitor cells are separated, using an 
albumen gradient, and stimulated with these thymic hormones 
a rapid increase in Thy-1, CD5, CD8 and Tdt expression occurs. 
This suggests that thymic hormones caused the expression of 
an already synthesised intracellular pool, rather than causing 
de novo synthesis. Whether they affect intra-thymic 
development is still questionable however the fact that 
thymic hormones are produced by epithelial cells that first 
contact thymocytes progenitor cells suggests that they may be 
important at the early stages of T cell development. 
Within the cortex some Type 2/3 epithelial cell are found 
completely engulfing thymocytes. These cells are known as 
thymic nurse cells (TNC) [74-79] TNC's are large structures 
(50pm in diameter) expressing MHC Class 1 and 2 but lacking 
slg and Thy-1 and have been isolated, following intensive 
trypsination, from chicken, sheep, mouse, rat and human 
thymic tissue. These structures are also observed early in 
fetal development, around day 17 in mice which is an 
important time in T cell ontogeny. 
Murine TNC's have been shown to contain 20-40 small to 
medium sized mitotic T cells although this number can vary 
between 10-200 (in man 1-2 up to 20-30). EM analysis has 
shown in vivo that small gaps exist in the surrounding TNC 
membrane such that lymphocytes can enter and leave this 
structure. T cells found within these complexes have a 
distinctively immature phenotype, CD4+8+, and are sensitive 
to cortisone and radiation. Removal and stimulation (with 
either alloantigens, mitogens and growth factors) results in 
intra-TNC T cell proliferation and IL-2 production. Thymocytes 
released from TNC's have been shown to express TCR at a 
higher density than other cortical T cells and in vitro these T 
cells are incapable of forming other associations with thymic 
epithelia. 
TNC and T cell interactions maybe due to receptor-mediated 
recognition of epithelial cells by thymocytes in a random 
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interaction, in as much as most cortical T cells express the 
receptor but only those coming in close proximity to TNC's 
bind. Monoclonal antibodies to CD8, CD4, MHC Class 1 and 2 
interfere with these interactions, with anti-CD4 and anti-MHC 
Class 1 or anti-CD8 and anti-MHC Class 2 combinations 
completely inhibiting TNC formation. 
Since TNC are closely associated with CD4+8+ T cells it has 
been suggested that they are involved in either positive or 
negative selection events, which shape the T cell repertoire, 
with most evidence implicating their involvement in positive 
selection events. Despite this, TNC tested in vitro for their 
antigen presenting properties were incapable of presenting 
antigen to Class 2 restricted TH cells. This maybe due to a 
lack of processing ability however they maybe capable of 
presenting previously processed peptides or endogenously 
synthesised membrane proteins. Even if they play no part in 
the selection events TNC epithelial cells produce a thymic 
hormone named Serum Thymic Factor which might affect T cell 
development. 
In the medullary region Type 6 epithelial cells form the 
Hassall's corpuscles (tubular clusters of epithelial cells). The 
function of these is unknown, however it is thought that they 
may act as a thymocyte "graveyard", since they are associated 
with cell debris and products of cell death. 
Epithelial cells are also involved in positive and negative 
selection events and their roles in each of these will be 
discussed in later sections. 
ii) Intra-thymic development. 
a) Thymocyte populations as described by surface markers, 
CD4 and CD8 (see Fig. 1-4). 
Committed bone marrow stem cells enter the thymus and these 
prothymocytes divide, mature phenotypically and functionally, 
whilst undergoing the already mentioned selection events. As 
they mature phenotypic changes occur which will be described 
in this section. 
Early T cell progenitors, in mice, enter the thymic rudiment 
through the capsule and once the thymus has been vascularised 
they enter via high endothelial venules in the CM junction 
before moving to the subcapsular region. The nature of the 
bone marrow cells seeding the thymus is unknown, however 
Ardavin et al (1 993)[80J isolated early pro-T cell precursors. 
These cells resembled bone marrow haematopoietic stem cells 
except they also expressed Sca-2 and low levels of CD4. These 
cells also express TCR genes in the germline configuration and 
up and yô positive T cells have been seen following intrathymic 
injection of these cells. It has also been observed that these 
progenitor cells can give rise to B cells as well as dendritic 
cells following intravenous and intrathymic injection 
respectively. 
Early T cell progenitors in the thymus give rise to the 
immature CD4-8-, the double negative (DN) T cells population. 
These cells make up 1-2% of the thymic population. This 
population of cells is heterogenous as shown by the expression 
of the heat shock antigen (HSA). HSA+ cells have precursor 
activity in that intravenous or intrathymic injection of these 
DN cells results in the repopulation of the thymus. HSA-ve DN 
are devoid of this property. DN cells have increased IL-2Ra and 
Thy-1 expression but a decreased Pgp-1 levels. 
It is at this stage that immature thymocytes rearrange their 
TCR genes in the order of y, o, p and a. The p TCR chain has been 
detected on the surface of DN cells in TCRp transgenic mice as 
well as on the surface of SCID thymus pre-T cell lines 
transfected with a TCRp gene. This TCRI3 protein is found in 
association with a glycoprotein, gp33 and CD3E. This is not a 
transgenic artefact since 20% of thymocytes from a 16 day old 
normal mouse embryo also express low levels of TCRP and 
gp33. 
DN differentiate further, some upregulate CD4 or CD8 to 
become immature single positive cells which either express 
some CD3 or none at all. Regardless of the route taken these 
immature single postive cells become double positive cells 
(DP) CD4+8+ after passing through a CD4+/-8-3+ stage. At this 
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stage of development there is an expansion of cells and the DP 
population make up 85-90% of the thymocyte population. 
This is also not a homogenous population of cells. In the mouse 
25% of the DP cells are large dividing cells whilst the rest, 
75%, are small dividing cells. These cells express 
intermediate levels of CD3 as well as the up TCR. Transition 
from DN to DP has been shown to be dependent on the 
expression of the p chain of the TCR. Transgenic mice lacking 
the p chain have T cell developmental arrest at the DN stage 
whilst mice lacking the a chain contain DP cells [81-84]. 
DP cells do not have progenitor activity nor are they 
functionally mature. 
This stage in T cell development has been implicated as the 
stage in which thymic selection processes are thought to 
occur since it coincides with an enormous loss of cells 
through apoptosis. About 97% of DP cells die. As mentioned 
above positive selection results in a population of thymocytes 
specific for self MHC whilst negative selection results in the 
removal of thymocytes that recognise self MHC plus self 
peptide with high affinity. The resulting population of T cells 
are the single positive (SP) cells either capable of recognising 
foreign antigen in association with either MHC Class 1, 
(CD8+4-3+) or MHC Class 2, (CD8-4+3+). These cells express 
high levels of ap TCR and they have aquired some of the 
properties of mature peripheral T cells [85]. Mature SP T cells 
leave the thymus probably via the CM junction high endothelial 
venules or via the lymphatics. 
Kinetics of the acquisition of these cell surface markers have 
been described elsewhere [86]. 
b) Changes in location. 
As desribed above fetal progenitors enter the thymus through 
the large venules in the medulla and at the CM junction, they 
then migrate to the subcapsular region. As the cells move 
through the subcapsular region their phenotype is DN. The main 
phenotype of the cortex T cells is that of the DP and it is here 
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or at the CM junction that selection occurs since only SP cells 
are present in the medulla. 
c ) T cell receptor expression in the thymus. 
Mature peripheral I cells recognise antigen in the form of a 
processed peptide in the context of an MHC molecule on an 
antigen presenting cell via the T cell receptor (TCR). There are 
two types of TCR's, Oo and a13  the most common being the later. 
Both receptors recognise MHC. 
The cq3 TCR consists of an outer variable region, a constant 
region, a transmembrane region and a cytoplasmic tail. It is 
the variable region that recognises specific antigen plus MHC. 
This region is a product of somatic rearrangement of both a 
loci V and J elements and the p loci V,D and J elements via a 
recombinase system, Tdt and RAG 1 and 2. 
In mice the p TCR loci is found on chromosome 6 and contains 
20-25 V elements which are separated from several constant 
regions by J and D regions. During rearrangements of these 
genes one D is juxtaposed to one J, and this DJ product is then 
combined to one of the variable elements. It has recently been 
shown that the rearrangement of the TCR p loci is not random, 
certain V regions combine with certain J segments. 
The p chain rearrangement occurs after the Oo TCR gene 
rearrangements and a decrease in the number of Oo TCR+ve 
cells in the murine coincides with the development of c4E TCR. 
The rearrangement and expression of the p chain protein 
results in allelic exclusion of further p chain rearrangements. 
Observations in transgenic mice in which a functionally 
rearranged TCR p gene was added suggested that the presence 
of the rearranged p gene product resulted in the inhibition of 
endogenous p TCR gene rearrangement. This "allelic exclusion" 
is dependent on expression of the TCR p protein, since 
transgenic mice expressing only full length RNA rather than 
protein could not suppress rearrangement. 
Mice in which both Vp2 and Vp8.2 transgenes were introduced 
expressed both receptors on the surface of mature peripheral T 
cells. These data suggest that allelic exclusion must occur at 
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the DNA rearrangement level to prevent co-expression of two 
distinct TCR genes [8711. 
The 13  chain of the TCR was shown also to be important for 
clonal expansion of immature thymocytes. Transgenic mice 
expressing a non-functional 13 gene (with a deletion in the 
variable region which inhibits rearrangement) have normal 
numbers of thymocytes with the CD4+8+ phenotype. 
Maturation, however, does not proceed past this point unless a 
functional 13  chain was introduced [88]. 
A further role for the TCR 0 chain was shown using transgenic 
mice lacking this chain. T cell development is arrested at the 
DN stage. In transgenic mice lacking the a chain genes, but 
which express the 13 TCR chain, have DP cells thus expression 
of the 13 chain is important for the transition from DN to DP 
[81-83]. 
Mice lacking recombinase activity, SCID mice and RAG 1 and 2 
deficient transgenic mice have T cell development arrested at 
the DN stage. Introduction of a rearranged TCR 13 gene into 
these mice and 13  TCR-ve mice results in the transition from 
DN to DP cell type. Therefore TCR 13  chain expression may 
induce CD4 and CD8 expression [81, 84]. 
The TCR a locus also undergoes recombinational events. In 
mice the TCR a and TCR 8 genes are both found on chromosome 
14, the 8 element found within the a loci. TCR a chain 
rearrangement occurs after the P chain. There are no D 
segments in the a loci and the recombination event is only a 
V-J rearrangement. These events are non-random. 
The TCR a chain is independent of the TCR P chain as shown in 
P knockout mice. In these mice thymocytes express TCR a [81]. 
Transgenic mice lacking TCR a have thymocyte numbers 
similar to non-transgenic littermates. They possess normal 
levels of DP cells but lack CD4+ and CD8+ single positive cells 
and a thymic medullary region suggesting that the role of the 
TCR a is for further differentiation to single positive 
thymocytes [81, 83]. 
TCR a rearrangement is not influenced by allelic exclusion and 
TCR a rearrangements occur until the time of positive 
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selection and RAG 1 and 2 gene switchoff. This would increase 
the available receptor repertoires [89].  TCR a chain expression 
does not affect ô thymocyte production [90].  TCR expression 
kinetics have been described elsewhere [91, 92]. 
1.4) Positive selection 
Positive selection is the event during which developing T cells 
become MHC restricted as well as becoming committed to 
either the CD4 or CD8 single positive cell lineages recognising 
MHC Class 2 or Class 1 respectively. Positive selection is 
influenced by the MHC molecule expressed by the thymus as 
well as the peptide bound to it. The specificity of the T cell 
receptor (TCR) and the co-receptors CD4 and CD8 have all been 
implicated in positive selection. 
i) MHC restriction and the importance of the TCR-MHC 
interaction in this process. 
Early bone marrow experiments suggested that T cells 
developing within a thymus became restricted to the MHC 
expressed in this organ. For example bone marrow from a Fl 
(axb) MHC haplotype offspring into a parental host with MHC 
haplotype 'a' resulted in T cells which recognised foreign 
antigen in association with 'a' MHC haplotype [93].  The 
mechanism of MHC restriction is now thought to depend on 
positive selection in the thymus. 
Transgenic mice have further confirmed the existence of MHC 
restriction and also indicated that the TCR specificity of the 
developing T cells was important [94-102]. 
These papers have provided evidence for the involvement of 
the TCR in MHC restriction. In general the experiments 
involved the use of mice expressing transgenic (tg) TCRaI3 
receptors ( 2C tg TCR, [94]; H-Y specific tg TCR, [95, 97]; 
lymphocytic choriomeningitis virus (LCMV) tg TCR, [102] and 
pigeon cytochrome c tg TCR [101, 103, 104] specific for 
antigen ( Ld Class 1, male H-Y antigen, LCMV and pigeon 
cytochrome c, respectively) in the context of a specific MHC 
Class 1 or 2 molecule. The above tg TCR's are positively 
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selected in mice expressing the following selecting MHC 
molecule; H20, H2Db, H2Db or lEk  respectively, and the 
resulting cells are CD4-8+ transgenic TCR+ve (high 
expression) for Class 1 or CD4+8- for MHC Class 2. On a non-
selecting background these cells are not present. 
Bone marrow transfer studies also confirmed the importance 
of MHC interactions for positive selection [95, 97]. 
Reconstitution of female H2Db (selecting MHC) but not H2Dk 
thymus (non-selecting MHC) with bone marrow cells derived 
from a H-Y tg TCR mice resulted in the elevated production of 
CD8+ve cells expressing the transgenic TCR [95]. A similar 
experiment was also performed by Kisielow et al (1988) [97] 
and the same results observed. No positive selection was 
observed on non-selecting MHC alleles Kk, Dk, Kd, Dd or  Kb.  The 
level of tg TCR on DP cells was high regardless of MHC 
background. (In these experiments female mice were used 
since they did not express the male H-Y antigen which has been 
shown to induce tolerance; see negative selection below). 
The DP stage in thymocyte development is the stage at which 
thymocyte differentiation is halted on a non-selecting MHC 
environment [100, 104].  Berg et al (1989) [100, 104] showed 
that this block in development could be reversed if the 
selecting MHC ligand was placed on cortical epithelial cells. In 
this model it would appear that positive selection occurred 
late in development since transgenic pigeon cytochrome c 
specific TCR cells develop to a relatively mature stage of DP 
in the absence of positive selection. Scott et al (1989) [98] 
crossed a TCR transgenic mice specific for H2b onto a SCID 
(H-2d) background (this resulted in H2d/d or H2 b/d ap TCR 
tg/SCID mice). In contrast to the small number of CD4-8-
thymocytes present in normal SCID mice, tg TCR/SCID mice 
had elevated levels of thymocytes regardless of their MHC 
haplotype, although CD4 and CD8 expression only occurred in tg 
TCR/SCID suggesting that the maturation into DP cells 
required TCR cq rearrangements. Heterozygous H-2b/d tg 
TCR/SCID mice had CD4-8+ cells and no CD4+8- cells. Both cell 
types were missing in the H2d/d mice, suggesting that 
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interaction of the tg TCR with H2b induced positive selection 
which resulted in CD8 single positive tg TCR+ve cells. 
ii) Cells involved in positive selection 
There has been much controversy over which cells induce 
positive selection since both thymic epithelia and thymic bone 
marrow derived cells have been implicated in this process. 
Class 2 expression on epithelial cells and fetal mesenchyme 
has been shown to be important for T cell thymic development 
[105]. Purified cortical epithelial cells expressing Class 2 
supported the development of DP and SP cells, but not DN 
thymocytes. However DN cells differentiated into DP c3 TCR 
expressing cells in the presence of both epithelial and 
mesenchymal cells suggesting that mesenchymal cells are 
essential for the early stages of thymocyte development. The 
beneficial effect of mesenchymal cells on DN cell 
differentiation can be replaced by fibroblasts. Class 2 
depleted thymic stromal cells did not support the development 
of DP cells. 
The importance of epithelial cells was also shown via the 
introduction of epithelial cell lines into the thymus of 
recipient mice [106, 107].  The thymus derived epithelial cell 
line 2E4 [106] expresses low amounts of H21(b and when 
injected intrathymically seeds both the cortex and medulla 
thymic regions. This cell line persists for a long period of 
time in the thymus. Injecting the 2E4 (H2Kb) cell line into an 
H2k mouse reconstituted with bone marrow or fetal liver 
cells from H2b/k Fl donors resulted in tolerance to H2b and 
no rejection of 2E4 cells. Therefore thymic epithelial cells can 
positively select T cells. This was confirmed with another 
thymic epithelial cell line [1 07]. 
Through the use of 132m transgenic mice Bix and Raulet (1 992) 
[108] also indicated the importance of radioresistant 
epithelial cells in positive selection. Irradiated 132m positive 
mice given fetal liver from MHC matched 132m negative donors 
had CD8+TCR+ve SP cells at the same frequency as mice give 
positive cells, suggesting that radioresistant epithelial 
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cells in the 132m recipient mice were capable of inducing 
positive selection. 
Positive selection has also been shown to occur following the 
interaction of TCRs with MHC on fibroblasts [109]. f32m 
negative mice given an intrathymic injection of MHC Class 1 
expressing fibroblasts had increased levels of CD8+ve SP cells 
compared with mice not given these cells. The V13  repertoire of 
the rescued cells depended on the MHC Class 1 molecule 
expressed by the injected fibroblasts. 
The role of fibroblasts in positive selection was analysed in 
TCR tg mice. The transgenic TCR expressed in these mice 
recognises the alloantigen HLd and is positively selected by 
H2Kb. Introducing H2Kb fibroblasts intrathymically into H-
2Kk (non-selecting MHC) mice resulted in large numbers of 
CD8+ tg TCR hi  cells, similar to the numbers seen on a 
selecting background. 
Bone marrow derived cells have also been implicated in 
positive selection. Irradiated 132 m negative mice were 
reconstituted with fetal liver from MHC matched 132m  negative 
or positive mice. A 4 fold increase in the number of CD8+ve 
TCR+ve cells capable of cytotoxic activity occurred if mice 
were given bone marrow from a 132m positive donor, as 
compared to mice given bone marrow from 132m  negative mice. 
The number of CD8+TCR+ve cells never equalled that of 132m 
positive mice suggesting that although bone marrow derived 
cells can induce positive selection they do so at an inefficient 
rate [108]. 
iii) The importance of the MHC molecule in positive selection. 
The importance of the MHC molecule was further shown in 
transgenic mice in which both Class 1 [110-112] and Class 2 
[11 3-1 1 5] were not present on the cell surface or had been 
altered in some way [116]. 
The MHC Class 1 molecule consists of c1 and cc2 polymorphic 
domains which are important for the binding and presentation 
of antigen peptide to TCR and an 0 non-polymorphic domain 
which binds to CD8. Aldrich et al (1 991) [116] created a 
transgenic mouse which expressed a hybrid Class 1 molecule, 
expressing the al and a2 domains from Ld MHC whilst the ct3 
domain was from Q7b. This molecule binds to Ld restricted 
peptides but does not interact with CD8 dependent CTLs. In 
these mice positive selection of virus-specific Ld CD8+ve 
CTL's does not occur. However in mice expressing normal Ld 
MHC positive selection did occur suggesting that the 0 
domain of the MHC Class 1 is important for positive selection. 
Class 2 negative transgenic mice were created by either 
deletion of the Class 2 promoter region [11 3, 11 4] or through 
mutation in the invariant chain [115]. Spleen, peripheral lymph 
node and thymic cells of these mice were shown to be Class 2-
I- although their physiology was unaffected. Class 2-I- mice 
had fewer CD4+8- thymic cells compared to Class 2+ve mice 
although some CD4+8- cells were present. These cells 
expressed markers of immaturity eg. J1 1 D and had a cortical 
location. Some also expressed low levels of TCR and CD8. In 
the periphery of Class 2-I- mice CD4+8- cells were present 
but in reduced numbers. CD4 and TCR expression was also 
reduced [11 3] and these cells failed to reject allografts [114]. 
In all the Class 2-I- mice there was increased numbers of 
single positive CD8 cells. Thus the absence of Class 2 
inhibited positive selection of CD4+ cells. 
Class 1 negative mice were created by disrupting the 132 
microglobulin (132m)  gene [110, iii] or through the disruption 
of the TAP-1 gene (transporter associated with antigen 
processing) [112]. Homozygous and heterozygous 132m+ve mice 
had equivalent numbers of DN, DP and CD4+8- cells however in 
homozygous P2 m-/-  mice the CD4-8+ cell population was 
significantly reduced. Thus the absence of Classi inhibits 
positive selection of CD4-8+ cells. 
Similar observations were made in TAP-1 -I- mice [117]. 
From these data it was concluded that although MHC 
expression was not involved in expression of the co-receptor 
(CD4+8+ cells were present in Class 1 and 2 -I- mice) it was 
important for positive selection and differentiation into 
single positive mature cells. 
iv) The importance of peptide bound to MHC in positive 
selection. 
From the experiments described above positive selection of 
antigen-specific tg TCR T cells occurred in the absence of the 
protein for which it was specific. However it has been shown 
that each MHC molecule presents a distinct allele specific 
peptide motif [118]. It has also been shown that from the HLA-
A2.1 MHC molecule 200 different species of peptides were 
bound [119]. 
The relevance of the peptide has been shown in transgenic 
mice which express variants of the MHC molecule shown to 
induce positive selection for tg TCR cells [120-123]. Mutations 
have been induced in the al and a2 regions (H2Kbm1  , H-
2Kbm3) which interact with the TCR and in the 13  sheet region 
(H2Kbm8 and H2Kbm5 ) on which the peptide is presented. 
Nikolic-Zugic and Bevan (1991) [120] investigated the 
selection of H21(b specific TCR+ve cells capable of 
recognising ovalbumin (OVA) in the context of H2Kb in mice 
with the forementioned MHC mutations. No positive selection 
occurred in the MHC H2Kb mutant mouse in which there has 
been substitution of amino acids on the 13  sheet facing into the 
MHC molecule. 
Crossing mice possessing a transgenic TCR specific for LCMV 
in association with H2Db with H2Db mutant mice (H2bm1  3 
and H2bm1 4) resulted in no positive selection when the H2b 
MHC molecule had mutations in the (x helix (H2bm1 4) which 
interacted with the TCR. However positive selection was 
enhanced in mice possessing mutations in the 13  sheet (H- 
2bm1 3) [121]. These observations were in contrast with the 
results of Jacobs et al (1990) [1 23] who crossed H-Y specific 
TCR tg mice with similar H-2 mutant mice. Positive selection 
did not occur if there was a mutation in the peptide or TCR 
specific regions of the MHC. Positive selection also did not 
occur for the 2C tg TCR cells in the presence of an H2Kb 
molecule which had mutations in part of the molecule expected 
to be involved in peptide binding [122]. 
Thus mutations in the peptide binding site inhibit positive 
selection of MHC specific TCR+ve cells indicating the 
importance of peptide in positive selection. 
The role of peptide in postive selection was also shown in 
Tap-1 -I- fetal thymic organ cultures (FTOC) [117]. As 
described earlier Tap-1-/- mice are defective in the positive 
selection process, probably due to the lack of MHC Class 1 on 
the cell surface of these mice. 
Fetal thymic lobes from day 16 Tap-/- transgenic mice were 
given various peptides, known to induce the surface expression 
of various Class 1 alleles, on the surface of Tap-!- spleen 
cells, in the presence of exogenous 132m. 10 days later the 
lobes were disrupted and the levels of Class 1 and 2 were 
measured. It was observed that peptides induced specific MHC 
surface expression on FTOC cells; OVA peptide 0VA257-264, 
influenza peptide lF366-374 and sendal virus nucleoprotein 
(NP) peptide SV 324-332 induced surface expression of Db  and 
Kb whilst vesicular stomatitis virus NP peptide VSV52-59 
induced Kb  expression. 
In TAP-!- FTOC the percentage of CD8+ve cells was reduced as 
compared to TAP+!+ cultures due to a defect in positive 
selection. After addition of IF and OVA peptides the level of 
CD8 in FTOC Tap-/- lobes increased above background whereas 
the SV and VSV peptides had no effect or variable effects, 
respectively, on CD8 expression. In this system it was found 
that each peptide-MHC combination selected a discrete CD8+ve 
T cell population. 
Over 1 000 naturally occurring peptides have been extracted 
from C57BL/6 thymic cells. Adding this mixture of self 
peptides to the Tap-1-/- FTOC also induced the appearance of 
a large number of polyclonal (as shown via the vp expression 
profiles) CD8+ve cells. Vukamovic et al (1993) [124] also 
noted this phenonomen using OVA recombinant peptide 
mixtures. The greater the diversity/complexity of peptides the 
more efficient CD8+ve selection. 
These data suggest that the sole role of peptide is not just the 
stabilisation of MHC but that it is also important in selection. 
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v) The importance of CD4 and CD8 co-receptors in positive 
selection. 
Early studies using monoclonal antibodies indicated the 
importance of CD4 and CD8 in selection. Anti-CD4 and anti-
CD8 inhibits maturation of CD4+ and CD8+ cells respectively. 
The importance of these co-receptors has also been shown in 
transgenic mice. 
Rahemtulla et al (1991) [125] created transgenic mice lacking 
CD4, through disruption of the CD4 gene by homologous 
recombination. These mice were healthy but the number of CD4 
single positive cells was reduced and CD4 cell mediated 
responses and T dependent antibody responses were severally 
affected. Thus disrupting this gene inhibited positive selection 
of CD4+ve cells. In contrast the CD8 positive population in 
these mice were unaffected and were present in the periphery. 
Thus the expression of CD4 on CD4+8+ cells is not required for 
the positive selection of single positive CD8+ve cells. Mice 
over expressing the CD4 molecule (CD4++) have been created 
and have demonstrated the importance of CD4 in positive 
selection. Crossing these mice with H-Y TCR tg mice (specific 
for Class 1) resulted in CD4++/TCR tg Dbl-tg mice. The number 
of TCR transgenic CD8+ve cells in these mice was reduced as 
compared to TCR tg mice only and these CD8+ve cells were 
Class 2 restricted. They did not recognise the Class 1 Db  MHC 
molecule. 
It was also found that the signaling transmembrane (TM) and 
cytoplasmic (CYT) region of CD4 was important in the 
commitment to a CD4+ve lineage [126]. This was shown in 
mice expressing the CD8+ve extracellular domain linked to the 
CD4 TM and CYT regions. Bone marrow from a cross between 
these mice and H-Y TCR tg mice was transferred into 
irradiated H2b recipient mice. These mice were found to 
possess Class 1 restricted CD4+ve cells. 
The importance of CD8 in positive selection was also studied 
in transgenic mice. The CD8 gene was disrupted by homologous 
recombination in embryonic stem (ES) cells resulting in CD8- 
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I- mice. Homozygous CD8-/- mice lack single positive CD8+ve 
Class 1 restricted cells and they lack CTL responses. The CD4 
developmental pathway in these mice seems unaffected by the 
absence of CD8 and they respond to MHC Class 2 alloantigens. 
There are normal numbers of DN and single positive CD4+ cells 
but there are no DP cells in the thymus thus the expression of 
CD8 is not required for CD4 development. Fung-Leung et al 
(1988) [127, 1281 also showed that the CD8 molecule was 
important for positive selection. In the absence of the CD8 
molecule, T cells possessing transgenic TCRs (H-Y or LCMV or 
2C) specific for MHC Class 1 are not skewed towards CD8 
positivity even in mice expressing the 'selecting' MHC Class 1 
background. The level of CD8 expression also influences 
positive selection. Comparison of wild type (CD8+I+) and 
heterozygous (CD8+/-) mice showed a reduction in the number 
of CD8+ve cells expressing TCR. 
Mice in which both the CD4 and CD8 were disrupted have also 
been created [129]. These mice have a developmental block at 
the DN stage although they have significant peripheral T cells 
which are TCR high and HSA-ve. This maybe due to the lack of 
positive selection since no CD4 nor CD8 molecules were 
present. Some positive selection must occur in the absence of 
these co-receptor since some TCR+ve cells reach the 
periphery. These cell recognise alloantigens in vivo and in 
vitro however self-MHC restricted recognition of either virus 
or minor histocompatibility antigens did not occur. 
vi) Models for commitment to single positive CD4 and CD8 
cells. 
Two models seek to explain the commitment to and the 
emergence of mature single positive cells from the thymus: 
the instructive and selective models. Both models involve the 
interaction of TCR and co-receptor CD4 or CD8 molecules with 
MHC. 
The instructive model suggests that positive selection and 
lineage commitment occurs at the DP stage of thymocyte 
development. Interaction of a Class 2 specific TCR with a 
Class 2 molecule on thymic epithelial cells induces the down 
regulation of CD8 and the cell becomes a CD4 single positive 
cell. On the other hand interaction of a Class 1 specific TCR 
with a Class 1 molecule results in down regulation of CD4 and 
the cell matures into a CD8 single positive cell. This model 
predicts that CD4 +ve cells will be restricted to Class 2 and 
not Class 1 whilst CD8+ve cells restricted to Class 1 and not 
Class 2. 
Various pieces of evidence have been put forward to confirm 
this model [130-132]. Borgula et al (1991) [130] created 
transgenic mice overexpressing the CD8Q chain. Crossing these 
mice with H-Y TCR tg mice (Class 1 restricted) resulted in 
CD4 +ve cells, in female mice, which expressed CD8a tg 
capable of inducing signals. In these double transgenic mice, 
on a selecting background, only a small proportion of CD4+ve 
cells expressed the Class 1 restricted receptor. 
Robey et al (1991) [131] also created mice in which the CD8 
transgene is present on all T cells. Mature CD4+ve cells 
expressed the CD8 tg at levels equivalent to normal cells, 
whilst mature CD8+ve cells expressed double the amount of 
CD8. These CD8 tg mice were crossed with H-Y TCR tg mice, as 
above, and the presence of CD4+ve Class 1 restricted cells 
analysed. In female mice CD8 /TCR tg mice the presence of the 
CD8 transgene did not permit positive selection of CD4+ve 
Class 1 restricted cells. The CD4 positive cells present in 
these mice expressed V1 regions known to preferentially 
interact with MHC Class 2. In these mice CD8 Class 1 specific 
TCR positive selection was not affected. 
Swat et al (1992) [132] presented data which also suggested 
an instructive model. In the presence of a positive and 
negative selecting MHC background H-Y TCR tg cells (Class 1 
restricted) and influenza (IF) TCR tg (Class 2 restricted) large 
DP TCRIO cells were present. However small DP TCRhI cells 
were only seen in mice with a positively selecting background. 
These small DP cells maybe a consequence of positive 
selection. The small DP cells in H-Y TCR tg mice, on a 
selecting MHC environment, had lower levels of CD4 whilst the 
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small DP cells in the IF TCR tg mice, on a selecting MHC 
environment, had reduced levels of CD8. This was also seen in 
vitro in the absence of thymic epithelial cells. Thus the ability 
of small DP TCRhi cells to mature in the absence of TCR 
crosslinking indicated that these cells had already received a 
positive selection initiation signal. It was also noted that no 
CD4+ve cells with Class 1 specificity were obtained in vitro. 
The second model to explain the lineage commitment is the 
selection model in which positive selection occurs not at the 
DP stage but at a later SP stage. In this model it is proposed 
that two steps involving TCR and MHC interaction occur. The 
first step initiates positive selection. This results in DP cells 
down-regulating either CD4 or CD8 randomly, stopping 
expression of RAG and Tdt, and upregulating the expression of 
mature T cell ligands e.g. CD69 [133]. From this model it was 
predicted that CD4+ve cells could express Class 1 restricted 
TCR and CD8+ve cells could express Class 2 restricted TCR. 
However if these cells do not receive the second signal from 
MHC Class 1 and Class 2 respectively, since they express the 
inappropriate co-receptor, they die. The second signal 
completes positive selection and results in CD4+ve and CD8+ve 
single positive cells with Class 2 and Class 1 specificity 
respectively. This model predicits that CD4+ve and CD8+ve 
cells which are Class 1 and Class 2 will be present as well as 
CD4 Class 2 and CD8+ve Class 1 immature intermediate cells. 
In Class 2-!- mice [113] a population of unusual CD4+ve cells 
were found, about 30% of the normal number of CD4+ve cells in 
normal mice. These CD4+ve cells appeared to be at an 
intermediate stage between immature (they express low 
levels of CD8, HSA and have a cortical location) and mature 
(TCRhi and express CD69) cells. This is the phenotype of 
positively selected cells suggesting that these CD4 cell 
express TCR specific for Class 1. In CD8-!- mice there are an 
equivalent CD8 intermediate population and this suggests that 
these cells maybe Class 2 restricted. This was investigated by 
Chan et al (1993) [134]. After crossing Class 1-!- and Class 2-
I- mice only a few single positive CD4+ve and CD8+ve cells 
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were found in these double transgenic mice which may have 
been positively selected on non-classical MHC molecules. Most 
of the TCRhi expression was on the DP cells. This result 
suggested that the CD4+ve cells present in Class 2-I- mice 
were restricted to Class 1 and that the CD8+ve found in 
Class 1 -I- mice were restricted to Class 2, since they are 
absent in double negative mice. These authors also 
investigated the existence of CD4+ve Class 1 specific cells in 
double transgenics lacking Class 2 but with TCR specificity 
for the H-Y antigen. CD4+ve T cells possessing a TCR specific 
for the H-Y antigen were found on a selecting but not on a non-
selecting MHC background. 
Davis et al (1993) [1 35] also presented data which fitted the 
selective model of positive selection. The selective model 
predicts that in mice which constitutively expressed a CD4 
transgene Class 2 restricted CD8 cells would be rescued from 
cell death. They created two lines of transgenic mice 
expressing CD4 under the control of Ick or CD38 promoters. 
The lckICD4 and CD38ICD4 transgenic mice expressed high 
levels or normal levels of CD4 on immature thymocytes 
respectively, whilst in both cases peripheral mature 
thymocytes expressed CD4 at normal levels. These mice were 
crossed with 132m-/- mice (Class 1 deficient) and the 
expression of CD8 was analysed. CD8(CD4tg)+ve cells were 
present in the thymus and lymph nodes of 32m-/-/CD4+/+ 
double transgenic mice, regardless of the promoter (although 
sufficient rescue of these cells occurred best if the CD4 
transgene was over expressed). These "rescued" cells had CTL 
activity and responded to allogeneic targets. They also 
expressed VP regions which were preferentially expressed on 
CD4+ve cells specific for Class 2, thus suggesting that these 
CD8+ve cells are Class 2 restricted. 
The presence of CD8+ve Class 2 restricted cells was also 
shown in (CD4 tg x pigeon cytochrome c TCR tg +ve) double 
transgenic mice. Mature CD8+(CD4 tg +ve) cells in the thymus 
and periphery expressed pigeon cytochrome c tg TCR. 
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viii) Positive selection summary 
In summary positive selection of thymoctes in the thymus 
results in mature CD8+ve T cells restricted to self MHC Class 
1 and mature CD4+ve I cells restricted to self MHC Class 2. 
The process of positive selection involves the interaction of 
the TCR, MHC plus bound peptide and both CD4 and CD8. 
1.5) Negative selection 
The removal of self-reactive cells is thought to occur in the 
thymus. Developing thymocytes expressing TCRs with high 
affinity for the MHC/peptide complex are removed from the 
thymocyte pool by a process called negative selection. The 
major method of negative selection is deletion, 95% of 
developing thymocytes die in the thymus through a mechanism 
known as apoptosis. Self-reactive cells are also rendered 
unresponsive, anergic or they down regulate their TCR or CD8 
co-receptor. The tolerance mechanism employed appears to 
depend on the antigen presenting cell that the self antigen is 
presented on: deletion if self peptide is presented by 
haematopoietic cells, whilst anergy and down regulation occur 
if antigen is on thymic epithelial cells. 
Thymic tolerance is however an incomplete process since self 
reactive TCR positive cells can be found in the periphery of 
TCR transgenic mice usually having a DN or CD4810 phenotype 
[136]. Tolerance to self proteins requires recognition of 
immunodominant epitopes plus MHC. It is possible that these 
"self-reactive" peripheral cell are T cells which escape thymic 
tolerance since they recognise subdominant or "cryptic" 
determinants plus MHC [137]. They could also be low affinity 
cells that are not deleted. 
It has also been shown that although the cells susceptible to 
negative selection are the same as those undergoing positive 
selection, negative selection can occur in the absence of 
positive selection [138, 139]. 
In the following sections thymic tolerance is discussed. 
i) Evidence for thymic negative selection 
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Early tolerance work focused on T cells, of 'normal' mice, 
utilising specific vp TCR elements which interact with MIs 
superantigens. These superantigens are encoded by the open 
reading frame (ORF) in the 3' long terminal repeat of 
endogenous and exogenous mammary tumour viruses [140]. Only 
certain vp TCRs can recognise MIs antigens presented by 
certain MHC Class 2 molecules, for example V138.1  expressing 
T cells recognise MIsa in association with H2d, H2band H2k 
[141]. It was observed that T cells with MIs reactive TCR were 
eliminated in mice expressing MIs antigen, MIsa mouse strains 
lack Vp8.1+ve and Vf36+ve [140-143] whilst MISC positive 
mouse strains lacked Vp3+ve cells [140, 144, 145] and Etc-1 
MTV-9 superantigen expressing mice lack V135.2  and Vpi 1 TCR 
positive T cells [146]. 
Thymic involvement in the removal of these T cells was shown 
in nude MISC mice: no V133  deletion occurred [145]. Injecting 
neonatal mice with CD8+ve MIsa+ve cells resulted in deletion 
of Vp8.1 and Vf36+ve T cells due to seeding of donor cells in 
the thymus [143]. It was also found that immature thymocytes 
expressed these Vp regions whilst mature cells did not, thus 
suggesting that the thymus was involved in deletion [141, 142, 
147]. 
Transgenic mice expressing rearranged TCR genes specific for 
an antigen provided further evidence that deletion of self-
reactive cells occurred in the thymus [94, 148-153]. CD8+veT 
cells expressing a transgenic TCR specific for the male 
antigen, H-Y, in association with H2Db MHC were deleted in 
male transgenic TCR+ve mice expressing both this antigen and 
MHC whilst no deletion occurred in female transgenic mice 
lacking this antigen [148, 150]. Several authors [161][151, 
1 54] have shown deletion of T cells bearing a transgenic TCR 
expressing \/f38.1 in MIsa expressing mice. 
Van Ewijik et al (1 988) [153] created transgenic mice 
expressing I-E genes in the cortex only or in the medulla and 
on peripheral macrophages. Analysing the frequency of Vpl 7a 
expressing T cells in these transgenics revealed that deletion 
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of these cells occurred if l-E was on either cortical or 
medullary cells or both. 
ii) At what stage does negative selection occur? 
As described above deletion of MIs antigen specific T cells 
occurred in the thymus of normal mice. For most of these 
studies the deleted V3 regions were found on the immature 
double positive cells whilst no expression was evident on 
mature single positive cells [141, 142, 147, 155]. These 
authors speculated that deletion occurred at a late stage of 
double positive development or in the transition from DP to SP 
cells. This was also confirmed by transgenic mice. Pircher et 
al (1989) [154] and Blackmann et al (1990) [156] showed that 
in MIsa expressing mice double positive T cells expressing 
transgenic Vf38.1+ve TCRs were present however Vp8.1 TCR +ve 
SP T cells were reduced. Mice expressing a transgenic TCR 
specific for cytochrome c in association with Class 2 l-E or I-
A have variable levels of DP cells but lacked CD4+ve single 
positive cells [157]. 
The stage at which negative selection occurs has also been 
analysed using in vitro assays [158, 159].  Day 14 thymic lobes 
from a 2C TCR transgenic mice specific for pigeon/moth 
cytochrome c bound to MHC Class 2 1[k  were dissociated and 
cultured with moth cytochrome c. Here elimination was shown 
to occur before or immediatley after CD4 and CD8 expression, 
thus this peptide induced tolerance in the DP thymocytes. A 
peptide not recognised by the 2C T cells did not induce 
deletion. By varying the concentration of peptide added to the 
cultures it was found that double positive immature T cells 
are deleted at very low peptide concentrations. The work of 
Vasquez et al (1992) [157] also indicated that deletion of DP 
cells was dose dependent: immature thymocytes are more 
sensitive to antigen than mature T cells despite having fewer 
ligands. Significant deletion of 2C TCR expressing DP cells 
occurred when moth cytochrome c concentration was at 
0.0251M. This concentration of peptide did not activate mature 
2C TCR+ve T cells. 
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Male H-Y TCR transgenic mice [ISO] have a dramatic reduction 
in the double positive thymic population suggesting that it is 
at this stage of thymocyte development that deletion occurs. 
Takahama et al (1992) [160] suggested that the reduction in DP 
cells in the H-Y TCR transgenics was due to the inhibition of 
CD4810 precursor development and that these cells are the 
targets for negative selection. 50% of CD48I0 H-Y TCR+ve 
thymocytes from transgenic mice developed into CD4+8+ cells 
in culture and this was blocked by anti-TCR antibodies and by 
male APC from male H2b nude mice but not female mice. 
Similarly in vivo, precursor fetal thymocytes from male, 
expressing H-Y and appropriate MHC, but not female transgenic 
mice did not develop into DP cells in vitro. It was also noticed 
that these CD810 immature precursors (HSAh1 and ICAMhi) 
expressed CD5, which was associated with antigenic 
stimulation, thus it appeared that antigenic stimulation 
inhibited the development of the DP cells. Since CD8I0  
immature cells did not accumulate, nor did they undergo 
apoptosis, it was hypothesised that these cells became the DN 
cells which are found in large numbers in these mice. Swat et 
al (1991 and 1994) [158, 161] have published conflicting data. 
In vitro culture of CD4+8+ thymocytes from female H-Y 
transgenic in the presence of male APC from thymus or spleen 
resulted in deletion of these DP cells such that after 48 hours 
in culture few DP cells remained. This was not seen if APCs 
expressed the wrong MHC or lacked the male antigen [158]. 
CD4810 immature thymocytes from a non-selecting H-Y TCR 
transgenic male mice in the absence of an antigenic signal 
developed into CD4+8+ cells. In contrast, in the presence of 
male cells (antigenic stimulus) there is a reduction of DP cells 
and no increase in DN cells was seen. However this stimulus 
did not entirely prevent DP generation. It was concluded that 
deletion either occurred before or after the expression of CD4 
and that deletion occurred at the DP stage and not at the CD4-
810 stage as described above. 
Overall, these data suggest that deletion of I cells occurs at 
the DP stage, early or late, or as they become single positive 
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cells. The difference in timing appears to depend on the TCR 
expressed and the antigen involved. This was confirmed 
further by Picher et al (1 989) [1 52] using double antigen 
specific TCR transgenic mice. The TCR of these mice 
recognises LCMV and MIsa. In MIsa TCR transgenic mice no 
reduction in DP cells occurred, as found in earlier studies, 
however there was a reduction in the SP TCR+ve cells. In 
contrast LCMV infected TCR transgenic mice had deleted DP 
cells. This difference may be due to the time dependent 
appearance of the antigen and localisation of antigen, as also 
seen by Zal et al (1994) [162]. Transgenic mice expressing TCR 
receptors for self circulating C5 antigen (C5 is the fifth 
component of mouse complement: a serum self protein) [163] 
developed tolerance late in ontogeny and DP cells were 
unaffected. This was attributed to the fact that dendritic cells 
in the CM junction presented CS which would involve uptake, 
processing and presentation. In the transgenic mice expressing 
ICR's specific for both LCMV and MIsa, interaction with LCMV 
in the cortex and medulla and with MIsa  in the outer cortex 
medulla may affect the cells that undergo deletion. Another 
possiblity is that high affinity interactions delete LCMV 
specifc cells whilst low affinity interactions delete MIsa 
specific cells. 
iii) AFFINITY. AVIDITY AND PEPTIDE 
The data above suggests that cells undergoing negative 
selection are similar to those undergoing positive selection. 
One hypothesis to explain this is that selection can be 
attributed to affinity; thymocytes with low affinity for MHC 
are positively selected whilst those of high affinity are 
deleted. An alternative hypothesis is the peptide model where 
both positive and negative selection requires high affinity 
TCR-MHC interaction. However the peptide/ MHC complex that 
mediates selection differs; bone marrow derived cells present 
a ubiquitous peptide whilst thymic epithelia present both 
ubiquitous and unique peptides. 
59 
There have been several models utilising transgenic mice 
which confirm the affinity model [164, 165].  On a selecting 
MHC background, H21(b, 2C TCR transgenic positive T cells 
were positively selected. When these transgenic mice were 
mated with CD8 transgenic mice (where CD8 is under the 
control of CD2 promoter element) the fate of the 2C TCR 
receptor positive T cells changed from being positively to 
negatively selected and in the thymus the total number of 
thymocytes were reduced. These authors hypothesised that if 
increasing the levels of CD8 induced negative selection then 
the remaining cells would have low CD8 levels. This was the 
case. This study was in contrast to H-Y transgenics where 
increasing CD8 increased the efficiency of positive selection. 
The authors suggested that H-Y specific TCRs were of very low 
affinity and that increasing CD8 levels increased affinity but 
not to the level required for negative selection. 
2C TCR transgenic mice were also crossed with transgenic 
mice expressing distinct and elevated levels of CD8, either 2, 
3 or 6-10 times more than normal [166]. T cells in mice 
expressing the 2C TCRs plus high or intermediate levels of CD8 
were deleted whilst those with low CD8 levels were selected 
to mature. Decreasing the affinity of the CD8 and MHC Class 1 
interaction allowed T cells to escape deletion [167]. 
In another experiment the CD2 promoter was used to direct 
Vi 1 expression. Two lines of mice were created; one with 
'low' V131  1 expression, another with 'high' V1 1 expression 
[165]. CD4V11+ cells are usually deleted in the presence of 
MMTV 8, 9 and 11 however no deletion of CD4Vp1 1 +ve cells 
occurred in the 'low' V31 1 expressing mice and these cells 
were found in the periphery. In contrast CD4Vp1 1 +ve cells 
were deleted in the 'high' Vi 1 expressing mice. These data 
suggest that high avidity cells are deleted whilst those of low 
avidity escape and are found in the periphery. Similar 
observations were made in TCR transgenic mice specific for 
murine haemoglobulinhIEk and expressing this ligand [168]. 
In vitro FTOC using transgenic TCR thymocytes specific for 
LCMV also supported the affinity and avidity model. Low 
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concentrations of peptide induced positive selection whilst 
high concentration resulted in tolerance [169, 170]. 
The peptide recognised by self-reactive cells is also 
important. Cabaniols et al (1994) [1 37] suggested that high 
affinity clones recognising the immunodominant peptides of 
HEL are negatively selected even in the presence of a low dose 
of antigen whilst those which have low affinity specific for 
cryptic peptides are not. 
iv) Contribution of CD8 and CD4 
As described above tolerance involves the removal of T cells 
with TCRs of high affinity. What is the role of CD4 and CD8 co-
receptors in tolerance induction? 
The role of CD8 was analysed by crossing H-Y, LCMV and 2C 
TCR transgenic mice with CD8-/- mice. It was found that 
there was a differential requirement for CD8 in deletion: no 
deletion of H-Y and LCMV TCR transgenic cells occurred in the 
absence of CD8 whilst deletion of the 2C TCRs occurred even 
in the absence of this co-receptor [128]. This result was 
explained with respect to affinity: cells with high affinity 
TCRs, for example the 2C TCR, do not require CD8 interaction 
with Class 1 for deletion, whilst cells with low affinity TCRs, 
for example H-Y and LCMV TCRs, require CD8 interaction with 
MHC Class 1 for deletion to occur. Further evidence for a lack 
of CD8 involvement in deletion was shown by Knobloch et al 
(1992) [171]. Crossing Class 1 mutant mice with TCR 
transgenic mice specific for Kb resulted in deletion of DP 
cells suggesting that the missing interaction between Class 1 
and CD8 did not prevent negative selection. 
CD8 was also shown to be required for negative selection in 
mice expressing MHC Class 1 with a3 domains which do not 
interact with CD8 [172]. 
Deletion of V136  or  V138.1  TCR expressing T cells in MIsa mice 
was prevented when mice were treated with anti-CD4 
monoclonal antibodies [173], thus CD4 appears to be important 
in tolerance induction. However like CD8, CD4 was shown to be 
a differential requirement for deletion [174]. V3 TCR 
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expression was analysed in CD4-/- knockout mice backcrossed 
onto an MIsa environment. V6, 9, 8.1 CD8+ve T cells were 
deleted whilst Vf37 expressing cells were not. This data 
suggested that T cells expressing TCRs with high affinity for 
MIsa are deleted without the participation of CD4 whilst T 
cells expressing TCRs of low affinity, as is the case with Vp7, 
require CD4 interaction with Class 2 for clonal deletion [174]. 
CD4 and CD8 positive cells are also associated with p56lCk. 
However inhibition of this molecule did not interfere with 
deletion [175]. 
v) Bone marrow cell tyres involved in thymic tolerance. 
Bone marrow chimaeric experiments have suggested that bone 
marrow derived cells other than T cells are involved in thymic 
tolerance [176, 1771 although thymocytes themselves have 
also been shown to induce thymic tolerance [178, 179].  FACS 
purifed CD4+8+ immature thymocytes from H-2Db mice 
expressing transgenic TCR specific for LCMV plus H-2Db under 
went apoptosis when cultured with LCMV. Thus antigen 
presenting immature DP thymocytes can tolerise antigen-
reactive immature thymocytes in vitro by deletion induced 
apoptosis 6-8 hours after antigen exposure [178]. Thymocytes 
were also shown to induce tolerance in vivo. Simpson et al 
(1993) [179] created transgenic mice expressing H2Kb under 
the control of the human CD2 gene such that all thymocytes 
and peripheral T cells expressed this antigen. These mice were 
tolerant to H-2Kb skin grafts. 
Pircher et al (1993) [138] suggested that negative selection 
did not require a specific APC. This was also shown by 
Iwabuchi et al (1992) [180] using an in vitro single cells assay 
in which thymocytes expressing LCMV specific TCRs were 
deleted after being co-cultured with various APCs and LCMV 
peptide. These experiments indicated that a whole host of 
cells were capable of inducing deletion, including embryonic 
and transformed fibroblasts, melanoma cells, cortical thymic 
epithelial cells, neural cells, TNC as well as macrophages, and 
DC from the thymus and spleen. Tolerance was induced in a 
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dose dependent manner with some cell types requiring 
nanomolar concentrations of antigen whilst splenic 
macrophage and DCs required only picomolar amounts. It was 
also found that there was a minimum amount of antigen 
required for negative selection. These data led the authors to 
suggest that the stage of thymocyte development, rather than 
the type of APC cell or antigen concentration, was important 
for deletion [1 80]. 
Many studies have highlighted the efficiency of DC in tolerance 
induction; a) thymic dendritic cells were xl 0 more efficient 
than thymic macrophages at inducing in vivo and in vitro 
tolerance [138], b) deletion of V36+ve T cells occurred in Mlsb 
FTOC reconstituted with MIsa DC and B cells and Mlsb 
thymocytes (here the presence of B cells was important since 
it is thought that these cells pass the MIsa antigen to Class 2 
positive cells) [181], c) male DC induced deletion of DP H-Y 
specific thymocytes in vitro [182] and d) DC from C5 
expressing mice stimulated C5 specific transgenic TCR+ve 
thymocytes since they retain C5 on their surface for a long 
period of time [163]. The properties attributing to the 
tolerising ability of DC are: a) their high Class 2 expression b) 
slow turnover of membrane Class 2 and c) adequate antigen 
internalisation [163]. 
The role of macrophages in tolerance induction was 
investigated in mice expressing an l-E transgene on 
macrophages [183]. Expression of l-E reactive V5, 11 and 17a 
T cells were examined in these mice. No deletion occurred. The 
remaining cells were anergic. This confirmed the finding of 
Pircher et al (1993) [1 38] that splenic macrophages were more 
effective than their thymic equivalents at tolerance induction. 
B cell effectivness in tolerance induction was shown by Aiba 
et al (1994) [184]. Murine thymic V138+ve  lymphocytes in the 
presence of SEB and a B cell lymphoma expressing Class 2 at 
high levels undergo deletion. However when these cells are 
fixed clonal deletion was inhibited. 
Mature thymocytes have been shown to require a second signal 
to undergo proliferation: crosslinking the TCR does not induce 
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proliferation. However signalling through CD28, via interaction 
with B7 on APCs, does induce proliferation. A second signal for 
thymocyte deletion has also been observed [184, 185]. 
Crosslinking the transgenic TCR from DP T cells specific for 
moth cytochrome c with murine Class 2 transfected 
fibroblasts plus antigen results in deletion via apoptosis. 
When the TCR was crosslinked in the absence of APC no 
deletion occurred but the CD4+8+hi cells down regulated their 
CD4 and CD8 co-receptors and became CD4+8+10. On addition of 
APCs deletion occurred [185]. This second signal was not 
provided by the B7/CD28 pathway, since blocking these 
receptors did not stop deletion [185-187] and CD28 deficient 
mice still undergo deletion. Other signals that may be involved 
include LFA-1/ICAM1, CD2/LFA3 and VLA4/VCAM. Antibodies 
to LFA-1 and ICAM1 have been shown to interfere with 
tolerance induction [186] but the murine fibroblasts used by 
Page et al (1993) [185] did not express LFA1 or ICAM1 and 
tolerance still occurred. CD2 has also been ruled out since 
disruption the CD2 gene did not interfere with thymic 
development [188]. 
vi) Thymic epithelium and tolerance 
Thymic epithelial components have also been shown to be 
involved in negative selection either through deletion of self 
reactive cells or by inducing unresponsiveness. 
Bone marrow chimaeras were constructed such that the 
antigen recognised by a specific Vf3 bearing T cells was 
presented on either the thymic epithelia or on donor bone 
marrow derived cells [177]. When H2k expression was limited 
to bone marrow derived cells MIsa deletion of Vpl7a and Vp6 
was found. However when H2k expression was limited to the 
recipient thymic epithelia then very little deletion of these 
V+ve cells occurred. These remaining cells did not respond to 
MlSa but did respond to a third party antigen and anti-TCR 
crosslinking. Similar results were found by Roberts et al 
(1990) [189]. l-E expression only on thymic epithelial cells did 
not result in deletion of Vpi 7a+ or V36+ cells and the 
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remaining cells did not respond to either Misa or l-E or anti- 
TCR crosslinking. Thymic epithelia therefore appears to induce 
anergy. A role for thymic epithelial cells in anergy induction 
was also seen using transgenic mice [176, 190].  H-2Kb 
expression was directed to the mammary tissue (KAL) [190] or 
keratinocytes (Kb) [176]. These mice did not reject H-21(b 
positive skin despite its alloantigenic nature. Crossing these 
H-21(b mice with mice possessing anti-H-2Kb TCRs indicated 
that this tolerance was not due to deletion of DP self-reactive 
cells nor was it due to down regulation of CD8 or TCR. However 
unlike the anti-H-21(b single transgenics no Kb-reactive CTLs, 
even in the presence of rlL-2, occurred in these double 
transgenic mice. These cells were also either non responsive 
[190] or responsive [176] to anti-TCR antibodies with or 
without rlL-2. Tolerance in KAL transgenic mice was 
attributed to expression of H-21(b by thymic epithelial cells as 
shown via bone marrow chimaeras and skin graft rejection 
experiments whereas tolerance in the Kb transgenic mice was 
attributed to both bone marrow and thymic epithelia H-21(b 
expression [176]. These experiments suggest that thymic 
epithelia are not capable of inducing deletion of self-reactive 
T cells. 
In contrast several authors have produced data which support 
the role of these cells in clonal deletion [191-193]. Bone 
marrow chimaeras in which l-E was expressed on host 
epithelia cells resulted in deletion of V136+ve  cells. Negative 
selection induced by thymic epithelial cells occurred after or 
during the DP to SP transition. Tolerance induction by thymic 
epithelial cells is not as efficient as tolerance induction by 
bone marrow derived cells; for example, T cells expressing 
low levels of TCR V36+ve regions are found if tolerance is 
induced by the former rather than the latter [193]. 
Bone marrow chimaera studies involving TCR transgenic 
agreed with these data [191]. Mice expressing I-E on the 
thymic medullary epithelia induced partial deletion of 
transgenic Vp5+ve T cells. However no deletion of transgenic 
vpi 1+ve T cells occurred. These observations were explained 
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by the fact that Vf31 1 +ve T cells required the high density of I-
E on bone marrow cells to induce tolerance [192]. Thymic 
epithelial cells expressed l-E at a low densities. 
Antigen expression on thymic epithelia has also been shown to 
induce what is known as "split-tolerance" such that deletion 
is found in vivo but not in vitro [194, 195].  This may be due to 
deletion of high affinity clones whilst low affinity clones 
escape tolerance and are activated in vitro. 
ICR and CD8 down regulation 
Tolerance can be associated with down regulation of the ICR 
rather than deletion [196]. KAL transgenic mice expressing H-
2Kb in the mammary gland are tolerant to H2Kb skin grafts. 
Tolerance was shown to be due to expression of H2Kb in the 
thymus. Crossing these mice with mice possessing T cells 
with antiH20 transgenic TCRs indicated that tolerance was 
not due to deletion: antiH2Kb expressing T cells were 
present in the resulting double transgenic mice. Tolerance was 
associated with the down regulation of transgenic TCRs on T 
cells. Down regulation of CD8 has also been found in chimaeric 
mice which expressed male H-Y antigen on thymic epithelia 
and not on bone marrow derived cells [197]. In this situation 
female H-Y transgenic cells developing in chimaeric thymic 
environment are tolerant to the H-Y antigen not through a 
process of deletion of DP cells. 
Programmed Cell Death/Apoptosis 
Cells which recognise self peptide plus self MHC with high 
affinity are removed from the thymocyte pool, as described. 
This process involves the programmed death of cells, or 
apoptosis, which is characterised by DNA fragmentation, 
chromatic condensing and T cell shrinkage. Double positive 
thymocytes from transgenic mice expressing a TCR specific 
for chicken OVA plus IAd undergo apoptosis if OVA is injected 
into these mice and this occurs within the thymus subcapsular 
and deep cortical areas [198]. Cells undergoing cell death show 
a marked change of surface phenotype [199]. CD4, CD8 and HSA 
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expression are decreased whilst TCR f3ICD3, CD69 and CD25 
expression increase. This may reflect a breakdown in 
intracellular trafficking leading to an accumulation of 
markers in the cell membrane [199]. 
The FAS cell surface protein has been shown to mediate 
apoptosis and is expressed throughout thymocyte development. 
Ogasawara et al (1995) [200] showed that both DP and SP 
thymocytes expressed the same amount of FAS however 
following an anti-FAS intraperitoneal injection DP thymocytes 
are deleted due to apoptosis. Despite the high expression of 
FAS in SP cells these cells are resistant to FAS mediated 
apoptosis. This may be due to the expression of bcl-2, a 
molecule which promotes survival of cells derived of essential 
growth factors in vitro. Its role in thymic tolerance has also 
been studied [201-204]. Crossing female H-Y transgenic mice 
on a non-selecting background with bcl-2 transgenics resulted 
in survival of DP cells in these mice. These cells did not 
differentiate further. Introducing the bcl-2 gene into male H-Y 
transgenics increased the number of DP cells 4-6 fold 
compared to mice lacking bcl-2 and over expression of bcl-2 
reduced the efficiency of DP deletion. Self-tolerance was still 
maintained in these mice since peripheral T cells did not 
respond to the H-Y antigen [201]. Similar data were obtained 
by other authors [202-204]. 
ix) Negative selection summary 
Removal of T cells expressing TCRs capable of recognising self 
peptide/MHC complex with a high affinity occurs within the 
thymus. This is known as negative selection. T cells 
undergoing negative selection die by apoptosis, or they are 
rendered anergic or they down regulate their TCR or CD8 co-
receptor. Various factors have been shown to influence this 
process including antigen, CD4 and CD8 co-receptor, MHC and 
TCR specificity. 
1.6) Peripheral tolerance 
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Workers investigating tolerance to alloantigens expressed in 
the periphery have looked mostly at the expression of MHC and 
viral proteins in tissues such as the pancreas and liver, as 
well as on erythroid cells. Targeting of genes to these organs 
involves the use of tissue specific promoters: expression of a 
transgene in the pancreatic islets involves the use of either 
the rat (RIP) or human (HIP) insulin promoter and enhancer 
elements, whilst expression on the acinar cells in the 
pancreas or liver is directed by either the elastase promoter 
and enhancer or the zinc inducible metallothionien promoter, 
respectively. Controlling elements of the human beta-globin 
gene have been used to direct expression of transgenes to 
RBCs. In the following sections tolerance in such transgenic 
mice is discussed with respect to the expressed transgene and 
it's tissue distribution. 
MHC Class 1 transgenics and erthyroid expression [205] 
H2Kk mice expressing transgenic H2Kb on 50% of their red 
blood cells accepted Kb  skin grafts and no Kb  CTLs were 
observed in vitro even in the presence of IL-2. These 
observations suggested that these mice were tolerant to H-
2Kb. The mechanism of tolerance was not one of deletion since 
lymph node cells from these mice proliferated to H2Kb 
expressing stimulators to the same extent as non-transgenic 
mice regardless of the presence of IL-2. Tolerance was not due 
to H2Kb expression in the thymus since no expression of this 
protein was found in this organ. However positive selection 
had occurred resulting in H21(b restricted T cell responses. 
MHC Class 1 expression in the pancreatic beta cells or 
acinar cells. 
The expression of Class 1 on pancreatic cells and its role in 
diabetes was analysed in H2Kb Class 1 transgenic mice. 
Diabetes occurred in some mice expressing transgenic H2Kb 
on pancreatic tissue [206-210]. Expression of transgenic Class 
1 on these cells caused diabetes by interfering with insulin 
production rather than inducing destruction of pancreatic islet 
cells by an immune response. No immune infiltrate was 
observed even after priming with H21(b spleen cells [210]. The 
lack of an immune response to the transgenic MHC suggested 
that these mice were tolerant to this alloantigen. Spleen cells 
from unprimed Class 1 transgenic mice did not kill H2Kb 
targets in vitro without addition of exogenous IL-2 [206]. Thus 
transgene specific cytotoxic cells remained in these mice but 
in a tolerant state. Their existence was confirmed in double 
transgenic mice expressing H21(b on pancreas islet cells and a 
transgenic I cell receptor specific for H2Kb [208, 210]. The 
H2Kb TCR specific T cells in single transgenic mice rejected 
H2Kb skin grafts rapidly compared to non-transgenic 
littermates and strong antiH21(b CTL responses were 
generated in vitro [208]. Double transgenic mice had similar 
numbers of TCR transgenic positive T cells in both the thymus 
and periphery but unlike the single TCR transgenic mice this 
large potential pool of auto-reactive T cells did not reject H-
2Kb skin grafts. Cytotoxic T cells from these mice were 
generated at a less efficient rate than in non-transgenic mice. 
The mechanism of tolerance appeared not to involve deletion 
of self-reactive clones nor was it due to TCR and CD8 down 
regulation, since expression levels of TCR and CD8 per cell 
were similar to non-transgenic animals [208]. The mechanism 
favoured was one of clonal silencing or anergy. As the 
pancreatic cells died tolerance subsided suggesting that the 
continuous presence of antigen was required for the 
maintenance of the tolerant state. 
Deletion of T cells specific for antigens expressed in the 
pancreas has been documented [211]. H2Ld transgenic mice 
expressing this protein on the surface of pancreatic acinar 
cells (without thymic or splenic expression) were tolerant to 
H21-d. Crossing these mice with mice expressing a transgenic 
receptor specific for H20, the 2C TCR transgenics, resulted 
in double transgenic mice which were also tolerant to this 
MHC molecule. Tolerance in these mice was found to be the 
result of elimination of 80% of the 2C TCR+ve T cells. Those 
cells escaping elimination had reduced H2Ld activity and 
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were in an anergy state. Anergy was not associated with a 
period of proliferation nor was it associated with the down 
regulation of TCR or CD8. 
Why should both Class 1 expressing pancreatic models have 
different outcomes? Both the transgenic MHC molecule and the 
transgene expressing cell are different in these models. It is 
possible that antigen presentation by pancreatic acinar cells 
results in deletion whilst antigen presentation by pancreatic 
islet cells results in anergy. Another explanation is that the 
affinity of the T cell dictates the outcome. For example, high 
affinity T cells in the H21-d model are deleted upon 
recognition of the transgene in the pancreas whilst T cells 
with a lower affinity for H21-d are rendered anergic. In 
contrast, high affinity T cells specific for H2Kb may have 
been deleted in the thymus (due to a few molecules of H2Kb 
being expressed in this tissue) [21 7] such that the remaining 
cells are only susceptible to silencing following contact with 
H2Kb in the periphery. 
iii) MHC Class 1 expression on neuroectodermal, hepatocyte 
and keratinocyte cells 
Expression of a H2Kb transgene under the control of either 
the glial fibrillary acidic protein promoter, albumin promoter 
or keratin IV promoter was directed to neuroectodermal 
(GFAPKb transgenics), hepatocytes (ALB-Kb transgenics) and 
keratinocytes (KlVKb transgenics) cells respectively [212-
214]. Each of these mice displayed distinct peripheral 
tolerance mechanisms. 
GFAPKb transgenic mice express H2Kb in cells of 
neuroectodermal origin including Schwann cells in the 
intestine and epithelial cells of the choroid plexus as well as 
cells in the brain. ALB-Kb transgenic mice expressed H2Kb in 
the liver (at different levels depending on the transgenic line) 
and KlVKb transgenic mice expressed H2Kb on epithelial 
cells of the tongue, skin and footpad. No H2Kb expression was 
found in the thymus of any of these transgenic mice. All 3 
transgenic mice accepted Kb  skin grafts. In addition GFAPKb 
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transgenic mice also accepted the EL-4 tumor cell line which 
expresses H21(b, and these mice did not show a primary anti-
Kb CTL response in vitro. These mice were mated with mice 
expressing a transgenic TCR (recognised by a clonotypic 
antibody) specific for H21(b. Despite the presence of many 
self-reacting cells the resulting double transgenic mice were 
tolerant to H2Kb. They all accepted H2Kb skin grafts and 
GFAPKb double transgenic mice retained their ability to 
support the growth of the EL-4 cells. No differences in 
tolerance levels were found in the three ALB-Kb lines 
expressing the transgene at different levels, suggesting that 
the density of self antigen does not play a crucial role in 
tolerance. 
In GFAPKb and ALB-Kb double transgenic mice the number of 
CD8+ve clonotypic+ve cells was reduced in both spleen and 
lymph nodes compared to control mice (the transgenic TCR-
only mice). No reduction in the number of CD4+ve clonotypic 
+ve cells was found. Analysis of the TCR-ve CDZ+ve cells, 
following CD4 and immunoglobulin positive cell removal, 
indicated a decrease (about 60%) in the number of cells 
expressing TCR in the double transgenics as compared to 
single transgenic TCR+ve mice. These data suggested that the 
mechanism of tolerance in these mice was one of TCR down 
regulation. 
In vitro culture of T cells from GFAPKb double transgenic 
mice with H-2Kb spleen cells resulted in the re-expression of 
TCRs although this did not occur with ALB-Kb T cells even 
after IL-2 stimulation. Re-expression of TCRs needed CD2 
cross Ii n k I n g. 
In contrast KIV-Kb double transgenic mice did not show any 
evidence of deletion, anergy or down regulation of TCR. H2Kb 
reactive T cells in these mice had enhanced levels of 
activation markers, such as CD44 and CD2, suggesting that 
these cells had come in contact with antigen [214]. Tolerant 
cells in the KlVKb double transgenic mice were long-lived and 
tolerance persisted only with continuous contact with the 
tolerogen. 
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The differences in tolerogenic mechanisms seen between these 
mice was attributed to; 1) different tolerogenic signals 
provided by various tissues, 2) varying numbers of antigen-
bearing cells within a certain tissue, 3) accessibility of the 
organ, 4) different adhesion molecules on cells and 5) the 
intensity, frequency and length of contact. 
Down regulation of both TCR and CD8 was also seen in double 
transgenic mice expressing H2Kb under the control of an LPS 
inducible human complement reactive promoter (CRP-Kb) and 
H21(b transgenic TCRs on T cells [21 5] These (CRP-Kb x anti-
Kb TCR) double transgenic mice were tolerant to H2Kb despite 
the extremely low levels of H2Kb in the liver. A reduction in 
H2Kb specific T cells was observed in these mice apparently 
due to down-regulation of CD8 and TCR. Further down 
regulation of these molecules occured following the increase 
in H2Kb levels through LPS stimulation. 4 weeks following 
LPS stimulation H2Kb levels decreased which resulted in the 
reappearance of H2Kb specific T cells, confirming the 
reversibility of this tolerance mechanism. From this study it 
appeared that tolerant cells can be driven deeper into a state 
of tolerance depending on antigen dose. 
This susceptibility to additional tolerising signals has been 
described as the multistep model of T cell tolerance [216, 
217]. Schonrich et al (1 994) [21 6] found that T cells 
expressing transgenic H2Kb reactive TCRs were not deleted in 
double transgenics expressing a mutant form of H2Kb (Kbml) 
although they were partially tolerant: in vivo they did not 
reject H21(b skin grafts but in vitro they were reactive to Kb 
positive splenocytes. In vitro activity was abolished following 
intravenous injection of Kb positive cells or when (antiH20 
TCR X Kbml)  were crossed with ALB-Kb mice. Contact with Kb 
on hepatocytes led to deletion of the tolerant T cells. 
Mice expressing a soluble form of Q10 (a non-classical Classi 
encoded molecule) in the liver [218-220] with serum levels of 
1 0-6opgs/ml were not tolerant to Q10 since H-2 unrestricted 
CTL activity to membrane bound Qi 0 was found [218]. However 
mice expressing membrane bound Q10 protein on the surface of 
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liver parenchymal were tolerant to this molecule [219, 220] 
with no evidence of cellular infiltrate into the liver before or 
after deliberate immunisation with this protein [219, 220] or 
cross-reactive antigens [220]. Following in vitro activation of 
CTLs however infiltration was observed [220]. Tolerance in 
this model was stable since transferring Qi 0 CTL cells into 
non-transgenic mice resulted in mice that were tolerant [219]. 
iv) Class 1 and H-Y TCR specific T cells. 
The fate of CD8+ve Tcells expressing transgenic TCRs specific 
for the male H-Y antigen in female mice has been documented 
[139, 221-224]. Female mice positively select these cells such 
that CD8+ve T cells specific for the H-Y antigen are found in 
large numbers in the periphery of these mice. No negative 
selection occurs due to the lack of the H-Y antigen. Tolerance 
to H-Y was induced in the periphery following the injection of 
male lymphoid cells expressing H-Y antigens into adult [223] 
and neonatal female transgenic mice [139] or via transfer of 
transgenic female lymphoid cells into male nude mice [221, 
Exposure to male antigen resulted in a reduction in the 
number of H-Y reactive T cells through deletion [139, 221, 
CD8+ve H-Y reactive were shown to undergo apoptosis 
following intravenous injection into female mice [139]. 
Deletion was either preceded by a period of activation and 
proliferation, as shown through the expression of CD44, [221, 
222] or it occurred rapidly without proliferation [139]. 
Deletion was however not complete since some CD8+ve male 
reactive cells remained in these models [139, 221-223]. These 
cells were found to be either; a) responsive to H-Y in vitro to 
1/3 the level of non-transgenic mice [139, 223] or b) 
unreactive to H-Y or anti-TCR stimulation in vivo or in vitro 
[221, 2221. This anergy was however reversible as seen by 
"parking" experiments. "Parking" anergic CD8+ve male reactive 
T cells in female but not male mice for 3-8 weeks resulted in 
CD8+ve TCR transgenic cells capable of proliferating in 
response to rlL-2 and anti-TCR stimulation in vitro .Therefore 
in the absence of antigen stimulation, tolerance is reversible 
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although time is a critical factor. "Parking" cells for a few 
days did not reverse tolerance [222]. 
The importance of the CD8 molecule in peripheral tolerance 
was shown by Zang et al (1994) [223]. B6 H-Y transgenic 
female mice were injected with B6 male lymph node cells 
from CD4-I- (CD8+ve) or CD8-I- (CD4+ve) knockout mice. Only 
following the transfer of CD4-/- cells did reduction of male 
specific cells occur. As above CD8+ve H-Y reactive cells 
remained in the periphery of these mice and were fully 
responsive to male antigen in vivo [225]. 
v) Class 2 transgenic expression in the pancreatic beta and 
acinar cells 
Class 2 molecules (both l-E and I-A) have been targeted to the 
pancreas using RIP and elastase promoters [226-234]. 
Although some l-E transgenic mice became diabetic this was 
not due to an immune infiltration of the pancreas [226, 227, 
233], even after priming with the alloantigen. The suggestion 
that these mice were tolerant to the expressed l-E was 
confirmed by Markmann (1 988) [229] by transplantation of 
transgenic l-E+ve pancreatic tissue to l-E-ve naive recipients: 
these mice accepted the l-E+ve graft. Gotz et al (1990) [226] 
showed that l-E reactive cells were present in l-E transgenic 
mice in vitro and in vivo despite the lack of autoimmune 
infiltration into the pancreas. These authors suggested that 
the l-E transgenic mice were not tolerant but that the immune 
system ignored the alloantigen due either to low l-E 
expression or lack of access to the pancreas. The hypothesis 
that l-E was hidden from the immune system was ruled out in 
another experiment: non-transgenic, non-tolerant, T cells 
destroyed the pancreas of l-E+ve transgenic mice [227]. 
The I-E molecule is recognised by T cells expressing either 
TCR Vf31 7a and V5 regions. In mice expressing l-E in the 
thymus T cells expressing these TCRs are deleted from the 
thymocyte pool. This however did not occur if transgenic I-E 
was expressed on either the pancreatic 3 [228] and on acinar 
cells [234]. The state of tolerance was thus not due to deletion 
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of self-reacting cells. The tolerance mechanism in these mice 
was not due to deletion of self-reactive T cells but due to 
anergy: cross-linking V1 7a and Vf5 positive cells from l-E 
tolerant mice resulted in a weak response as compared to non-
transgenic controls [227]. T cells from these mice also 
responded weakly to irradiated l-E spleen targets [233]. 
Tolerance to I-A was also found in transgenic mice expressing 
I-A on the islet or acinar cells of the pancreas: no cellular 
infiltrate was found in these tissues nor did these mice reject 
I-A expressing alloantigenic skin grafts even after primimg 
with the alloantigen [225, 230-232]. Transgenic I-A was 
accessible to the immune cells since priming of transgenic and 
non-transgenic cells in vitro with l-A+ve cells resulted in 
pancreatic destruction in vivo and lymph node cells from these 
mice reacted strongly to I-A in-vitro [230-232]. Thus in this 
model it appeared that tolerant mice possessed T cells 
reactive to I-A in an inactive state [232]. Although deletion of 
self-reactive cells did not occur in these mice the authors did 
not rule out the possiblity that T cells with high affinity for 
I-A were deleted, whilst those with low affinity were not. The 
latter cells responding in the in vitro MLR assay [230]. 
vi) Viral transgenic mice with pancreatic expression. 
SV40 [235-238], LCMV [239, 240], vesticular stomatitis virus 
glycoprotein (VSV-GP) [241] and influenza virus hemagglutinin 
(HA) [242, 2431 antigens have been targeted to murine 
pancreatic p islets [236-239, 241-243] and acinar cells [235]. 
These transgenes had organ specific expression since no 
thymic expression was detected. 
Transgenic mice (RIP-Tag) expressing the SV40 T/t antigen 
(Tag) in the pancreas were found to be either tolerant or non-
tolerant to this transgene [235, 238]. No tolerance to Tag was 
found when RIP-Tag transgenic mice were crossed with ICR 
transgenic mice specific for this antigen in the context of MHC 
Class 1 H2Kk. In these animals destruction of the pancreatic 
acinar cells occurred after immune infiltration [235]. This 
lack of tolerance was attributed to the late expression of the 
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transgene [235, 238] and was further investigated by Ye et al 
(1 994) [237]. These author created two RIP-Tag transgenic 
mice: RIP-Tag2 and RIP-Tag4 [237]. The former mice being 
tolerant to Tag due to expression of the transgene during 
embryonic development. In contrast RIP-Tag 4 mice transgene 
expression occurred late in development at 1 0-1 2 weeks of 
age. These mice developed insulinomas and following 
immunisation produced, in vitro, anti-Tag CTLs. Once the 
transgene was expressed these mice became tolerant to Tag 
but anti-Tag CTLs were still produced in vitro [237]. Tolerance 
in these mice was not through deletion of self-reactive cells. 
LCMV-GP transgenic mice expressing LCMV in the islet beta 
cells were crossed with LCMV-GP specific TCR+ve transgenic 
mice [239]. The resulting double transgenic mice were tolerant 
to LCMV and no diabetes occurred, even though positive 
selection of the LCMV CD8+ve cells was evident. 70-80% of the 
cells in these double transgenic mice expressed the transgenic 
TCR, and no TCR down regulation was evident. In vitro these 
cells proliferated in response to LCMV infected macrophages 
and could be stimulated by in vivo immunisation with LCMV-GP 
resulting in the development of diabetes. Thus in these mice a 
reversible state of anergy was evident. 
Anergy was also shown to occur following injection of soluble 
LCMV-GP into LCMV TCR specific transgenic mice following a 
period of cellular proliferation [240]. 
Tolerance to HA and VSV-GP molecules in the pancreas has 
also been demonstrated [241, 242]. TH cell tolerance to VSV-
GP was shown by the inability to switch from 1gM to lgG in 
VSV-GP transgenic mice [241] whilst tolerance in HA 
transgenic mice was shown by the lack of diabetes [242]. The 
latter mice were also tolerant to HA following in vivo priming 
with Vaccinia-HA and this was also shown in vitro following 
HA stimulation [242]. In contrast some HA transgenic mice 
developed diabetes. The lack of tolerance was attributed to 
low levels of HA on islet cells [243]. 
vii) Cytokines and peripheral tolerance. 
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Transgenic mice expressing the cytokines IFNy [244] and IL-2 
[245, 2461 on pancreatic islet cells have been created. IFNy 
transgenic mice become diabetic, due to a progressive 
destruction of pancreatic cells by the influx of inflammatory 
cells and lymphocytes from these transgenic mice are 
cytotoxic to normal islets. Crossing these tg mice onto a SCID 
mouse background resulted in no infiltration of the pancreas 
and no destruction of this tissue. The authors suggested that 
pancreatic expression of lFNy results in the loss of tolerance 
to normal tissue by inducing the co-stimulatory activity 
essential for lymphocyte activation during an immune 
response [244]. Pancreatic infiltration by lg+, CD4+ and CD8+ 
cells was also observed in transgenic mice expressing 
biologically active IL-2 on beta cells (RIP-IL-2 mice) [245, 
246] No autoimmunity occurred [245]. Crossing RIP-IL-2 
transgenic mice with RlPH2Kb resulted in double transgenic 
mice which showed no sign of autoimmune disease despite an 
impressive early islet infiltration. This suggested that 
although IL-2 can attract inflammatory cells to the pancreas 
it could not activate cells specific for islet autoantigen Kb.  
Thus although IL-2 can break tolerance in vitro it maybe 
unable to prevent the induction of anergy. Another molecule 
associated with anergy, 137-1 was also placed under the rat 
insulin promoter [247]. Autoimmunity resulted when 137-1 
transgenic mice were crossed with mice expressing TNF(x on 
the islet cells, suggesting that the 137-1 co-stimulator alone 
is not sufficient to abrograte tolerance to peripheral antigens. 
viii) Peripheral tolerance and superantigens 
Peripheral tolerance to superantigens has also been shown in 
both non-transgenic and transgenic mice. Non-transgenic mice 
expressing Mlsa and l-E were treated with anti-1-E antibodies 
and the presence of MIsa reactive cells; i.e. T cells expressing 
a TCR utilising V6, were analysed [248]. Vf6+ve T cells were 
usually deleted in mice expressing both l-E and the MIsa 
antigen however following anti-1-E treatment V36+ve cells 
were present in both the thymus and periphery. These cells 
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were not functionally tolerant since they proliferated and 
produced cytokines following TCR stimulation. Upon cessation 
of antibody treatment, l-E was re-expressed in the periphery 
with a concomitant reduction in number of V136+ve  cells in 
both lymph nodes and spleen. 
Peripheral deletion in non-transgenic mice was also shown by 
Webb et al (1 990) [249]. In this model transfer of H-2 
compatible MIsa antigen positive lymphoid cells into Mlsb 
mice resulted in clonal elimination of MIsa reactive V1E 6+ve 
cells. However unlike the Jones model deletion was preceded 
by a powerful in vivo immune response. Activation prior to 
deletion was also shown by Fink et al (1 994) [250] with cell 
activation markers CD44 (Pgp-1) and VLA-4 being expressed at 
high levels. 
Injection of normal mice with high and low doses of 
Staphylococcal enterotoxin B (SEB) resulted in anergy of SEB 
reactive V138+ve  T cells [251]. Anergy following injection of 
either a low or high dose of SEB was short or long-lived 
respectively. 50% of these anergic Vp8+ve cells had down 
regulated their TCR/CD3 complex as well as CD2, CD4 and CD8 
accessory molecules [251]. 
Transgenic mice have also been used to look at the effect of 
superantigens in the periphery [252-258]. Transgenic mice 
expressing Vf38.2 TCR+ve cells (99% of CD4+ve and CD8+ve) 
plus an endogenous TCRa chain, were injected with SEB. This 
resulted in a rapid increase in the number of both CD4+V138.2+ 
[252, 253] and CD8+Vp8.2+ spleen and peripheral lymph node 
cells [252]. During this proliferative phase there was an 
increase in activation markers CD44, LY6A/E and Hi .2F3 as 
well as an increase in IL-2 expression [254]. Following this 
short burst of activation the absolute number of cells 
decreased due to either deletion or re-distribution to other 
tissues [252-254]. However some V38.2+ve T cells remained 
which were anergic: unable to respond to SEB in vitro and did 
not produce IL-2 [252]. This unresponsiveness was reversible 
in the presence of rlL-2 or by crosslinking either the TCR or 
CD3 with antibodies. Perkins et al (1 993) [253] also found that 
the CD4+V138.2+ T cells remaining were unresponsive to SEB 
(although they produced IL-2) and also to rlL-2, IL-4 or IL-6. 
They were also unresponsive to restimulation with 
superantigens, ConA, phytohaemagglutinins (PHA) or anti-CD3. 
Unresponsiveness was only broken if stimulation via cell 
surface receptors resulted in PKC and Ca2+ activation. 
Similar results were observed following repeated injection of 
Staphylococcal enterotoxin A (SEA) into V33+ve transgenic 
mice [255]. Anergic CD4+V133+cells remaining after 
proliferation did not respond to rlL-2 and reduced IL-2 and 
TNFa mRNA levels were detected in these cells. In contrast the 
number of CD8+V3+ cells, with CTL activity, increased 
following SEA injection and there was no reduction in IFNy 
levels. This cytokine being predominantly released by CD8+ve 
cells. This study suggested that there was selective 
tolerisation of CD4+ T cells. 
The effect of MIsa antigens in the periphery was also studied 
in transgenic mice expressing V8.1+ve transgenic TCR [256-
258]. As above, exposure to MIsa in the periphery either 
through injection of MIsa spleen cells, mating onto an MIsa 
background or in bone marrow chimaeras, resulted in tolerance 
to MIsa in vitro, following a period of proliferation. The 
remaining cells were anergic, they were found either not to 
produce IL-2 [258] or produce it in low concentrations [256] 
and they did not respond to rlL-2 [257]. The mechanism of 
tolerance was shown to vary depending on how MIsa was 
introduced into the recipient [256]. 
To investigate this mechanism of tolerance, Mlsb (V1381+ve) 
mice were injected with MIsa+ve cells before being grafted 
with MIsa skin. These mice showed delayed allograft rejection 
as compared to uninoculated transgenic mice [257]. 
Like the superantigen models described above, tolerance in the 
mature T cell population was found using transgenic mice with 
T cells specific for LCMV. Injection of soluble LCMV into these 
mice resulted in tolerance through deletion and anergy of LCMV 
specific T cells after an initial expansion period [240]. 
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ix) Peripheral tolerance summary 
Peripheral tolerance to extrathymically expressed antigens 
has been described. Mechanisms implicated in peripheral 
tolerance are similar to those of central tolerance, for 
example; deletion, anergy and down regulation of CD8/TCR. 
Deletion of self-reactive peripheral I cells, through apoptosis, 
may follow a period of activation. Self-reactive T cells, in an 
anergic state, have been found following this process although 
in other circumstances anergic T cells have been found 
independent of deletion. In some experiments anergic I cells 
can become functional either following in vitro stimulation 
with rlL-2 or after the removal of antigen in vivo. Although 
anergy is reversible the presence of antigen ensures that a 
tolerogenic state persists. 
Anergic T cells are susceptible to further tolerogenic signals 
resulting in; 1) a T cell in a deeper anergic state, which is 
still reversible or 2) deletion of the cell. 
TCR/CD8 down regulation may also occur in the periphery. This 
process is also reversible following an appropriate signal, for 
example, rIL-2 or anti-CD2 stimulation. 
Other routes of introducing extrathymic antigens have been 
studied. Soluble antigens have been introduced intravenously, 
intraperitoneally, nasally and orally. In all these cases 
tolerance can result. The next section is restricted to a 
discussion of oral tolerance. 
1.7) Oral tolerance 
Exogenous administration of an antigen to the peripheral 
immune system via the gut results in systemic and mucosal 
tolerance [261-263] at both the antibody and I cell level. This 
phenonomen is known as oral tolerance. This tolerogenic state 
is antigen specfic and is influenced by age [264], genetic 
background [265-267], nutritional status of the animal [268], 
rate of antigen uptake [264, 269],  intervals between feeding 
[264] and the persistance of antigen [269]. Primed animals 
cannot be orally tolerised to the priming antigen [270]. 
ME 
Recently, oral administration of an autoantigen has been 
shown to result in suppression of autoimmune diseases such 
as experimental autoimmune encephalomyelitis (EAE) [271-
276], uveitis [277], myasthenia gravis [278], collagen and 
adjuvant induced arthritis and diabetes in NOD mice [279]. 
Prolonged graft survival and suppressed alloreactivity has 
also been demonstrated through oral administration of the 
alloantigen [279]. 
The above experiments and those looking at the effect of 
feeding protein antigens such as ovalbumin [269, 270, 280-
282], HEL [283, 284] and SEB [285] have provided insight into 
the mechanisms of oral tolerance induction. Deletion has been 
ruled out as a possible mechanism since following a single 
oral dose of protein tolerance lasts for about 60 days before 
recurrence of a systemic response (following challenge). 
Strobel and Ferguson (1 987) [286] also showed differences in 
the duration of oral tolerance for antibody and I cell 
responses: antibody tolerance lasted 3 months whilst T cell 
tolerance lasted 6 months. 
Two mechanisms have been suggested to explain the 
phenonomen of oral tolerance; suppression (direct or indirect) 
and anergy, although these mechanisms may not be mutually 
exclusive. Suppression involves the generation of regulatory 
cells that suppress an immune response in vitro and in vivo via 
the secretion of cytokines. On the other hand, anergy describes 
the unresponsivness of I cells. 
The dosage of antigen given orally has been shown to affect 
which of these mechanisms occurs [277, 284]. A low dose of 
antigen, for example 5 intragastric feeds of 250-300jigs of 
experimental autoimmune uveitis (EAU) autoantigen S-antigen 
or S-antigen peptide [277] resulted in suppression, whilst a 
high dose of antigen, for example a single 5mg feed resulted in 
anergy [277]. It is thought that suppression was a result of 
antigen processing and presentation by gut associated APC's 
whilst anergy occurred after antigen had passed into the 
periphery via the gut [279]. The latter occurred rapidly (within 
a 24 hour period) in the absence of activation, 
differentation or proliferation [270, 280]. The mechanism of 
anergy in this case may have been due to the exposure of a 
soluble protein to the systemic immune system in the absence 
of co-stimulation [280]. Confirmation of this was found in OVA 
feed mice. Soluble OVA was present in the serum of mice 5 and 
60 minutes following a 25mgs OVA feed [287]. Injection of 
serum taken 60 minutes after feeding into a secondary 
recipient transferred systemic tolerance. 
i) Suppression 
Early experiments suggested that a suppressor mechanism was 
induced following oral administration of an antigen [259-261, 
266, 288-290]. Feeding of substances thought to inhibit 
suppressor cells, eg. cyclophosphamide [261], deoxyguanosine 
[290] and oestradiol [288] resulted in the lack of oral 
tolerance to OVA at the antibody and cell mediated level as 
well as inducing a local DTH response similar to that seen 
during food allergy. 
Recent data on the induction of tolerance following 
autoantigen feeding has confirmed the existence of 
suppression in vivo and in vitro [265, 273-275, 278]. In these 
experiments suppression appeared to be antigen specific. For 
example feeding Lewis rats with nicotinic acetylcholine 
receptor (ACHR) resulted in suppression of experimental 
induced myasthenia gravis but these rats developed EAE 
following parenternal immunisation with myelin basic protein 
(MBP) [278]. 
Both CD4+ve [276, 279] and CD8+ve [265, 274, 275, 278, 279] 
cells have been implicated as the suppressor elements. Whole 
and CD4-I- depleted spleen cells but not CD8-/- depleted 
spleen cells from MBP fed Lewis rats suppressed MBP specific 
responses in vitro, indicating the importance of CD8+ve cell in 
this disease [265]. CD8+ve T cells were also shown to be the 
mediators of orally induced suppression in adoptive transfer 
experiments. 
Suppression did not require cell to cell contact. Tolerance 
occurring through the release of non-antigen specific 
cytokines [265, 274, 275]. CD4+ve clones isolated from mice 
fed MBP secreted TGF, IL-4 and IL-10 following MBP 
stimulation [276]. CD8+ve suppressor cells were also thought 
to induce tolerance through the secretion of TGFI3 [265, 275, 
278, 279]. The active form of TGFI3 was found in vitro in the 
supernatants of antigen stimulated T cells from mice orally 
tolerised to MBP and OVA [275]. The importance of TGFf3 was 
further documented; 1) anti-TGFf administered in vivo 
abrograted the effect of oral tolerance to MBP and resulted in 
EAE in susceptible mice. 2) systemically administered TGFf3 
(1-5pgs) suppressed the severity of the pathology in animal 
models of autoimmune diseases such as EAE and arthritis. 3) 
Peyers' patches cells from mice given antigens orally produce 
TGFp and can transfer tolerance. 4) TGFp has also been found to 
be elevated in the brains of MBP orally tolerised Lewis rats 
[272]. After feeding MBP and LPS to Lewis rats EAE pathology 
was suppressed and the levels of TGFp, IL-4 and prostaglandin 
E2 (PGE2) produced were increased [272]. However the transfer 
of serum from orally tolerised animals does not suppress EAE 
suggesting that these antigen non-specific cytokines may act 
at a local level [274]. 
Suppression may also work through a mechanism known as the 
"bystander effect" [265, 2741. This "bystander effect" was 
shown using a transwell system in which irradiated spleen 
cells from mice fed tolerogenic MBP were separated from an 
OVA specific T cell line. In the presence of MBP the reactivity 
of the OVA cell line to OVA was inhibited. No suppression was 
found with PBS fed irradiated spleen cells in the presence of 
MBP. This "bystander effect" was also seen in vivo. For 
example feeding rats OVA followed by a OVA+MBP-FCA footpad 
immunisation resulted in a suppressed immune response to 
injected MBP. 
ii) Anergy 
In vitro stimulation of T cells from the Peyers' patches, 
spleen and mesenteric lymph nodes of OVA fed tolerant mice 
produced a cytokine profile similar to that found for T cell 
clones rendered anergic through exposure to high doses of 
synthetic peptide or fixed APC's [291]: GMCSF and IFNy but no 
IL-2, IL-4 or IL-3 cytokine were found in the supernatants 
[271, 281]. Melamed and Friedman [270, 280] also 
demonstrated that anergy occurred following an OVA feed. In 
vitro culturing of peripheral lymph node cells from tolerant 
mice with OVA resulted in reduced IL-2 and IFNy production, 
whilst IL-4 levels were unaffected compared to saline fed 
controls. Incubation of these tolerant cells with rlL-2 for 5 
days resulted in a slight increases of IL-2 and IFNy production. 
Migita and Ochi (1994) [285] demonstrated anergy in mice 
given 4 feeds of 50mgs of SEB. Spleen cells from these mice 
were hyporesponsive to SEB in vitro as compared to controls. 
Cytokine production measured following SEB stimulation 
indicated that these cells did not produce IL-2. These non-
responsive cells did not respond to anti-CD3, non-specific T 
cell mitogens, rIL-2, ConA or PHA. 
Cytokine production was also analysed in peripheral lymph 
nodes cells from mice fed HEL (20mgs/mouse or 1mg X 5 
doses/mouse) [283]. It was found that IL-4 mRNA levels had 
increased following re-exposure to antigen by immunisation. 
This was not seen if re-exposure was via feeding. IFNy mRNA 
levels were found to be reduced in the lymph nodes and no 
increase in IL-10 or TGFI3 could be detected in these orally 
tolerant mice. More recently it has been shown that IL-10 is 
not important for the induction nor the maintenance of oral 
tolerance [292]. Friedman and Weiner (1 994) [284] have also 
investigated cytokine production following feeding tolerising 
doses of HEL (5-20mgs/mouse). They found that in the absence 
of immunisation, spleen cells from HEL tolerised mice secrete 
IL-4 and TGF3, without proliferation, however upon antigen 
stimulation an increase level of IL-4 occurred whilst TGFp 
levels remained constant. Anergy was also found when feeding 
an auto-antigen, MBP [273]. 4 X Smgs feeds of MBP in the 
presence of soyabean trypsin inhibitor (STI), resulted in 
systemic tolerance and suppression of EAE in rats. 
Transferring PLN or serum from MBP-fed donors into naive 
recipients did not induce tolerance. Suppression was also ruled 
out since encephalitogenic MBP-specific T cell lines 
stimulated with antigen plus APC transferred into orally 
tolerant mice induced clinical disease. It was found that there 
was a 5-10 fold reduction in the number of MBP-specific 
lymphocytes capable of secreting IL-2 in the lymph nodes of 
orally tolerant rats. lFNy was also reduced. 
As described, tolerance to OVA in mice following a single 
20mg feed was shown by Melamed and Friedman [270, 280]. 
These authors found a reduction in lgG2a anti-OVA antibodies 
in tolerant mice following OVA and FCA immunistion although 
IgGi was produced at levels similar to control mice. From 
these data it would appear that there was a decrease in TH1  
dependent responses with decreased lgG2a, IL-2 and IFNy, 
suggesting selective TH1 tolerance following oral 
administration of an antigen. On the other hand oral 
administration of an antigen had no effect on TH2  cells; IgGi 
responses were not reduced nor was the level of IL-4 reduced. 
In some cases it appears that TH2  cells are primed following 
feeding which results in an increase in IL-4. 
iii) Oral tolerance summary 
Oral administration of an antigen can induce a state of 
systemic tolerance at both the antibody and T cell level. Two 
mechanisms implicated in this phenonomen are suppression 
and anergy. Suppression of an immune response is through the 
generation of regulatory cells, either CD4 or CD8, and through 
the release of cytokines, for example TGFI3. Anergy appears to 
affect TH1  cells preferentially. 
1.7) I-lactoqIobulin (BLG) transqenic mice 
As described above, transgenic mice expressing a foreign 
protein under the control of either a ubiquitous or tissue 
specific promoter have been central to recent investigations 
into the mechanisms underlying both T and B cell tolerance. 
Transgenic mice expressing the ovine milk protein BLG in the 














Fig. 1 .5. Drawing of the BLG 3D structure 
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been produced by Simons et al (1987) [293] and have been used 
in this study to investigate whether tolerance at the B and T 
cell level occurred in mice carrying or expressing this 
mammary-specific gene. 
DJ- I a c tog lob u Ii n 
Milk proteins are classed as the acid insoluble, the caseins, or 
as acid soluble, the whey proteins 13-lactoglobulin (BLG) and a-
lactalbumin [294, 295]. BLG is present in the milk of cows 
(where it is the major milk protein at 0.3g/1 OOml) sheep, 
deer, pigs, goats, horses, donkeys, camels, buffalos, dolphins 
and kangaroos [296-300]. Human and rodent milk lacks this 
protein [301]. BLG is usually present as a dimer which is 
relatively pH stable, resisting a pH of 2 [302, 303] (thus 
ensuring that it remains intact until having passed through the 
stomach [303]). At pH 3.5 BLG dimers dissociate to give 18kDa 
monomers. At pH 7.5 conformational changes were shown to 
occur and at pH 9.1 BLG was shown to be denatured [303, 304]. 
The overall BLG structure was defined using standard 
crystallographic techniques [303, 305]. It has a high helical 
content and an unusual folding pattern which is described as a 
flattened cone, the core consisting of a short cc-helix segment 
and 9 strands of anti-parallel 13-sheets which wrap round to 
form an anti-parallel beta-barrel [303] (see Fig. 1.5). 
Hydrophilic residues were found on the exterior of this cone, 
whilst the interior of the 'barrel' is essentially hydrophobic. 
Comparison of the 3D structure with other proteins, such as 
Retinol Binding Protein (RBP) has suggested that BLG belongs 
to a superfamily of proteins with fat-transporting 
capabilities [297, 303, 306]. Despite their 3D similarities 
there is limited sequence homology, only 25-30% between the 
members of this family [297]. 
RBP binds Vitamin A [307] thus suggesting that BLG maybe 
important in Vitamin A uptake in the immature gut. This was 
further confirmed since BLG has been shown to bind Vitamin A 
[308] and 1125-labelled BLG -retinol complexes bound 
specifically to purified microvilli prepared from the lower 
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segment of calf small intestine but not to older animal tissue 
[303]. These data suggested that specific receptors for BLG 
plus Vitamin A complexes existed in neonatal calves' 
intestines. The importance of these receptors and subsequent 
intake of Vitamin A by the newborn animal can be seen in 
animals deprived of both. Those animals failed to develop, 
became blind and sterile [297, 309] 
Apart from complexing with Vitamin A, BLG has been shown in 
vitro to bind a variety of hydrophobic substances such as long-
chain fatty acids and triglycerides. BLG isolated from cow, 
sheep and goats milk is associated with between 0.5-0.7 
molecules of fatty acids per monomer [300]. This confirmed 
the idea that BLG was a member of a group of molecules 
capable of binding hydrophobic ligands as well as having some 
importance in the delivery of Vitamin A to the young. Vitamin 
A in milk is associated with fat globules [300]. 
ii) BLG-transgenic mice. 
The BLG-transgenic mice were created to study the effect of 
manipulating milk proteins: i.e. adding an ovine milk gene into 
the mouse genome. The ultimate aim was to investigate; 1) 
whether adding a foreign milk gene resulted in the expression 
of the product of the gene in milk and 2) what mechanisms 
were involved in controlling gene expression in mice before 
manipulating milk protein expression in larger animals such as 
sheep, pig and cows. Mice were chosen since; a). It was 
possible to microinject the transgene of interest into a 
significantly large number of eggs b). The length of pregnancy 
is relatively short and the time to wait from gene transfer 
until collecting milk samples is about 3 months as compared 
to a minimium of 3 years for sheep and c). More progeny are 
produced. 
A gene construct encoding sheep BLG was injected into 
fertilised eggs as a 16.2 kilobase (kb) insert containing 4kb of 
DNA 5' to the capsite, the 4.9kb BLG transcription unit and a 
7.3kb of 3' flanking sequence or as a fragment with 5.7kb 
removed from the 3' flanking regions [293]. Regardless of the 
DNA sequence, 16 transgenic mice were created carrying 1 to 
20 copies of the transgene per cell. Transgenic mice were 
identified via Southern blotting and probing with a nick-
translated p931 BLG cDNA probe [293]. DNA preparations from 
tails. It was found that 5 of these mice were capable of 
passing the BLG-transgene to their offspring. 
The presence of BLG was confirmed in the milk of lactating 
transgenic mothers from line 7, 14 and 45 by SDS page gels 
electrophoresis and Western blotting. The concentration of BLG 
in the whey was measured by densitometry of Coomassie Blue 
stained SDS gels using internal BLG controls. The 
concentration of BLG in the milk of line 45 BLG-transgenic 
mice, used in this project, was 14.1+1-0.41 to 21.6+/-1.6 
mgs/ml-1 of ovine BLG [293]. 
The expression of the BLG transgene was analysed via RNA 
extraction and Northern blotting. BLG mRNA was present only 
in the mammary tissues [293] specifically in the secretory 
epithelial cells [310] and in virgin transgenic females at very 
low levels with increasing expression during pregnancy and 
lactation [310, 311]. When transgenic kidney, liver, spleen, 
salivary and lachrymal glands were analysed for the presence 
of BLG mRNA no expression was found [293, 311]. 
Immunohistochemical analysis indicated that BLG mRNA 
expression was present in the salivary glands of these 
transgenic mice, although no protein expression was found 
[311]. 
In summary, ovine BLG-transgenic mice carrying the BLG gene, 
under the control of its own promoter sequences have been 
made and the mice and offspring are healthy and fertile. The 
translation of the ovine BLG gene is tissue specific, ie: to the 
mammary epithelial cells. 
The low level of expression in virgin mammary tissue 
increases throughout pregnancy and lactation such that ovine 
BLG protein is present in the milk of transgenic mothers at 5 
times the concentration of ewes milk 	[293, 310, 311]. 
Developmental regulation of BLG in both sheep and mice was 
shown to be similar [310].Thus cis-acting sequences, which 
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determine ovine BLG mammary expression, are recognised in an 
animal which is negative for an equivalent gene [310]. 
1.8) Aims of the thesis 
The aims of the thesis were; 
To develop a simple method of purification for ovine BLG 
from sheep's milk. 
To develop an enzyme linked immunosorbant detection 
assay (ELISA) and a DTH assay for ovine BLG. 
To investigate whether ovine BLG was immunogenic. Could 
this protein induce antibody and DTH responses? 
To investigate whether possession or expression of the 
BLG-transgene interfered with the normal immune response to 
ovine BLG; were mice possessing the BLG transgene tolerant to 
the product of their gene? 
To investigate whether expression of the BLG-transgene 
occurred in the thymus. 
To investigate whether ovine BLG was an oral tolerogen 
when administered during suckling. 
To investiagte whether adult animals could be rendered 
tolerant to bovine BLG following oral administration. 
Mice transgenic for the protein ovine BLG are good models for 
the study of tolerance to a self and foreign protein since; 
As described in previous sections mice transgenic for 
various proteins, expressed in the periphery, are tolerant at 
the T and/or B cell levels. Recent data has suggested that 
tolerance to peripheral transgenes is due to expression of 
protein in the thymus. Unlike these models expression of the 
BLG protein is both temporally controlled and tissue specfic, 
only being expressed in the lactating mammary gland. This 
makes them good models for peripheral tolerance. 
As most food allergies, for example cow's milk allergy, 
occurs in childhood this mouse model allows the effect of 
protein administration throughout postnatal development to be 
investigated. Unlike other mouse models relatively high 
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concentrations of protein (BLG), present in transgenic mouse 
milk, can be delivered orally to newborn mice via a natural 
suckling mechanism and exposure to this protein continues 
until weaning. This obviates the need for potentially damaging 
and traumatic oral routes of immunisation, for example 
intubation. 
As BLG has been implicated as one of the main antigens of milk 
this model allows further investigation of this protein with 
respect to its causation of allergic responses in the newborn. 
iii) The experiments can be internally controlled since the 
transgene can be inherited either from the paternal or 




MATERIALS AND METHODS 
All reagents and chemicals supplied by SIGMA (Poole, UK) 
unless stated. 
2.1) Beta-Lactoglobulin (BLG) purification and 
analyses 
Source of ewes milk. 
Ewes from the laboratories and farms of the BBSRC Roslin 
Institute, Roslin, Midlothian, were used as the sources of 
sheep's milk. Following alcohol sterilisation of teats, 
lactating ewes were milked by hand (Dr. M McClenaghan and 
staff of the Roslin Institute farms kindly helped with the 
milking operation). Milk was stored at -700C until required. 
BLG purification 
Since ovine BLG was not commercially available the 
purification method of Armstrong et al (1967) [312] was 
adopted. The methodology is summarised below. 500 - 1 000 
mIs of milk were used per purification. 
264gs of solid (NH4)2 SO4 was added to one litre of ewes' milk 
over a period of 35-45 minutes. The solution was stirred 
constantly for 2 hours before being suction filtered through 
Whatman 541 filter paper. The collected supernatant was then 
re-filtered through Whatman 542 paper and stored overnight at 
4°C. 
The pH of the solution was adjusted to 3.5 over a period of 40 
minutes with IM HCI, and precipitated proteins removed after 
a 40 minute centrifugation, 1 3,200g at 1 60C. The remaining 
supernatant was then adjusted to pH6 using IM NH3 (BDH Ltd, 
Poole, UK) and precipitated further with (NH4)2 SO4. The 
precipitated proteins were then pelleted out following 
centrifugation, as described, and then dissolved in a small 
quantity of dialysis buffer. The proteins were dialysed against 
all 
a 0.1 2M Sodium Acetate- 0.04M Acetic acid (BDH Ltd, Poole, 
UK) buffer (pH5.2) for 24 hours with fresh buffer being added 
after the first 12 hours. The solution was then re-dialysed 
against distilled H20 (dH20) for a period of 3 days. This 
resulted in a colloidal solution of fine white crystals which 
was then collected and stored at 700C before being freeze 
dried overnight. 
iii) Protein analysis 
Following purification and freeze drying the protein powder 
was weighed and the percentage of protein present in the 
sample was calculated using the Lowry procedure [313-315]. 
The components of this assay were supplied as a standard 
protein assay kit which included all reagents necessary to 
perform the test. These were the protein standard, Bovine 
Serum Albumin (BSA) at a concentration of 400pgs/ml, the 
Lowry reagent and the Folin and Ciocalteu's Phenol Reagent all 
of which were reconstituted as described in the manufacturers 
instructions. Two types of protein assay could have been 
performed, the direct (not involving protein precipitation) and 
the indirect (involving precipitation) assay. The former method 
was employed in this study. Each step used in the procedure 
can be summarised as follows; 
STEP 1; Both the standard and test samples were diluted to 
give a range of concentrations as described below (*). 1 ml of 
each dilution was added to appropriately labelled tubes. The 
test blank was 1 ml of H20. 
(*) A BSA stock solution (400pgs/ml) was prepared to give 5 
protein concentrations; 50, 100, 200, 300, 400pgs/ml. 
Following freeze drying of purified ovine BLG, 1 Omgs of the 
resulting precipitate was weighed out and dissolved in 1 ml of 
dH20. This BLG 'stock" solution was then further diluted to 
give a concentration range of 62.5, 125, 250, 500, 1000 
jigs/ml. 
STEP 2; 1 ml of Lowry reagent solution was added to each tube 
and following a vigorous mixing each solution was left at room 
temperature for 20 minutes. 
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Fig. 2.1. Standard curve of a range of a BSA standard 
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Each point represents the mean of 5 Lowry tests, 
+1- 1 standard deviations. 
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STEP 3; 0.5mIs of Folin and Ciocalteu's Phenol Reagent was 
added to each tube whilst vortexing and the solutions left at 
room temperature for a further 30 minutes during which time 
a colour change occurred. 
STEP 4; The absorbancy of each tube was measured at a light 
wavelength of 600nms with the test blank being used as the 
zero. A plot of the absorbancy of the BSA standard solution 
versus appropriate protein concentration provided a standard 
calibration curve from which the protein concentration of test 
samples was calculated. The mean BSA standard 
concentrations curve is shown in Fig. 2.1 (raw data shown in 
Appendix 1). 
STEP 5; The protein concentration of the BLG samples was read 
from the standard curves. The percentage protein in the sample 
was then calculated using the following equation; 
PROTEIN CONC ON X-AXIS 	X 	100 
CONCENTRATION OF PROTEIN IN TUBE 
Each of the samples' OD values, were plotted and the 
concentrations noted. The percentage protein content was then 
worked out for each of the sample dilution and an average 
taken. The amount of protein recovered from the purification 
steps was calculated as; 
AVERAGE PROTEIN PERCENTAGE X TOTAL WEIGHT OF SAMPLE 
RECOVERED. 
Of the six BLG purifications performed the total amount of 
protein recovered from each was as follows; 
Purification number Amount of protein recovered 
1 3l7mgs 
2 586mgs 
3 7lOmgs - 
4 - 	- 	-- 750m2s - 
5 52Omgs 
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Differences in the amount of protein recovered may have been 
due to the point in the lactation cycle from which the milk 
sample was collected or may reflect the fact that these 
samples were purified at different times. 
iv) Purity testing of the BLG isolates 
To prove 1) that the protein isolated from the sheep's milk 
was indeed BLG, 2) that no other milk protein had 
contaminated the preparation and 3) that antigenic intergrity 
was maintained, each of the six preparations of BLG were 
dissolved in PBS to give 31.7, 58.6, 71, 75, 52 and 42mgs/ml 
respectively. To test for purity the BLG preparations were 
subjected to SDS page gel electrophoresis and either stained 
with Coomassie blue or Western blotted. Antigenic integrity 
was assessed by Western blotting and [LISA assay. 
a) SDS page gels. 
All solution recipes can be found in Appendix 2. 
A 15% polyacrylamide gel solution was poured into a minigel 
apparatus (Hoefer Scientific Instruments, UK). The gels were 
allowed to set over a period of 2 hours and to ensure that no 
evaporation occurred, as well as maintaining the flat surface 
of the gels, a small amount of dH20 was layered on to the top 
of each gel. Once the SDS gel had solidified the stacking gel 
solution was added which was then left for 30 minutes to 
solidify. 1 OpIs of protein sample was diluted in 1 Opls of dH20 
plus 20pls of sample buffer and each sample was boiled for 2 
minutes. 2.5pls of the protein plus buffer mixture was added 
per well and samples were then run for 45 minutes at 20mA 
per gel. 
Following electrophoresis, gels were carefully removed from 
the minigel apparatus and then stained overnight in Commassie 
Blue stain. Following destaining gels were dried under suction. 
Figure 2.2 shows the Commassie Blue staining profile of the 



















Fig. 2.2. SIDS-Page gels (A) and Western Blots (B) of 6 BLG 
purifications from different batches of sheeps milk. 
Pairs of SIDS gels (A) and Western Blots (B) are shown for 6 ovine 
BLG purifications which yielded 31.7, 58.6, 71, 75, 52 and 42mgs 
of BLG/ml. The first pair of photographs labelled (SM) represent 
a SIDS gel and Western Blot of unpurified whole sheeps' milk. The 
pairs of photographs labelled BOVINE and OVA are SIDS gels and 
Western Blots from commercially purified bovine BLG (SIGMA, 
Poole, UK) and Ovalbumin (SIGMA). 
SIDS gels were stained with a Coomassie Blue dye and Western 
Blots were stained with a rabbit (Rabbit 669) anti-ovine BLG 
antiserum and an anti-rabbit HRP (SAPU, Carluke, UK) and 
developed with H202  (SIGMA). 
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that most of the samples contained, in addition to BLG, many 
other protein bands. This may be a reflection of the stage in 
the lactation cycle from which the milk sample was taken or 
may reflect inefficiencies in the protein purification 
procedures. 
b) Western blotting. 
Western blots were performed following SIDS Page gel 
electrophoresis to check the purity of each protein sample as 
well as to test whether BLG remained antigenically intact 
after the purification procedure. 
Sheep's milk and the newly purified protein samples were 
electrophoresed on a 15% SIDS page gel, as described above, and 
afterwards the proteins were transferred from the gel onto a 
nitrocellulose membrane (Schleicher and Schuell, Dassel, 
Germany) by electrical transfer, 5mAmps, overnight with 
transfering/blotting buffer. 
The membrane was then blocked for one hour, with a PBS 
solution containing 5% BSA plus Tween 20, before the first 
antibody was added; an anti-ovine BLG lgG, raised in a New 
Zealand Black rabbit 669 (see Fig. 2.3). Rabbit 669 serum was 
diluted (1/100) in blocking buffer before being added to 
filters. After overnight incubation, with gentle constant 
agitation, excess anti-ovine BLG antibodies were removed by 
washing the filter 3 times in PBS-Tween. Horse radish 
peroxidase (HRP) enzyme linked second step antibodies (donkey 
anti-rabbit lgG; Scottish Antibody Production Unit (SAPU), 
Carluke, UK), were then added to the filters at a 1/500 
dilution in PBS-Tween. Again filters were incubated overnight 
with constant agitation. 
Unbound, excess antibodies were removed by washing the 
filter 3 times with PBS-Tween. Before the substrate, 4- 
Chloro-1 Naphthol, was added filters were washed with a 
Tris-saline solution. A 4-Chloro-1 Napthol tablet, 
30mgs/tablets, was dissolved in 23.3mls of methanol (BDH 
Ltd, Poole, UK) and 1 OmIs of this solution plus 50mls of Iris-
saline buffer was added to each filter. 1 5pls of H202 was then 
Fig. 2.3 Inlection and bleeding protocol for measuring 
Rabbit anti-ovine BLG lgG responses 
BLEEDING SCHEME 
PRE 	1st 	2nd 	3rd 
0 14 28 38 42 56 DAYS 
11 1 
BLG + FCA 	BLG + FICA 
INJECTION SCHEME 
A New Zealand Black rabbit (Rabbit 669) was immunised 
with purified ovine BLG (J-M Michard, J D Ansell and 
S Micklem, unpublished data) plus Freunds Complete Adjuvant 
(FCA) (PIERCE). Secondary immunisations were performed 
with Freunds Incomplete Adjuvant (FICA)(PIERCE). 
2001igs of BLG was made up in 1 ml PBS and to this 1 ml of 
adjuvant was added. The mixture was emulisified before 2mls of 
Tween 80 were added and the mixture re-emulsified. Rabbit 669 
was immunised with 2mIs of the resulting mixture. 
Rabbit 669 was bled following each of the three immunisations 
and the anti-BLG titres analysed using [LISA. Serum taken after 
the third immunisation was used in both Western blot and ELISA 
assays. Normal rabbit sera was derived from the prebleed sera. 
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added. If BLG was present on the filter and had been detected 
by the BLG-specific antibodies, black insoluble precipitate 
bands appeared. 
Figure 2.2 describes the purity of the BLG purification 
samples. Following Western blotting it was observed that each 
purified protein sample contained BLG. Rabbit anti-ovine BLG 
recognises two bands, the low molecular weight band 
(probably 1 8kDa BLG momomers) and a higher molecular weight 
band. No molecular weight markers were included in these gels 
so the molecular weight of this band is unknown. It is possible 
that it represents the 36kDa dimer form of BLG. Both these 
bands were present in sheep's milk. 
From the Western blot data it appeared that each of the BLG 
purifications contained one or more contaminating milk 
proteins which were not recognised by anti-ovine BLG 
antibodies. Samples 71, 75, and 58mgs/ml appeared to contain 
the most contaminants whilst samples 31.7, 52 and 42mgs the 
least. Although each BLG purification had protein 
contamination to differing degrees the vast majority of 
protein purified was BLG. 
The Western blot data also confirmed the specificity of the 
rabbit anti-ovine BLG antibody. Bovine BLG was recognised by 
the rabbit anti-ovine BLG antibodies whilst OVA was not. It 
was interesting to note that the anti-ovine BLG antibodies 
also recognised two bands of low and high molecular weights 
in bovine BLG, suggesting also that perhaps this was the 1 8kDa 
momomer and 36kDa dimer form of BLG. It was also noted that 
bovine BLG (SIGMA) also contained contaminating high 
molecular weight proteins. 
v) Enzyme linked immunosorbent assay (ELISA). 
Solutions used in the ELISA system are described in Appendix 
3. 
Although newly purified BLG samples were recognised on a 
cellulose filter by anti-ovine BLG antibodies it was important 
to further investigate protein recognition, again with 






Fia. 2.4a Cartoon of an ELISA well 
STEP 1 = Coating plate with antigen followed by 
the blocking antigen. 
STEP 2 = Dilutions of sera 
STEP 3 = Anti-lgG Urease conjugated antibody 
STEP 4 = Urease substrate 
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Fig. 2.4b. Representation of a typical end point dilution 
assay 
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phase. An ELISA technique was developed based on a urease 
detection system [316]. Figs 2.4a and 2.4b describe the 
principle of the ELISA and the titration system used in this 
particular assay. 
The [LISA protocol used was as follows; 
BLG samples were diluted in coating buffer at a 
concentration of 20pgs/ml. This protein concentration was 
chosen since coating [LISA plates with 20, 50 or 1 O0pgs gave 
similar OD values for each dilution point of Rabbit 669 anti-
ovine BLG sera, see Figs 2.5, 26, 2.7 and 28. Thus to conserve 
stocks of protein the lower concentration of 20pgs was 
chosen. 
1 OOpls of the antigen dilution was then added to each well 
of a 96 well flat bottomed plastic [LISA plate (IMMUNOL 2, 
DYNAT[CH, Highwycombe, UK) and plates were incubated for 2 
hours at 370C. 
After incubation, unbound excess antigen was discarded and 
plates washed 3 times in wash buffer (WBF) then patted dry. 
1 OOpls of diluting buffer (DBF) was then added per well and 
the plates reincubated at 370C for 30 minutes. This step 
ensured that any available binding sites in each well were 
coated with BSA present in the DBF. 
Plates were washed 3 times as before with WBF and various 
dilutions of rabbit anti-ovine BLG sera (Rabbit 669) were then 
added. Rabbit sera was firstly diluted 1/10  (20pls of sera + 
1 8Opls of DBF) then doubling dilutions were made; 1 O0pls of 
the 1/10 dilution + lOOpls of DBF=1/20 and so forth) to give a 
sera dilution range of 1/10-1/20480.  1 OOpls of each sera 
dilution were added to the appropriate wells, 1/10  dilution 
into well 1, 1120 dilution into well 2 and so on. Triplicates of 
each sera dilution was made. Plates were then incubated for 
30 minutes at 370C. Control wells contained normal rabbit 
sera diluted as described above. 
Again plates were washed with WBF 3 times. 1 00pls of a 
1 /100 dilution of urease coupled anti-rabbit lgG antibodies 
(SERA-LAB, Sussex, UK) were added per well and plates 
incubated for 30 minutes at 370C. 
of 
Fig. 2.5. Determination of optimum concentration of 
ovine BLG with which to coat ELISA wells. 
0.5 
[i1 
0 	2 	4 	6 	8 	10 
L092 Rabbit 669 anti-BLG sera 
Wells were coated with either 200, 500 or 1000 pgs/ml 
of ovine BLG from the '31m-q' purification batch. 
For all coating concentrations the endpoint dilution for 
binding of Rabbit anti-BLG serum was 9. 
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Fig. 2.6. Determination of the optimium concentration of 
ovine BLG with which to coat [LISA wells. 
M. 
0.5 
C 0.3  
0.2 
0.1 
0 	2 	4 	6 	8 	10 
Lo92 Rabbit 669 anti-BLG sera dilution 
Wells were coated with either 200, 500 or 1000 jigs/ml 
of ovine BLG from the '58mg' purification batch. 
For all coating concentrations the endpoint dilution for 
binding of Rabbit anti-BLG serum was 9. 
Fig. 2.7. 	Determination of optimium concentration 
of ovine BLG with which to coat ELISA wells. 
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0 	2 	4 	6 	8 	10 
Lo92 Rabbit 669 anti-BLG sera dilution 
Wells were coated with either 200, 500 and 1 000 jig/ml 
of ovine BLG from the '71mg' purification batch. 
For all coating concentrations the endpoint dilution 
for binding of Rabbit anti-BLG serum was 9. 
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Fig. 2.8. Determination of optimium concentration 










0 	2 	4 	6 	8 	10 	12 
Lo92 Rabbit 669 anti-BLG sera dilution 
Wells were coated with either 200, 500 or 1 000 jigs/ml 
of ovine BLG from the !75mg1 purification batch. 
For all coating concentrations the endpoint dilution for 
binding of Rabbit anti-BLG serum was 9. 
After washing with WBF, the plates were next washed with 
dH20 to remove residual WBF which interferes with the pH of 
the substrate thus causing false positives. 
1 OOpls of substrate was then added to each well. The 
substate used was urea (SERA-LAB, Sussex, UK) and the 
system works as follows; the urease coupled to the second 
step antibody converts urea in the substrate to ammonia, this 
increases the pH of the solution, which causes a change in the 
colour of the bromocresol purple, also in the substrate, from 
yellow to purple. 
The substrate was incubated on the plates for 20 minutes 
again at 370C. Plates were read at the 405nm wavelength 
using an automatic [LISA reader. The mean OD value for the 
triplicates of each dilution was calculated and plotted against 
a Log2 transformation of each dilution, for example 1/10 
dilution =0, 1120 dilution= 1, 1 /40 dilution=2 ..... 
As the dilution of the rabbit sera increased the colour change 
gradually went from purple - red - yellow and correspondingly 
the OD value increased with this change. In this system the 
lower the OD value the more purple the solution, the higher 
dilution the more yellow the solution. 
Using the urease detection system in an [LISA allowed a visual 
approach to working out the antibody titre. In this case the 
titre would be the reciprocal of the dilution end point and the 
dilution end point would be the well with the last purple/red 
colour before a yellow well. For example if a well containing a 
1 /640 dilution contained a purple/red colour and the next 
well, 1/1280  was yellow the dilution end point would be 
1 /640. The titre is the reciprocal of the dilution and in this 
example the titre is 640, its I092  transformation is a titre of 
6 (see Fig. 2.4b). 
Given that the supply of sheep's milk was limited and 
intermittent it was important to demonstrate that different 
batches of purified BLG gave similar end points in the above 
[LISA for a given sera. An [LISA test for each of the six BLG 
purifications was performed and each BLG sample coated on 
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Table 2.1. Summary of ELISA assays of Rabbit 669 anti-
ovine BLG against various BLG purifications 
BLG purification(nos) Rabbit anti-BLG titre Rabbit NRS titre 
31mgs/mI >11 (-) 
58mgs/mI >11 (-) 
71mgs/mI >11 1 
75mgs/mI >11 (-) 
52mgs/mI ND ND 
42mgs/mI >11 (-) 
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the ELISA plates was recognised by the anti-ovine BLG Rabbit 
669 sera. The anti-ovine BLG titres are shown in Table 2.1. 
From this data it was concluded that following purification, 
ovine BLG retained its antigenic properties, and that coating 
this antigen to plastic ELISA plates allows correct orientation 
of the protein. Figure 2.9 shows that rabbit anti-ovine BLG 
sera recognises each purification batch of ovine BLG whilst 
normal rabbit sera does not (Fig. 2.10). 
2.2) MOLECULAR BIOLOGICAL TECHNIQUES 
i) Polymerase Chain Reaction (PCR) 
For all PCR solution recipes see Appendix 4 
a) DNA extraction. 
BLG-transgenic and non-transgenic mice were identified via a 
PCR which amplified sections of transgenic DNA. 
Two methods for the extraction of DNA were employed: i) 
Proteinase K digestion of tail biopses [317] or ii) isolation 
from peripheral blood [318]. 
Following halothane anaesthesia, using a heat sterilised 
scalpel blade, 1-2 cm of tail were removed. Each tail section 
was then cut into 3 smaller pieces before being placed into a 
screw capped Eppendorff (Corning, Bibby Sterilin Ltd, 
Staffordshire, UK). 0.5mIs of tail buffer plus Proteinase K 
were then added to each tube and samples were digested at 
370C. Once the tail had been completely digested samples were 
stored at -200C until used. 
Tail samples were thawed on ice, vortexed and then 
centrifuged in the cold to pellet out SDS from the tail buffer 
which can interfere with the PCR reaction. 
Following halothane anaesthesia, 3 drops of blood from the 
retro-orbital sinus were collected via a non-heparinised 
capillary tube (Hawksley and sons Ltd, Sussex, UK) into a 
sterile Falcon tube (Corning, Bibby Sterilin Ltd, Staffordshire, 
UK) containing 1 OmIs of red cell lysate. Tubes were inverted 
to mix the red blood cells with the buffer thus allowing RBC 
lysis and tubes were left at room temperature for 10 minutes. 
After centrifuging for 10 minutes at 400g, supernatants were 
Fig. 2.9. Comparison of ovine BLG from different 
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Lo92 Rabbit 669 anti-BLG sera dilution 
All wells coated with 200 pgs/ml of different BLG purifications. 
In all cases except the 75mg' purification the end point 












Fig. 2.10. Comparison of ovine BLG from differnt 
purification batches against normal Rabbit 669 serum. 
0 	2 	4 	6 	8 	10 
Lo92 Rabbit 669 normal serum 
All wells coated with 200 pgs/ml of different BLG purifications. 
No specific binding of normal rabbit serum was detected 
with the exception of purification '71mgs". 
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discarded and the pellet, consisting of some red (RBC) and 
white (WBC) blood cells, resuspended in 1 ml of sterile PBS. 
This suspension was then transferred to a 1 .5m1 sterile 
Eppendorff tube. After microcentrifugation the supernatant 
was decanted and the remaining pellet resuspended in 200pls 
of a 1 g/ml solution of Chelex 100 (Bio-rad laboratories Ltd,, 
Hertfordshire, UK) (an Fe2+ chelating agent) in sterile PBS. The 
samples were then heated (by microwaving) for 30 seconds and 
during this time any Fe2 +, from the RBC haemoglobin, 
remaining in the sample, was absorbed by the Chelex and DNA 
was liberated from the remaining white blood cells. After 
heating 	the samples were cooled at 40C before being 
centrifuged for 30 seconds, using a microcentrifuge. The 
remaining supernatants, containing DNA, were used for the 
PCR. 
b) PCR method 
1) Primers 
Two primers were used, 5' BLG oligo primer which amplifies a 
246bp segment of the 5' end of the BLG gene. 
5' primer: 5' gct tct ggg gtc tac cag gaa c 3' 
3' primer: 5' tcg tgc ttc tga gct ctg cag 3' 
These primers were diluted from stock to give 20pM and equal 
volumes of these 20pM oligos were mixed to give a 5' BLG 
oligo mix. The final concentration of primer used was 0.1pM 
(O.5pl per PCR). 
The second was the control primer mix which amplified a 
332bp segment of the Hypoxanthine Guanine PhospoRibosyl 
Transferase (HPRT) gene. The enzyme HPRT is ubiquitously 
expressed in all cells and thus serves as a DNA control. In DNA 
samples from non-transgenic animals a PCR band 
corresponding to HPRT should always be present if there is 
DNA in the tube. 
5' primer: 5' gag ttc cgg aac tgc ctt tgg tg 3' 
3' primer: 5' ctg tgc cac cgg gcg cat gg 3' 
These primers were diluted from stock to 20pM and equal 
volumes of 20pM oligos were mixed to give a control oligo 
mix. The final concentration of primer used was 0.1pM (0.5pl 
per PCR). 
2) DNA amplification 
Once DNA had been isolated it was PCR amplified. 1 p or l0pls 
of DNA isolated from tail samples or blood, respectively, were 
pipetted into an Eppendorff containing mineral oil and 
denatured for 10 minutes at 950C. SOpls of the following PCR 
mixture was then added to each tube; 
For each sample:- 5 pls 	1 OxPCR buffer 
	
5 pls DMSO 
0.5 pls 	BLG primer mix 
0.5 pls HPRT control primer mix 
0.25pls 	Taq DNA polymerase (Boehringer 
Mannheim Biochemica, East Sussex, UK) 
38.75p1s 	 dH20 
(A small excess of this mixture was made each time to 
compensate for pipetting losses and the pipette tip was 
changed for each tube to avoid cross contamination.) 
Controls were included; DNA extracted from the tail of a 
known BLG-transgenic mouse (from the offspring of a 
homozygous BLG-transgenic male x CBA/Ca cross), DNA 
extracted from the tail of a known non-transgenic mouse 
(CBA/Ca) as well as tube containing no DNA. 
Once the PCR mixtures had been added DNA was amplified 
using a 30 cycle PCR program:- 
940C for 1 minute, the denaturing step 
650C for 5 minutes, the annealling and extension steps. 
At the end of the PCR programme the amplified DNA solution 
was removed into another labelled Eppendorff tube and 1 2.5pls 
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Fig. 2.11 : Picture of a PCR gel 
HPR 
B L G 
Lane Nos 1 2 3 * 	 * * 
Figure 2.11 represents a picture of an ethidium bromide 
stained gel containing amplified PCR reactions performed 
on DNA extracted from digested mouse tail tissue. HPRT and 
BLG primers, added simultanously, were used in this reaction. 
Lanes 1, 2 and 3 are control tail DNA samples containing 
amplified DNA from known BLG transgenic mouse, a normal 
CBA/Ca mouse and a sample containing no DNA respectively. 
Lanes 4-20 contained DNA samples from mice of unknown 
genotype. 
BLG positive mice are marked with an * 
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of loading buffer was added to each DNA sample. Following 
mixing,1 2.5pls of this suspension was loaded onto a 2% 
agarose gel containing 0.5pgs of ethidium bromide and DNA 
samples were electrophoresed in TAE running buffer for 30 
minutes at 80volts. BLG and HPRT DNA bands present in the gel 
were then observed following UV illumination. Figure 2.11 
represents a typical PCR gel showing both the HPRT and BLG 
DNA bands. 
ii) RNA ANALYSIS 
For all RNA solution recipes see Appendix S. 
a) RNA extraction 
RNA extraction was performed using RNAzoI B solution 
(Biogenesis Ltd, Bournemouth, UK). This preparation promotes 
formation of complexes of RNA with guanidinium and water 
whilst DNA and protein are removed in an aqueous phase. The 
procedure is very rapid, usually taking less than 3 hours, and 
is very simple. 
Tissues of interest were removed sterilely, to minimise any 
RNAase contamination, and homogenised with RNAzol B, 2mls 
of this solution being added per 1 OOmgs of tissue. The 
homogenate was transferred to a screw capped tube and 
1 OOpls of Chloroform (BDH Ltd, Poole, UK) was added per 1 ml 
of homogenate. This mixture was then vigorously mixed for 15 
seconds before the tubes were placed on ice for 5 minutes. 
During this period the RNA is extracted. Following 
microcentrifugation, at 1 2000gs at 40C for 15 minutes, RNA 
found in the upper aqueous phase of the resulting supernatant 
was removed into a new tube (DNA and protein being left in the 
interface and lower aqueous phase). RNA was then precipitated 
with an equal volume to volume of propan-2-ol (BDH Ltd, 
Poole, UK) for 15 minutes at 40C and following centrifugation, 
1 2,000gs at 40C for 15 minutes, RNA was observed as a 
white-yellow pellet. After decanting the remaining 
supernatant, the RNA pellet was washed in 1 ml of 75% ethanol 
(BDH Ltd, Poole, UK) by vortexing and subsequently centrifuged 
(7500gs at room temperature, for 8 minutes). The RNA pellet 
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was air dried before being dissolved in diethyl pyrocarbonate 
(DEPC)-treated 1 mM EDTA, pH7 (this step required heating for 
1 0-1 5 minutes at 600C) before the concentration of RNA was 
calculated. The amount of RNA was calculated from the 
OD260nm value of the sample. RNA samples were stored at 
-200C until used. 
Electrophoresis of RNA samples 
RNA samples were run on a 1% formaldyhde reducing gels 
containing ethidium bromide. 5pgs of RNA was dissolved in 
1 2pls of sample buffer by heating for 5 minutes at 600C and 
after cooling, 2pls of staining buffer, bromophenol blue 
(0.1 mg/ml), was added. Gels were run for 2 hours at 1 OOV and 
destained in several changes of DEPC sterile dH20. A 
photograph was taken before a Northern blot transfer was set 
up to show the presence of the 1 8S and 28S RNA bands. 
Alongside experimental samples an RNA molecular weight 
marker was also included. 
Northern blotting 
Following destaining of the above gels RNA bands were 
Northern blotted by capillary transfer onto a Hybond N filter 
(Amersham International Plc, Buckinghamshire, UK) using the 
transferring buffer, 20xSSC. Capillary transfer occurred over a 
period of 18 hours and at the end of this period filters were 
washed, briefly in 2xSSC buffer, and RNA was fixed onto the 
filter by baking at 800C for 2 hours. 
Probe labelling 
BLG mRNA was detected using a 32P labelled BLG cDNA probe 
[293]. 30ngs of unlabelled probe were denatured for 10 
minutes and the following reagents added:- 
21ils of Hexanucleotide mix (Boeringer Mannheim Biochemica,, 
East Sussex, UK) 
3pls of dATP, dGTP, dTTP mix (Boeringer Mannheim Biochemica 
East Sussex, UK) 
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5pls of dCT32P 
lpl of Kienow enzyme (Boeringer Mannheim Biochemica, East 
Sussex, UK) 
32p labelling occurred over a 2 hour period at 370C. At the end 
of this period 80p1s of TE buffer was added and 2pls of the 
sample removed to estimate the 32P incorporation. The 
remaining labelled probe solution was then spun over a G50 
Sephadex column to remove any remaining unlabelled probe. 
Before the 32P BLG cDNA probe was added to the filters it was 
denatured with NaOH (final concentration of 0.1 5M) 
e) Filter hybridisation 
Filters were placed in hybridisation containers before being 
incubated, at 650C in a hybridisation oven (Hybaid, Uxbridge, 
UK), with 25mls of a pre-hybridisation solution. This solution 
contained 5xSSC, 5x Denhardts' solution, 0.5% (w/v) SDS and 
0.5mls of a 1 mg/mI solution of sonicated non-homologous 
spermwhale DNA which had been heated at 1 00°C for 5 
minutes and cooled prior to addition. After an hour the labelled 
probe was added to the hybridisation containers containing the 
pre-hybridisation solution and filters. Probe hybridistion took 
place over a period of 12 hours at 650C, in a hybidisation oven. 
At the end of the hybridisation process filters were washed to 
reduce non-specific binding of the probe. The washing process 
was as follows:- 
2xSSC plus 0.1% (w/V) SDS at 650C for 10 minutes. Repeat. 
	
1 XSSC 	" 	" 	" 	 " 	" It 	 . Repeat. 
0.1 xSSC " " " 'I 	 " 	 if 	 . Repeat. 
Washed filters were wrapped in Saran-Wrap before being 
sandwiched between 2 sheets of autoradiograph paper (Kodak 
Ltd, London, UK) in cassettes. Filters were stored at -700C for 
24 hours before one of the autoradiograph paper was 
developed. The second was developed a week later for further 
detection of weak signals. 
103 
2.3) Experimental mice 
Mice were bred and maintained under standard conditions in 
the Ashworth Laboratories animal facility and either fed on a 
maintenance diet (SDS special diets Ltd, Essex, UK) containing 
whey protein (Appendix 6) or on a whey deficient feed (Harlan 
OLAC Ltd, Bicester, UK) (Appendix 7). 
Breeding stocks were maintained on a breeding diet (Appendix 
6). However breeding stocks were maintained on a whey 
deficient diet when the effect of whey protein in the diet was 
analysed. 
Control mice 
Control mice used were male and female CBA/Ca (H2k),. 
C57BL/6 (H2b), CBA x C57BL/6 Fl (H2kXb)  and BALB/c (H-
2d) mice were used to investigate the effect of MHC 
background on anti-BLG responses. For both antibody and T cell 
responses mice were immunised at 8-12 weeks of age 
although some of the exbreeder females were about 20 weeks 
old at the time of immunisation. 
Transgenic mice 
Transgenic mice used in my research were transgenic for the 
ovine BLG gene. These transgenic mice were created by 
injecting a 16.2 kilobase clone of the sheep BLG gene into 
fertilised CBA x C57BL/6 mouse eggs. This resulted in three 
mouse lines, 7, 14 and 45, which were capable of passing the 
BLG transgene onto their offspring [293]. Line 45 was chosen 
as the founder line for this project since heterozygous female 
derived from line 45 transgenic founder mice produced 14.1-
21 .6mgs of ovine BLG in their milk during lactation [293]. All 
this work was done by Drs John Clark and Paul Simons group at 
the BBSRC Roslin Institute, Roslin, Midlothian. 
Line 45 homozygous males were crossed with CBA/Ca females 
and the resulting heterozygous BLG-transgenic offspring were 
tested for both antibody and T cell responses to ovine BLG. 
These Fl mice were also crossed with CBA/Ca males or 
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Fig. 2.12. Inlection and bleeding protocol for 
measuring antibody responses 
BLEEDING SCHEME 






28 42 	49 56 70 	77 DAYS 
INJECTION SCHEME 
Mice were injected (ip) with BLG + ALUM on the days specified 
and were bled for antibody responses as described. 
lo5a 
females (Fl BLG-transgenic male X CBA/Ca female or CBA/Ca 
male X Fl BLG-transgenic female) and the transgenic status of 
the resulting offspring, either BLG-transgenic or non-
transgenic was determined by PCR using BLG primers (see 
section 2.2). These animals were also tested for both antibody 
and I cell responses to ovine BLG. 




At the beginning of an experiment, mice were randomly 
allocated to specific experimental groups and from each of 
these groups a few were bled for sera (pre-bleed). Each mouse 
was immunised intraperitoneally (ip), using a 21 G needle 
(Becton Dickinson UK Ltd, Oxford, UK) with a total volume of 
0.4mls of antigen (50pls in 0.32mls of PBS) with an aluminum 
hydroxide adjuvant (0.08mls), Alum (Pierce and Warriner, 
Chester, UK). The protein antigen was firstly diluted in PBS 
and to this solution Alum was added in a dropwise manner. The 
antigen/adjuvant solution was then mixed over a 30 minute 
period. 
4 weeks following primary immunisation mice were bled. 10 
drops of blood were collected from the retro-orbital sinus into 
1 .5m1 Eppendorff tubes via heparinised capillary tubes 
(Hawksley and sons Ltd, Sussex, UK). Eppendorff tubes 
containing blood were left at room temperature for 1 hour 
before being incubated overnight at 40C to allow the blood clot 
to form and separate from the sera. After removal of the blood 
clot, with forceps, any remaining RBCs were pelleted by 
centrifugation and sera collected into fresh tubes. Sera were 
stored at -700C until use. 
Mice were re-immunised 7 and 9 weeks after the primary 
immunisation. 7 days after each of these immunisations mice 
were bled and sera collected as described above. 
The injection and bleeding protocol is summarised in Fig. 2.12. 
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Fig. 2.13. Comparison of ELISAs using developing reagents 
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For both "sigma" and "sera-lab" reagents non-specific binding 
was only seen at low dilutions (both had an endpoint of 2) and 
equivalent endpoint dilutions for specific binding (9). 
lo6a 
b) Analysis 
The antibody titre of each serum sample was estimated using 
the ELISA technique previously described. In brief, serum 
samples from immunised mice were diluted 1/10 in DBF and 
then double diluted to a dilution of 1/20480. The diluted sera 
were then added to the appropriate wells of a previously 
coated, and blocked, [LISA plate. Each sample was tested in 
triplicate. The second step antibody was an anti-mouse IgG 
(whole molecule) and was used at a dilution of either 1/100 
(SERA-LAB) or 1/1000  (SIGMA). Finally the substrate was 
added and the plates incubated for 30 (SERA-LAB) or 45 
minutes (SIGMA) at 370C. The second step antibody 
concentration and substrate development time varied with 
reagents purchased from different companies. However both 
gave similar OD values for most dilutions of Rabbit 669 anti-
ovine BLG sera as well as the same endpoint titre see Fig. 2.13. 
It should be noted that in the following results sections that 
no pre-bleed data is shown. All pre-bleed sera analysed had no 
detectable anti-ovine BLG, anti-bovine BLG or anti-OVA 
reactivity. 
ii) T Cells 
Immunisation 
Following halothane anaesthesia, each mouse was injected, in 
the left hind footpad using a 27G needle (Becton Dickinson UK 
Ltd, Oxford), with a total volume of 50pls containing 50pgs of 
antigen plus adjuvant; Sopgs of antigen was diluted in 25p1s 
of PBS and emulsified with 1 2.5pls of FCA using an omnimixer 
(Sorvall, Newtown, USA). 1 2.5pls of 2% Tween 80 was then 
added and the solution remixed. 
In vivo T cell responses (see Fig. 2.14) 
7 days after the primary footpad injection mice in 
experimental groups received a challenge dose of antigen, 
50pls of 2% heat aggregated protein solution, in the right hind 
footpad using a (21G). Control mice were given a PBS 
challenge. A 2% protein solution was made up in PBS and this 
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Fig. 2.14. Iniection and footpad measurements for 
T cell responses 
INJECTION SCHEME 
FOOTPAD MEASUREMENT SCHEME 
Mice were injected (sc) as described above. 
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solution was added to a 700C water bath for one hour to 
aggregate the protein. The solution was then cooled at room 
temperature before being used. 
Immediately prior to challenge the right footpad was measured 
using callipers (Draper, Japan) and the footpad thickness 
noted. 24 hours after challenge the footpad was remeasured 
and the response calculated by subtracting the footpad 
measurement before injection with the measurement 
following challenge for each mouse in the experimental and 
control groups. The mean footpad difference +1- standard 
deviations was calculated for each group. 
c) In vitro T cell responses 
7 days after primary immunisation mice were killed and the 
popliteal lymph node draining the immunised footpad was 
removed sterilely. For each node a cell suspension of 2.5 x 106 
cells per ml was made in sterile RPMI-FCS (Gibco, Paisley, UK) 
and 1 OOpls of this suspension dispensed into 15 wells of a 
sterile 96 well culture plate (Corning, Bibby Sterilin Ltd, 
Staffordshire, UK). A range of antigen concentrations were 
made in sterile RPMI-FCS; 1000, 500 and 1 Oopgs/ml. 1 00pls 
of each antigen concentration was then added to the 
appropriate 3 wells containing cells. 1 OOpls of media as well 
as 4pgs of Con A were added to 3 control wells. Plates were 
then incubated for 3 days at 370C/CO2 before lpCi of 3H-
Tritium (Amersham International Plc, Buckinghamshire, UK) 
was added per well. Plates were reincubated for a further 24 
hours before the cells were harvested, using a cell harvester 
(Hewlett Packard, USA), onto fibre-glass filters (ICN 
Biomedicals Inc, California, USA) which were dried at 370C 
before being placed into scintillation fluid (National 
Diagnostics, New Jersey, USA). The amount of 3H incorporated 
per well was counted in a beta counter (Hewlett Packard, USA) 
and the counts per minute (CPM) noted for each sample. 
iii) Bovine BLG oral immunisation 
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8-12 week old CBA/Ca male and female mice were orally 
challenged with bovine BLG dissolved in sterile dH20 supplied 
as drinking water. Dosage and exposure time varied. Some mice 
received 25mgs of bovine BLG for 24 hours or 21 days whilst 
others received 50mgs of bovine BLG for 24 hours or 21 days. 
Three weeks after the end of the feeding regimen mice were 
immunised with 50pgs of bovine BLG plus FCA in the left hind 
footpad (see above). 2 weeks later mice were bled for sera, as 
described, and challenged with 2% heat aggregated bovine BLG 
in the right hind footpad. Immediately prior to and 24 hours 
after challenging footpad measurements were taken (see in 
vivo T cell immunisation procedures). 7 days following the 
secondary challenge mice were bled for sera. Antibody titres 
were analysed using bovine BLG coated [LISA assays. 
2.5) Bone marrow transplantation 
Radiation dosage. 
Three groups of 4 non-transgenic mice were exposed to 8, 9 or 
1 O.5Gy of gamma irradiation from a 1 37Cs source (Nuncatom, 
London, UK). Exposure to 1 0.5Gy resulted in death 9-12 days 
later and this dose was chosen for future experiments. 
Bone marrow preparation. 
Bone marrow donor animals were killed by ether anaesthesia 
or cervical dislocation. Femora, humeri and tibiae bones were 
dissected out and excess muscle removed. The epiphyses of 
each bone was cut off with fine scissors and bone marrow 
flushed out by passing 1 ml of sterile PBS through the centre of 
each bone via a 25G (Becton Dickinson UK Ltd, Oxford) needle. A 
single cell suspension was produced by aspiration and 
explusion of bone marrow flushings through decreasing needle 
gauges, from a 1 9G to a 25G needle. The cell count was 
determined using a Coulter counter (Coulter Electronics Ltd, 
Luton, UK) and adjusted to give a final concentration of 1 x 
107 cells per 0.4m1 of sterile PBS. 
iii) Mouse immunisations. 
I]= 
Following irradiation, recipient mice received jx107  donor 
cells intravenously into the lateral tail vein using a 25G 
needle. Animals were kept on neomycin sulphate treated water 
for 7 days following irradiation. Control mice, not receiving 
bone marrow, died 9-12 days after irradiation. 
3 months following bone marrow transfer mice were 
immunised for antibody as described (see section 2.3). 
2.6) STATISTICS 
Antibody responses. 
Antibody titres were analysed using a non-parametric test, 
the Mann Whitney test, on the Minitab software. Significance 
was taken as p<0.05 at a 95% confidence level. 
T cell responses 
T cell responses following footpad immunisation and challenge 
were analysed using a 2-sample T-test on the Minitab 




THE EFFECT OF MHC HAPLOTYPE ON IMMUNE 
RESPONSES TO BLG 
Early experiments using guinea pigs immunised with a 
synthetic homopolmer PLL coupled to DNP demonstrated that 
these animals either made good antibody and T cell responses 
to this molecule (responder animals) or they did not respond at 
all (non-responders) [319-321]. Differences in response to 
synthetic polymers were also shown in mice [322-325]. Mice 
of haplotype H-21), H-2q and H-25 failed to respond, at both the 
B and T cell level, to polyGlu60 A1a3° Tyr1 0 (GAT) whilst mice 
with the haplotype H2a, H2b and H2d did respond to this 
molecule. Analyses of the immune responses to another 
synthetic polymer, polyGlu50Tyr50 (GT) showed that over 40 
inbred strains of mice were unresponsive to this molecule 
[326]. However it was found that bml 2 mice respond to GT by 
producing anti-GT antibodies [327]. 
Immune response studies have also been extended to many 
other protein molecules which are presented by either Class 1 
or Class 2 MHC molecules. Mice possessing certain alleles of 
Class 1 and Class 2 MHC do not respond to particular antigens: 
1). Kb and  Dd expressing mice do not respond to the H-Y male 
antigen. 2). Dd, Kb, Dk and Ld expressing mice are non-
responsive to the influenza nucleoprotein. 3). lAk expressing 
mice are unresponsive to bovine insulin. 4). lAd mice do not 
respond to HEL and 5). I-Ed mice do not respond to pigeon 
cytochrome c. 
The reverse is also true. Mice possessing certain MHC alleles 
are responsive to certain proteins: 1). Db and Kk expressing 
mice respond to the H-Y antigen. 2). Mice possessing Db or  Kd 
respond to the influenza nucleoprotein. 3). lAb mice respond 
to bovine insulin. 4). lAk respond to HEL and 5). lEk mice 
respond to pigeon cytochrome c [328]. 
"Ii] 
Genes determining responsiveness and non-responsiveness 
were named immune response genes. 
Recently it has been shown that both Class 1 and Class 2 MHC 
molecules could bind to a diverse range of peptides but not 
every peptide, for example lAk  can bind the immunodominant 
peptide of HEL whilst lAd does not bind this molecule. Binding 
of the peptide to correct MHC is a crucial step for T cell 
recognition and ultimately the ability to induce both antibody 
and T cell responses. Non-responsiveness in some cases 
appears to be a failure in the binding or presentation of 
peptides although in others presentation can occur but no T 
cells capable of recognising this complex are present [328]. 
Since the original transgenic stocks were on a mixed MHC 
background, systemic antibody and T cell responses to purified 
ovine BLG were investigated in mice possessing relevant MHC 
haplotypes. The influence of sex on the immune response was 
also analysed. Ovalbumin was used as a positive control 
antigen. 
3.1) Antibody responses to ovine BLG 
Female and male mice expressing different MHC genes were 
investigated for their ability to mount antibody responses to 
ovine BLG. CBA/Ca (H-2k), C57BL/6 (H-2b), BALB/c (H-2d) and 
C57BL/6 X CBA/Ca (H2kXb) were immunised intraperitoneally 
(ip) for antibody production as described (see Chapter 2). 
Mice were bled at various time points following primary and 
secondary challenges (see Chapter 2) and lgG antibody levels 
analysed using a BLG-specific ELISA. The secondary step 
antibody used in this assay was an anti-lgG whole molecule. 
Theoretically this antibody would cross-react with the light 
chains of any 1gM present in the serum samples following 
primary immunisation since the dominant antibody class 
produced would be 1gM. This was overcome by analysing the 
primary response 28 days following immunisation. The 
specificity of the secondary antibody should not interfere with 
the antibody results following challenge since the predominant 
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Figures 3.1 a, 3.2a, 3.3a and 3.4a illustrate the anti-ovine BLG 
lgG titre detected in the sera of ovine BLG immunised mice, 
each mouse being represented as a single point, for CBA/Ca, 
C57BL/6, CBA/Ca x C57BL/6 Fl and BALB/c respectively. 
Primary, secondary and tertiary antibody responses are shown. 
CBA/Ca mice (Fig. 3.1 a). 
Figure 3.1 a represents the anti-BLG responses of CBA/Ca male 
and female mice from 2 experiments. The analysis is from the 
pooled data. 
Male and female CBA/Ca mice were immunised with ovine BLG 
and the primary and secondary anti-BLG lgG titres were 
analysed by ELISA. Female and male CBA/Ca mice made a 
small, but significant amount of anti-BLG lgG antibody 
following primary immunisation with this antigen in adjuvant 
compared to mice challenged with ovine BLG and saline (data 
not included). 
Following a second immunisation the anti-BLG lgG response 
increased significantly (p<0.01) compared to the primary 
response, for both male and female CBA/Ca mice. Significant 
increases in the response to ovine BLG were also found after a 
third immunisation in male CBA/Ca mice (p<0.01) and female 
CBA/Ca mice (p<0.001). However at an individual experimental 
level a significant increase only occurred in one experiment. 
In conclusion, CBA/Ca mice responded to both primary and 
secondary immunisation with ovine BLG plus Alum by 
producing anti-ovine BLG specific lgG antibodies. Titres of 
these antibodies were low following primary immunisation 
however they increased following a second and third BLG 
immunisation. This increase in lgG response is characteristic 
of a memory response. In both experiments male and female 
primary and secondary titres were comparable. 
C57BL/6 mice (Fig. 3.2a) 
The data shown in Fig.3.2a is from one experiment. Following a 
secondary immunisation with BLG there was a significant 
increase in the response for male (p<0.01) C57BL/6 mice. This 
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was not found for female mice however following a third 
immunisation a significant increase in anti-BLG responses did 
occur (p<0.05). No further increase in the antibody response 
occurred following a third immunisation for male C57BL/6 
mice. 
Male and female C57BL/6 mice following a first and third 
immunisation made equivalent antibody responses. However 
after a second immunisation male mice made a significantly 
greater antibody response than female C57BL/6 mice (p<0.05). 
CBA/Ca x C57BL/6F1 mice (Fig. 3.3a). 
Figure 3.3a shows the anti-ovine BLG responses of Fl mice 
from one experiment. Following a primary immunisation the 
anti-BLG titres ranged from 0 to 5 for female and 2 to >5 for 
male Fl mice. A significant increase in BLG-specific antibody 
titres occurred following a second immunisation for both male 
(titre range 11 to >11, p<0.001) and female (titre range 7 to 
>11, p<O.Ol) Fl mice. However no significant increases in anti-
BLG titres occurred following a third challenge for either male 
or female mice. 
In conclusion, Fl male and female mice can respond to ovine 
BLG following a primary or secondary immunisation by 
producing high titres of anti-BLG specific antibody and both 
female and male Fl mice made comparable antibody responses 
to this protein. 
BALB/c mice (Fig. 3.4a) 
The anti-BLG responses shown in Fig. 3.4a are data from two 
experiments. The observations and p values described below 
are for the pooled data. 
Following a primary immunisation with ovine BLG male and 
female BALB/c mice producing low anti-BLG titres (titres 
ranging from no detectable antibody to 4 for females and from 
no-detectable antibody to 3 for males). A significant increase 
in anti-BLG lgG titres occurred following a second BLG 
immunisation for both male (p<0.001) and female (p<0.0001) 
BALB/c mice. 
113 
Although at an individual experiment level no significant 
increase in antibody levels occurred following a third 
immunisation in one experiment pooling the data revealed a 
significant increase in antibody titres for male (p<0.05) and 
female (p<0.01) mice following a third immunisation. 
BALB/c males and females made comparable anti-BLG lgG 
responses after each immunisation. 
3.2) Antibody responses to Ovalbumin. 
Groups of mice were immunised with a "control" antigen 
Ovalbumin (OVA), plus Alum. The primary and secondary 
response to OVA for CBA/Ca, C57BL/6, Fl and BALB/c male and 
female mice are shown in Figures 3.1 b, 3.2b, 3.3b and 3.4b 
respectively. Each mouse is represented as one point and the 
data from one experiment. 
CBA/Ca females (no males were tested) and both sexes from 
C57BL/6, Fl and BALB/c mice made low anti-OVA lgG 
responses following primary immunisation. Following a 
secondary immunisation a significant increase in anti-OVA 
specific lgG (p<0.01 for CBA/Ca females, p< 0.05 for C57BL/6 
male and female mice, p<0.01 for Fl male and female mice and 
p<0.05 and p<0.01 for BALB/c males and females respectively) 
occurred. After a third challenge with OVA only the Fl mice 
and female CBA/Ca mice significantly increased their anti-
OVA titres (p<0.01 for male and female Fl and p<0.05 for 
CBA/Ca females). This was not found for BALB/c or C57BL/6 
mice. 
Thus male and female Fl, C57BL/6 and BALB/c and female 
CBA/Ca mice can produce equivalent primary and secondary 
anti-OVA lgG responses following immunisation with OVA plus 
Alum adjuvant. Male and female mice making comparable 
responses. 
3.3) Summary of antibody data 
All groups of mice tested made good primary and secondary 
responses to ovine BLG when injected ip with the adjuvant 
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bovine BLG + FCA and 7 days later were challenged with 
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levels for individual mice in each group. This could not be 
attributed to the sex of the responding animal, since male and 
female mice of each group made comparable lgG responses to 
ovine BLG challenges. The data indicated that this protein was 
immunogenic in all strains of mice tested. 
3.4) T cell responses to bovine BLG. (Individual T cell 
responses are shown in Appendix 8). 
The secondary responses of T cells to BLG were analysed in 
vivo using a simple and rapid protocol, i.e. measurement of a 
DTH response via footpad thickening. 
In order to preserve our stocks of purified ovine BLG, initial 
DTH experiments were performed using bovine BLG which is 
commercially available and at the antibody level at least 
immunologically cross-reactive with ovine BLG (see Chapter 
4). 
CBA/Ca female mice were primed with either 1 OOpgs or 
50pgs of bovine BLG plus FCA in their left hind footpad and 
seven days later they were challenged with either soluble or 
heat aggregated bovine BLG in the right footpad. 24 hours post 
challenge the thickness of the right footpad was measured 
using callipers. The difference in footpad thickening pre and 
post challenge corresponded to the secondary T cell response 
to the BLG protein. The mean footpad differences, in 
millimeters, and standard deviation (SD) of the means for each 
experimental group were calculated and are shown in Fig. 3.5. 
Challenge with a soluble antigen, regardless of initial priming 
dose, gave poor secondary responses. However good secondary 
T cell responses were evident following a challenge with a 
heat aggregated antigen and again this was not significantly 
influenced by the priming dose. 
Systemic T cells, from female CBA/Ca mice, can therefore be 
primed and respond to a secondary challenge with bovine BLG. 
This response was dependent on the antigen being aggregated 
for secondary immunisation, presumably since large protein 
aggregates are retained in the skin [329]. Both 1 OOpg and SOpg 
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Fig. 3.6a 
I cell responses of CBA/Ca mice to ovine BLG 
Mice were immunised with ovine BLG+FCA and 7 days 
later challenged with 2% Hag ovine BLG or PBS. 
(nos) = number of mice tested. 
Error bars are +1SD 
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Fig. 3.6b 
T cell responses to ovine BLG for C57BL/6 mice 
Mice were immunised with ovine BLG+FCA and 7 
days later were challenged with either 2% Hag 
ovine BLG or PBS. 
(nos) = number of mice tested. 
Error bars are +1SD 
E!1 2% Hag ovine BLG 
El PBS 
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following challenge, and for this reason 50pgs of antigen was 
designated the priming dose for future T cell experiments. 
3.5) T cell responses to ovine BLG. 
Female and male CBA/Ca, C57BL/6, CBA/Ca X C57BL/6 Fl and 
BALB/c mice were immunised as described above with ovine 
BLG. Control mice were challenged with PBS whilst 
experimental groups were challenged with 2% heat aggregated 
ovine BLG. The mean+l SD of pooled data from two experiments 
(unless otherwise stated) are shown in Figs 3.6a, b, c and d. 
The mean footpad differences of the experimental groups were 
compared with the equivalent values of PBS controls using a 
2-sample T-test available on Minitab software. 
In the following sections the observed results and p values are 
from the data of 2 pooled experiments. The observations made 
were also noted at the level of the individual experiment 
unless indicated. Individual T cell data are shown in Appendix 
9. 
CBA/Ca mice (Fig. 3.6a) 
Compared to their respective controls, male and female 
CBA/Ca mice, made small but significant secondary I cell 
responses to ovine BLG (p<O.00l). Male and female CBA/Ca 
made equivalent T cell responses to this protein. 
C57BL/6 mice (Fig. 3.6b). 
Male and female C57BL/6 mice made significant T cell 
responses to ovine BLG (p<O.Ol and p<O.00l respectively) as 
compared to control mice. Thus suggesting that C57BL/6 mice 
can produce a T cell response to ovine BLG following this 
immunisation protocol. Males in experiment one made a greater 
response than females (p<0.05) whilst the opposite was 
observed in the second experiment. However when the data 
from both experiments was pooled no significant difference in 
responsiveness was observed between the sexes. 
iii) Fl mice (Fig. 3.6c). 
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Fig. 3.6c 
T cell responses to ovine BLG for Fl mice 
Mice were immunised with ovine BLG+FCA and 7 days 
later challenged with 2°!0  Hag ovine BLG or PBS. 
(nos) = number of mice tested. 
Error bars are +1SD 
D 2% Hag ovine BLG 
D PBS 
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MALES MALES FEMALES FEMALES 
Fig. 3.6d 
T cell responses of BALB/c mice to ovine BLG 
Mice were immunised with ovine BLG+FCA and 7 days 
later challenged with 2% Hag ovine BLG or PBS. 
(nos) = number of mice tested. 
Error bars are +1 SD 
EB 2% Hag ovine BLG 
El PBS 
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The footpad measurement for El males in Fig. 3.6c is from one 
experiment only. Comparing the experimental mean footpad 
difference with control data indicated that male Fl mice were 
capable of producing significant T cell response to ovine BLG 
(p<O.00l). 
The T cell data in Fig.3.6c for female Fl mice is pooled from 
two experiments. Comparing the experimental female data 
with that of control data indicated that female Fl mice made a 
significant T cell response to this protein (p<O.00l). 
Comparing the T cell responses of Fl male and female mice 
indicated that both sexes made equivalent T cell responses to 
ovine BLG. 
iv) BALB/c mice (Fig. 3.6d). 
Figure 3.6d represents the T cell responses of male and female 
BALB/c mice from two experiments. Both male and female 
BALB/c made significant (p<O.00l) T cell responses to ovine 
BLG as compared to control mice. Male and female BALB/c mice 
made equivalent T cell responses to this protein. 
3.6) Summary of T cell data 
Male and female mice, regardless of MHC background respond 
to ovine BLG and produce small but significant in vivo T cell 
responses to this protein as measured by a DTH reaction. 
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CHAPTER 4. 
BLG-SPECIFIC ANTIBODY RESPONSES IN BLG-
TRANSGENIC MICE 
Virgin BLG-transgenic female and male mice as well as 
exbreeder BLG-transgenic females variously exposed or not to 
BLG in milk or whey protein in their diet were immunised 
parenterally with ovine BLG and the antibody responses 
measured by an ELISA techique described in Chapter 2. 
4.1) Fl BLG-transgenic offspring from a homozygous 
transgenic male x CBA/Ca female. 
The first group of transgenic mice tested for antibody 
responsiveness to ovine BLG were derived from mating line 45 
homozygous BLG-transgenic males with CBA/Ca females. All 
offspring from this mating, the Fl BLG-transgenics, carried 
the ovine BLG gene as shown by PCR and BLG specific primers 
(see Chapter 2). To test for BLG gene expression RNA 
extraction was performed on various tissues from BLG-
transgenic mice. Following gel electrophoresis and Northern 
blotting the presence of BLG RNA was analysed by using a BLG 
cDNA probe [293]. Expression of BLG RNA was only evident in 
lactating mammary tissue from BLG expressing female mice, 
as previously described [293] see Figs 4.1a and 4.1b. No BLG 
RNA expression was evident in either the thymus or lymph 
nodes of BLG-transgenic mice, see Figs 4.la and 4.1b. 
At three months of age, these mice were immunised with 
either ovine BLG, bovine BLG, or OVA, as described and any 
resulting serum lgG titres were analysed using an ELISA. 
Plates were coated with either ovine or bovine BLG or OVA, 
respectively. Each mouse serum was tested in triplicate and 
the antibody titre plotted. The anti-BLG titres derived from 
the sera of these BLG-transgenic mice were compared with the 
anti-BLG response of CBA/Ca mice, these mice having been 
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Fig. 4.1a RNA gel and Northern Blot 
28S 
18S 
Lanes 	i 2 3 4 5 6 7 8 
BLG 
RNA 
Lanes 	2 3456 7 8 
Fig. 4.1a represents pictures of 1) an ethidium bromide and 
UV exposed formaldehyde gel containing RNA samples 
(upper picture) and 2) a Northern blot of the gel following 
labelling with a BLG eDNA probe (lower picture). 
Lanes 1, 2 and 3 contains RNA from the mammary 
glands of three lactating transgenic females. Lane 4 
contains thymic RNA from a lactating BLG-transgenic female, 
lanes 5 and 6 contains thymic RNA from two CBA/Ca males. 
Lane 7 contains no RNA. An RNA ladder (SIGMA) was added 
to lane 8. It was noted that the BLG eDNA probe bound to the 
RNA ladder. 
51jgs of RNA added per well. 
1•18a 
Fig. 4.1b RNA G& and Northern Blot 
28S 
18S,  
Lanes 1 2 3 4 5 6 7 8 
Lanes 1 2 3 4 5 6 7 8 
Fig. 4.1 b represents pictures of 1) an ethidium bromide and UV 
exposed formaldehyde gel containing RNA samples (upper picture) 
and 2) a Northern blot of this gel following labelling with a 
BLG eDNA probe (lower picture). 
Lane 1 contains RNA from the mammary gland of a 
lactating BLG-transgenic female. Lanes 2 and 4 contain 
RNA from BLG-transgenic male and females lymph nodes, 
respectively. Lanes 3 and 5 contain thymic RNA from virgin female 
and male BLG-transgenic mice respectively. 
Lanes 6 and 7 contain RNA from BLG-transgenic fetal thymus 
and liver respectively. Lane 8 is the RNA ladder. Lane 8 was 
removed from the Northern blot picture however the probe bound as 
shown in Fig 4.1 a. 
5pgs of RNA added per well. 
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Fig_42a 
Antibody responses of Fl DLG-tronsgenic 
male () and female (..!J mice to ovine DL6. 
Each point is the data for serum from a single  
mouse. 
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previously shown, in Chapter 3, to produce good secondary 
antibody responses to ovine BLG. 
The antibody responses of El BLG-transgenic mice to ovine 
BLG 
The antibody data shown in Fig. 4.2a is from two experiments 
in which Fl BLG-transgenic male and female mice were 
challenged with ovine BLG. Following the first immunisation 
with ovine BLG, in the first experiment, no detectable anti-
BLG lgG antibodies were found in the serum of male transgenic 
mice, and for 3/5 female transgenic mice. The remaining 2 
female mice made very low titres of antibody. When this 
experiment was repeated Fl BLG-transgenic male and female 
mice made no detectable anti-BLG antibody. 
Visual comparison of the anti-BLG lgG titres following 
primary immunisation with those titres following a secondary 
immunisation indicated that no significant increase in anti-
BLG lgG titres occurred following challenging in both 
experiments (titre ranged from no detectable antibody to 2 for 
experiment 1 whilst the range was from no detectable 
antibody to 0 for experiment 2). Statistical confirmation of 
this observation was not carried out. 
Following a third immunisation with ovine BLG male and 
female Fl BLG-transgenic mice, in experiment one, had anti-
BLG titres (titre range 3-4) significantly greater than those 
detected after a second immunisation (titre range no 
detectable antibody to 2 (p<0.01 (males) and p<0.005 
(females)). This small increase in antibody response was not 
detected in the repeat experiment. 
Comparing the antibody responses of BLG-transgenic and 
CBA/Ca mice, after immunisation with ovine BLG. 
Although both CBA/Ca and Fl BLG-transgenic mice produced 
quite low anti-BLG titres (range 0 to 4 for CBA/Ca mice (see 
Fig.4.2b) and no detectable antibody to 0 for Fl BLG-transgenic 
mice (see Fig4.2a) following primary immunisation, the 
responses of Fl BLG-transgenic mice were slightly lower than 
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Fig- 4.3 
Antibody responses of virgin and exbreeder 
CDA/Cn and Fl flI..6-tninsgenic female mice 
to ovine 11L6. 
Each point is the data for serum from a single 
mouse. 
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those of CBA/Ca mice. Fl BLG-transgenic mice also made a 
reduced immune response to ovine BLG compared to CBA/Ca 
mice following a second immunisation; the anti-BLG IgG titres 
produced by CBA/Ca male and female mice ranged from 2 to 12 
(data from 2 experiments) whilst the anti-BLG IgG responses 
of El BLG-transgenic male and female mice ranged from no 
detectable antibody to 2 (data from 2 experiments). 
Statistical analyses of the pooled anti-BLG IgG responses, 
from each group of mouse, confirmed that Fl BLG-transgenic 
males and females made significantly lower responses than 
equivalent CBA/Ca mice (p<0.0001 (males) and p<0.001 
(females)). This was also the case following the third 
immunisation (p<0.001 (males) and p=0.0001 (females)). 
In conclusion, male and female BLG-transgenic mice appeared 
to be hyporesponsive, at the antibody level, to the protein 
product of the gene they possess. Comparison of the systemic 
anti-BLG IgG titres of transgenic mice and control CBA/Ca 
males and females indicated that both the primary and 
secondary IgG responses were affected. 
iii) Antibody responses to ovine BLG in exbreeder female mice. 
Exbreeder CBA/Ca and BLG-transgenic mice were immunised 
with ovine BLG to test whether pregnancy and lactation in 
female BLG-transgenic females would affect unresponsiveness 
at the antibody level as compared to virgin CBA/Ca and Fl 
BLG-transgenic controls. In this experiment the exbreeder 
mice had undergone three pregnancies. 
The antibody titres following the first and third 
immunisations are shown in Fig. 43. No sera was collected 
following the secondary immunisation. 
The absence of antibody production in 3/4 virgin El BLG-
transgenic mice and 2/3 exbreeder El BLG-transgenic mice 
indicated that following a primary immunisation transgenic 
mice made little or no antibody responses to ovine BLG. 
CBA/Ca mice, in this experiment, also made low anti-BLG IgG 
titres following the first BLG immunisation. 
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Fig. 4.4 Cross-reactivity of anti-bovine and anti-ovine 
BLG antibodies 
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Fig. 4.4 Cross-reactivity of anti-ovine and anti-bovine 
BLG antibodies. 
Gel A. Is a picture of a Coomassie Blue stained SIDS Page gel 
containing in Lane 1 a prestained high molecular weight ladder 
(SIGMA), in Lane 2 bovine BLG (1 00mg/mi) (SIGMA, Poole, UK), 
in Lane 3 ovine BLG (31mg/mi) and in 
Lane 4 OVA (50mg/mi) (SIGMA). 5pls of protein was added to 
5pls of stacking buffer and 2pls of this mixture was added to 
the SIDS Page gel. 
Gels B-G are Western blots of similar SIDS page gels incubated 
with different dilutions (see below) of anti-bovine, ovine or OVA 
antisera to detect cross-reactivity between reagents. Bands 
were visualised using a peroxidase linked second step antibodies. 
Gel B. Rabbit anti-bovine BLG (1/200) (Nordic Immunological 
Laboratories, Tilburg, The Netherlands) and anti-rabbit lgG-HRP 
(1/500) (SAPU, Cariuke, UK). 
Gel C. Rabbit anti-ovine BLG (1/100) and anti-rabbit lgG-HRP 
(1/500) (SAPU). 
Gel D. Pooled mouse anti-ovine BLG (1/500) from CBA/Ca mice 
immunised with ovine BLG and anti-mouse lgG-HRP (1/500) 
(SAPU). 
Gel E. Pooled mouse anti-ovine BLG (1/10) from BLG-transgenic 
mice 	immunised 	with ovine BLG and anti-mouse 	lgG-HRP 
(1/500) (SAPU). 
Gel F. Pooled mouse anti-ovine BLG (1/500) from non-transgenic 
mice immunised with ovine BLG and anti-mouse lgG-HRP (1/500) 
(SAPU). 
Gel G. Pooled mouse anti-OVA from CBA/Ca mice immunised with 
OVA. 
Results can be summarised as follows; 
Gel B; antibodies against bovine BLG recognise bovine BLG and 
are cross-reactive with ovine BLG and OVA. 
Gels C and D; antibodies against ovine BLG, raised in both 
rabbits and mice, react with ovine BLG and are cross-reactive 
with bovine BLG. 
Gel E; antibodies against ovine BLG raised in BLG-transgenic 
mice recognise ovine BLG and are weakly cross-reactive with 
bovine BLG. 
Gel F; antibodies against ovine BLG raised in non-transgenic 
mice recognise ovine BLG and are cross-reactive with bovine 
BLG. 
Gel G; antibodies to OVA recognise OVA and not BLG. 
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Fig- 45 
Antibody responses of CUA/Co () and Fl 
BLG-transgenic(13 ) male mice to bovine 
DL 
Each point is the data for serum from a single  
mouse- 
>1 I 1 
10- 	 0000 	-4 	. 
.: 	. 
N 	6 	 0 	 0 	
. 
00 
-J 	4- 	 00 
0 	0. 	0 	-2 
2 	 no ODD 
0000 	00 	0 




I 	 I 	 NDAh 
1 2 	 3 
Bleed 
NDAb = no detectable antibody 
121a 
Following a third immunisation virgin and exbreeder Fl BLG-
transgenic mice made equivalent anti-BLG responses. This was 
also found for the CBA/Ca virgin and exbreeder groups (p<0.5). 
Comparing the anti-BLG responses of CBA/Ca and BLG-
transgenic exbreeder females confirmed that there was a 
significant difference (p<0.05) between these two groups of 
mice; transgenic mice made lower anti-BLG IgG titres than 
mice not possessing this gene. 
These data suggest that pregnancy did not affect the antibody 
hyporesponsiveness to ovine BLG seen in BLG-transgenic mice. 
iv) The antibody responses of Fl BLG-transgenic and CBA/Ca 
male mice to bovine BLG 
Bovine and ovine BLG are immunologically cross-reactive as 
shown via Western blotting analysis (see Fig.4.4). Bovine and 
ovine BLG were electrophoresed on a 15% polyacrlyamide gel 
and Western blotted. Detecting antibodies used were derived 
from the pooled sera of non-transgenic and transgenic male 
and female mice immunised with ovine BLG as well as rabbit 
anti-bovine BLG and rabbit 669 anti-ovine BLG. Data from the 
Western blotting analysis showed that antibodies to bovine 
and ovine BLG were cross-reactive (Fig. 4.4). It was thus 
predicted that mice possessing the ovine BLG gene would be 
tolerant to bovine BLG as well as ovine BLG. 
To test this hypothesis Fl BLG-transgenic male (no female 
mice were analysed) were immunised with bovine BLG and the 
anti-bovine BLG IgG responses, following each immunisation, 
analysed using a bovine BLG specific ELISA. CBA/Ca male mice 
were also immunised with bovine BLG. Antibody responses are 
shown in Fig. 4.5. 
CBA/Ca males responded to a primary immunisation with 
bovine BLG by producing a low level of anti-BLG IgG antibody 
(titres ranged from 1-3). Male and female Fl BLG-transgenic 
mice also produced a low antibody response (titre ranged from 
no detectable antibody - 1). Immunological memory in CBA/Ca 
mice was generated, indicated by the significant increase in 
antibody titres following a second (range of 4-6, p<0.05) and 
121 
Fig- 45 
Antibody responses of CBA/Co (•), F1 
5L6-tronsgenic(•) female mice and Fl 
DLG-transgenic male() mice to OVA. 
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third immunisation (titres of 10, p<0.05). In contrast, this did 
not occur for the El BLG-transgenic mice. 
Fl BLG-transgenic male mice also made significantly lower 
antibody response to bovine BLG than the controls following 
each of the three immunisations (p<0.01 (1st), p<0.005 (2nd 
and 3rd)). (Although female mice were not included in this 
experiment it is predicted that the BLG-transgenic female 
would have a reduced response to bovine BLG as compared to 
female CBA/Ca mice). In conclusion, possession of the ovine 
BLG-transgene results in unresponsiveness to bovine BLG as 
well as ovine BLG following both primary and secondary 
immunisations compared to non-transgenic mice. 
v) The antibody responses of Fl BLG-transgenic and CBA/Ca 
mice to Ovalbumin 
Following a first immunisation with OVA, CBA/Ca females (no 
CBA/Ca males were tested) and Fl BLG-transgenic male and 
female mice produced low anti-OVA specific responses; the 
antibody responses ranged from a titre of 1-2 for CBA/Ca 
mice, and from no detectable antibody to 4 for transgenic 
mice, see Fig. 4.6. High anti-OVA lgG titres were observed 
following a second immunisation with OVA in all groups of 
mice, as compared to the primary antibody response (p<0.01 
(CBA/Ca) p<0.05 (transgenic males) and p<0.01 (transgenic 
females)). Secondary anti-OVA lgG responses of Fl BLG-
transgenic female mice were comparable to those of CBA/Ca 
mice. A further increase in the anti-OVA response for all 
groups of mice occurred after a third immunisation (p<0.05 for 
CBA/Ca, transgenic males and transgenic females) and the 
tertiary anti-OVA responses of CBA/Ca and transgenic females 
were comparable. 
In conclusion, Fl BLG-transgenic female mice do not appear 
hyporesponsive to the control antigen OVA and although no 
comparison between the anti-OVA response of CBA/Ca and Fl 
BLG-transgenic males was possible these transgenic mice also 
appear responsive to this protein. 
122 
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4.2) Heterozygous BLG male X CBA/Ca females (non-
BLG-suckled) vs CBA/Ca male X Heterozygous BLG 
female (BLG-suckled) 
The second group of transgenic and non-transgenic mice tested 
for antibody responsiveness to ovine BLG were derived from 
mating Fl heterozygous BLG-transgenic mice with CBA/Ca 
partners in such a way that offspring were either exposed to 
BLG via milk produced from lactating transgenic females or 
they suckled on "normal" CBA/Ca mouse milk. These crosses 
were set up to investigate whether suckling BLG-containing 
milk would induce oral tolerance. The mating protocol is 
illustrated in Fig. 4.7. 
To ensure that lactating BLG-transgenic females produced 
milk containing the ovine BLG protein and that it was being 
passed to suckling pups, a few mice suckling BLG-containing 
or "normal" milk were killed, stomach contents run on an SIDS 
gel and any BLG present identified, using rabbit 669 anti-ovine 
BLG, following Western blotting. A known ovine BLG sample 
(sheep's milk) was included. 9/9 mice suckled on BLG-
containing milk had BLG protein present within their stomachs 
following feeding whilst 5/5 mice suckled on "normal" mouse 
milk did not, see Fig. 4.8. 
After the pups had suckled for 21 days they were weaned and 
placed on a diet known to contain bovine BLG. At 3 months of 
age, adult mice were identified as transgenic or non-
transgenic, and immunised with ovine BLG or OVA as described 
in Chapter 2. Sera were collected at various intervals and 
anti-ovine lgG or anti-OVA lgG titres were estimated for each 
mouse, as before. 
I) The antibody responses of BLG-transgenic and non-
transgenic mice to ovine BLG. 
Three separate experiments were conducted. The first two 
experiments (represented by triangles and squares, 
respectively, in Figs 4.9-4.12) only had a few mice per group 
such that no statistical comparison between groups was 
carried out. The third experiment (represented by circles in 
123 
Fig. 4.8. Testing the milk of a lactating BLG-
transgenic mouse for the presence of ovine BLG. 
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Fig. 4.8. Testing the milk of a lactating BLG-transgenic 
female mice for the presence of ovine BLG. 
Picture of a Coomassie blue stained SIDS Page gel containing 
the stomach contents of four 7-10 day old pups from a lactating 
BLG-transgenic female (samples 5, 6, 7 and 8) and five 7-10 day 
old pups from a lactating non-transgenic female (samples 2, 3, 
4, 9 and 10). Sample 1 is ovine BLG purified from sheeps milk. 
Pups were killed and their stomachs contents removed. 501ils of 
PBS was added to each of the stomach contents and following 
homogenising 5pls of this mixture was added to 5pls of PBS plus 
lOpIs of sample buffer. 2.5pls of this mixture was then added to 
a 15% SDS Page gel. 
Picture of a Western blot of a similar SIDS Page gel. 
The detecting antibodies used in this Western Blot were rabbit 
anti-ovine BLG. Second step antibodies were anti-rabbit-HRP. 




Antibody responses of female mice suckled 
on BI-6-containing milk to ovine DLG 
Each point is the data for serum from a 
single mouse. 
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the aforementioned figures) however did allow statistical 
analysis of groups of mice and the p values given represent 
those from analysis of this experiment. In the following 
sections the anti-BLG responses of BLG-transgenic mice 
compared with their non-transgenic littermates are discussed. 
Female mice suckled on BLG-containing milk (Fig. 4.9). 
The antibody data in Fig. 4.9 represents data from experiments 
2 and 3. Although experiment 2 contained only a few mice, it 
was noted that there was an obvious difference between 
transgenic and non-transgenic individuals' anti-ovine BLG lgG 
titres following secondary immunisation; transgenic mice 
made lower antibody titres to BLG than non-transgenic mice. 
This was also the case for mice in experiment 3, although 
following a secondary immunisation transgenic mice made 
significantly greater (p<0.05) antibody responses to BLG than 
following a primary immunisation; both the primary and 
secondary anti-BLG lgG titres were significantly lower than 
their non-transgenic littermates (p<0.02 and p<0.01, 
respectively). This was also the case following a third 
immunisation (p<0.01). 
Female mice suckled on "normal" mouse milk (Fig. 4.10) 
Figure 4.10 contains data from all three experiments. Each 
experiment showed that there was an obvious difference 
between transgenic and non-transgenic mice, again transgenic 
mice made lower antibody responses than non-transgenic mice 
following each immunisation. 
The primary responses of transgenic mice in this experiment 
were comparable to the responses of non-transgenic mice. A 
significant increase (p<0.05) in the anti-BLG response 
occurred in transgenic mice following a secondary 
immunisation however these were significantly reduced 
compared to the non-transgenic mice (p<0.001). This was also 
found after a third immunisation (p<0.001). 
c) Male mice suckled on BLG-containing milk (Fig.4.1 1) 
124 
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Antibody responses of mole mice suckled 
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Fig- 4-12 
Antibody responses of male mice suckled 
on -normal- mouse milk to ovine DLG. 
Each point is date for serum from a single  
mouse- 
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Figure 4.11 contains data from three experiments and as for 
female BLG-transgenic mice, male BLG-transgenic mice had 
obviously lower anti-BLG lgG titres than their non-transgenic 
littermates. However, in the first two experiments a 
convincing difference between these mice only occurred 
following a third immunisation. The reason for this is 
unknown. In the third experiment, transgenic mice made a 
significant lower anti-BLG responce following both the second 
(p<0.01) and third (p<O.00l) immunisations as compared to 
non-transgenic mice. 
Male mice suckled on "normal" mouse milk (Fig. 4.12) 
Comparing BLG-transgenic and non-transgenic mice from 
experiments 2 and 3, no non-transgenic mice were analysed in 
experiment 1, also indicated that BLG-transgenic mice made 
lower anti-BLG lgG responses following a second (p<0.01, 
experiment 3) and third (p<0.001, experiment 3) immunisation 
than non-transgenic littermates. No significant difference was 
found following a primary immunisation. 
Comparing the anti-BLG IgG responses of mice suckled on 
either BLG-containing or "normal" mouse milk. 
When non-transgenic females from the "suckled" and "non-
suckled" groups in the third experiment were compared a 
significant difference, following each immunisation, was 
observed; exposure to BLG from birth appeared to reduced BLG-
specific lgG levels (p<0.05, p<0.005 and p<0.05 when the 
primary, secondary and tertiary titres were compared). It 
should be stated that although lgG titres were reduced, 
antibody levels never fell to those of their transgenic 
littermates and some mice appeared unaffected by exposure to 
BLG, making high anti-BLG lgG titres. 
Since the antibody responses to BLG from each of the three 
experiments was comparable the data was pooled to further 
check if the difference seen above (i.e. non-transgenic mice 
suckled on BLG-containing milk having reduced antibody 
responses to BLG) remained. The primary anti-BLG lgG 
125 
Fig_4.13 
Antibody responses of male (circles) and 
female (squares) mice suckled on DLG-
containing milk to OVA 
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Fig_414 
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responses of non-transgenic female mice suckled on BLG-
containing milk was significantly reduced as compared to 
those suckled on normal mouse milk (p<0.05). However no 
significant reduction in the anti-BLG response was evident 
after both a second and third immunisation. 
Suckling on BLG-containing milk did not result in reduced anti-
BLG IgG responses to this protein in non-transgenic male mice; 
the anti-BLG IgG responses of non-transgenic males suckled on 
either BLG-containing or "normal" mouse milk were 
comparable after each immunisation. This was also the case 
after the data from each experiment was pooled. 
Comparing the anti-BLG IgG responses, from the third 
experiment, of transgenic mice suckled on BLG-containing milk 
with those of transgenic mice suckled on "normal" mouse milk 
revealed that the anti-BLG IgG responses of these two groups 
of mice following any of the challenges were comparable. This 
was also the case after the data was pooled. These data 
suggest that; 1) suckling on BLG-containing milk did not induce 
oral tolerance to Ovine BLG and 2) exposure to BLG-containing 
milk was not responsible for the reduced anti-BLG IgG 
responses seen for mice carrying the BLG transgene 
ii) The antibody responses of female and male transgenic mice 
to Ovalbumin 
To investigate whether BLG-transgenic mice were 
hyporesponsive to other proteins these mice were immunised 
with an unrelated protein, OVA, and the anti-OVA IgG 
responses of BLG-transgenic mice were compared with the 
anti-OVA IgG responses of non-transgenic littermates. Despite 
the wide range in anti-OVA IgG titres (see Figs 4.13 and 4.14) 
both BLG-transgenic and non-transgenic male and female mice 
were obviously capable of responding to OVA. The antibody 
responses of BLG-transgenic and non-transgenic mice were 
equivalent. These data are similar to those shown for Fl BLG-




Fig- 4-15  
Antibody responses of G6 female mice 
suckled on UL6-containing milk to ovine 
BLG 
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Fig- .11 
Antibodyresponses of 66 males suckled 
on ULO-containing milk to ovine ULII 
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It was also noted that suckling BLG-containing milk did not 
interfere with the ability of transgenic or non-transgenic 
mice to respond to OVA. 
iii) The antibody responses of mice fed a diet lacking whey 
protein to ovine BLG 
El BLG-transgenic mice and CBA/Ca mice were placed on a 
diet lacking whey protein following weaning and at 8 weeks of 
age these mice were mated as described in Fig. 4.7. Following 
weaning offspring from these crosses were also placed on a 
diet lacking bovine BLG. This experiment was set up to 
investigate whether bovine BLG in the diet interfered with the 
development of tolerance to ovine BLG. The antibody responses 
are not shown here but can be found in Appendix 10. 
The data indicated that the presence or absence of whey 
protein in the diet did not affect the observed 
hyporesponsiveness in transgenic mice nor the development of 
oral tolerance; adult BLG-transgenic mice mice exposed to 
BLG, in their mother's milk, during the first 21 days of life 
were not rendered orally tolerant to this antigen. 
4.3) Generation 6 (G6)-backcrossed mice. 
During the backcrossing of the BLG transgene onto a CBA/Ca 
background, G5 mice were crossed with CBA/Ca mice such that 
the resulting offspring either suckled on BLG-containing milk 
or on "normal" mouse milk. At three months of age these G6 
offspring were indentified as BLG-transgenic or non-
transgenic via PCR and then immunised with ovine BLG as 
previously described. This experiment was set up to eliminate 
any possible background genetic effects. 
i) The antibody responses of G6 mice to ovine BLG (Figs 4.15 to 
4.18) 
a) Female and male mice suckled on BLG-containing milk (Figs 
4.15 and 4.17). 
BLG-transgenic and non-transgenic G6 male and female mice 
suckling on BLG-containing milk produced anti-BLG lgG 
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Fig- 4-16  
Antibody responses of 66 female mice 
suckled on -normal" mouse milk to ovine 
LG. 
Each point is the data for serum from 
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responses following each immunisation. As expected, 
transgenic mice were hyporesponsive to BLG as compared to 
non-transgenic littermates although significant differences in 
responses were only evident after the third immunisation in 
the case of male (p<0.005) and female (p<0.005) BLG-
transgenics. 
Female and male mice suckled on "normal" mouse milk (Fig 
4.16 and 4i8 ). 
Like above, BLG-transgenic and non-transgenic G6 male and 
female mice suckling on "normal" mouse milk produced anti-
BLG IgG responses following each immunisation. As expected 
transgenic mice made a significantly reduced anti-BLG IgG 
response as compared to non-transgenic mice and significant 
differences in the responses were evident after each 
immunisation (p<0.05 (first) p<0.005 (second) and p<O.Ol 
(third)) in the case of male G6 BLG-transgenics. No statistical 
analyses were done on the female data as only two G6 
transgenic female mice were analysed. 
Comparing the anti-BLG IgG responses of mice suckled on 
either BLG-containing or "normal" mouse milk. 
To analyse whether suckling BLG-containing milk reduced 
systemic antibody responses to this protein the anti-BLG IgG 
responses of transgenic and non-transgenic mice suckled on 
BLG-containing milk were compared with the anti-BLG IgG 
responses of transgenic and non-transgenic mice suckled on 
"normal" mouse milk. 
Suckling on BLG-containing milk did not reduce the anti-BLG 
IgG responses of non-transgenic and BLG-transgenic mice 
suggesting that backcrossing onto a CBA/Ca background did not 
result in mice capable of being orally tolerised to BLG through 
suckling BLG-containing milk. 
4.4) Overall conclusions. 
These experiments show that male and female mice 
heterozygous for the ovine BLG gene are hyporesponsive, at the 
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antibody level, to the product of this gene when exposed to 
ovine BLG and adjuvant administered parenterally. These mice 
were also hyporesponsive to the cross-reactive protein bovine 
BLG. 
Reduced anti-BLG lgG responses could not be attributed to; 1) 
poor immunogenicity of this protein since non-transgenic and 
other groups of mice (see Chapter 2) made good secondary lgG 
responses to BLG, 2) to the exposure of these mice to BLG 
protein during pregnancy and lactation since transgenic 
offspring of CBA/Ca or non-transgenic mothers were also 
hyporesponsive to this protein. 
These data are intriguing in the light of the absence of 
detectable transgene expression in female virgin and male 
mice. Even after multiple pregnancies and lactations female 
BLG-transgenic mice remain tolerant to BLG. Thus although 
expression of the BLG gene is specific to the lactating 
mammary gland the presence of the transgene in male and 
virgin female mice appears to cause this antibody tolerance. 
The presence of the BLG-transgene or exposure to BLG during 
the neonatal period did not interfere with the ability to 
respond to an unrelated protein; male and female BLG-
transgenics and non-transgenic mice made equivalent anti-
OVA responses. Thus hyporesponsiveness in BLG-transgenic 
mice is specific to the BLG protein (both ovine and bovine) and 
does not reflect a generalised defect in the B cell 
compartment of these mice. 
Although significantly reduced anti-BLG lgG responses were 
observed in female non-transgenic mice that had suckled on 
the BLG-containing milk (following a secondary immunisation) 
in one experiment pooling the anti-BLG lgG titres from female 
mice in all experiments, however eliminate the significance of 
this phenonomen. Male non-transgenic mice suckled on BLG-
containing milk also showed no reductions in anti-BLG 
responses. These observations suggest that exposure to the 
BLG protein during the neonatal period does not induce oral 
tolerance. The possiblities that the lack of oral tolerance to 
BLG was MHC phenotype related or that bovine BLG presence in 
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the food, following weaning, interfered with tolerance were 
eliminated by the finding that no suckling-related tolerance to 
ovine BLG was found in mice on a CBA/Ca background or when 
mice were placed on a diet lacking bovine BLG. 
130 
CHAPTER 5 
BLG-SPECIFIC I CELL RESPONSES IN BLG-
TRANSGENIC MICE 
As shown in Chapter 4, transgenic mice passing the ovine BLG 
transgene were hyporesponsive to ovine BLG; male and female 
transgenic mice produced a lower anti-ovine BLG specific 
antibody response as compared to non-transgenic littermates 
and CBA/Ca controls. This chapter details the results of 
experiments to test for T cell hyporesponsiveness to ovine and 
bovine BLG in BLG-transgenic mice both in vivo and in vitro. 
5.1) T cell responses in heterozygous transgenic mice 
Transgenic mice derived from mating line 45 homozygous BLG-
transgenic males with CBA/Ca females were tested for T cell 
responsiveness to BLG in viva or in vitro using either a footpad 
thickening assay or lymph node proliferation assay 
respectively. 
In the following sections the results described are from 
pooled experiments and unless otherwise stated agree with 
the results of individual experiments. Individual footpad data 
are shown in Appendices 11 to 14. 
i) In viva T cell responses to bovine BLG. 
Heterozygous Fl BLG-transgenic male mice were immunised 
and challenged, with bovine BLG, for T cell responses as 
described (see Chapter 2). Control mice received a PBS 
secondary challenge. Figure 5.1 represents the pooled T cell 
data from 2 such experiments. Mice receiving PBS (the control 
mice) made significantly lower T cell responses (p<O.00l) than 
those receiving heat aggregated (Hag) antigen. 
Female Fl BLG-transgenic mice were also tested for T cell 
responses to bovine BLG (see Fig. 5.1) Once again a significant 
response to bovine BLG was observed (p<O.Ol) for mice given 
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Fig. 5.1. T cell responses to bovine BLG. 
Mice were immunised with bovine BLG+FCA and 7 days 
later challenged with 2% Hag bovine BLG (EXPT) or PBS 
(CONT). 
(nos)= number of mice tested 
CBA/Ca males 
Fl BLG-transgenic males 
CBA/Ca females 
E Fl BLG-transgenic females 
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Fig. 5.2. T cell responses to ovine BLG. 
Fl BLG-transgenic mice were immunised with ovine 
BLG and 7 days later challenged with 2% Hag ovine BLG 
or PBS. 
(nos) = number of mice tested. 
Error bars are + 1 SD 
2% Hag ovine BLG 
PBS 
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Pooled T cell responses of Fl BLG-transgenic mice were 
compared with the pooled T cell responses of CBA/Ca mice 
(see Fig.5.1). Following a 2% Hag bovine BLG challenge both 
female and male Fl BLG-transgenic mice and CBA/Ca mice 
made comparable T cell responses to BLG. These data 
suggested that the presence of the BLG-transgene does not 
influence T cell responses to bovine BLG and the tolerance 
seen at the antibody level to bovine BLG is not evident at the T 
cell level. 
In vivo T cell response to ovine BLG. 
Fl BLG-transgenic male and female mice were immunised for 
T cell responses to ovine BLG and Fig. 5.2 represents data from 
one experiment. Male BLG-transgenic mice made small but 
significant secondary T cell responses to 2% Hag ovine BLG as 
compared to control mice challenged with PBS (p<0.05). This 
was not the case for female BLG-transgenic mice. 
To test whether Fl males BLG-transgenic mice were 
hyporesponsive to ovine BLG, T cell responses of Fl BLG-
transgenic mice were compared with the pooled T cell 
responses of male CBA/Ca mice (see Fig.36a, Chapter 3). 
Following a 2% Hag ovine BLG challenge male Fl BLG-
transgenic mice and CBA/Ca mice made comparable T cell 
responses to BLG. These data suggested that the presence of 
the BLG-transgene does not influence I cell responses to ovine 
BLG for male BLG-transgenic mice although the responses 
were small. 
In vitro T cell responses 
Two experiments were set up to look at the T cell responses to 
ovine BLG and the cross-reactivity of ovine BLG primed I cells 
to bovine BLG in vitro. Mice were immunised in the footpad 
with a mixture of antigen plus an Alum or FCA adjuvant and In 
vitro I cell assays were set up as described in the Materials 
and Methods (see Chapter 2). Figures 5.3 and 5.4a show the in 
vitro T cell responses following either an antigen plus Alum or 













Fig. 5.3. In vitro T cell responses to ovine and bovine 
BLG following immunisation with ovine BLG plus Alum 
U 	 100 	DUU 	IUUU 	IUUU 
OVINE 	 BOVINE 
BLG concentration (pg/mi) 
Mice were immunised with ovine BLG 	+ Alum and 7 days later popliteal 
lymph nodes were removed. 	For each node a cell suspension of 2.5x106  
cells per ml was made. 	1 OOpls of this 	suspension was cultured for 3 	days 
with either 	100, 500, 1 000pgs/ml 	of ovine 	BLG or 	1 000pgs/ml 	of bovine 
BLG. Proliferation of 	cells 	was measured using 31-1-tritium 	incorporation 
and is given as mean counts per minute. 
LI CBA/Ca males (n=5) 
BLG Fl males (n=4) 
El CBA/Ca females (n=4) 
BLG Fl females (n=5) 
* = responses to BLG is significantly greater than the control (p<0.05) 
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Fig. 5.4a. In vitro T cell responses to ovine and bovine 
BLG following immunisation with ovine BLG plus FCA 
OVINE 	 BOVINE 
BLG concentration (pg/mi) 
Mice were immunised with ovine BLG + FCA and 7 days later popliteal 
lymph nodes were removed. For each node a cell suspension of 2.5x106  
cells per ml was made. 1 OOpls of this suspension was cultured for 3 days 
with either 100, 500, 1 000pgs/ml of ovine BLG or 1 000pgs/ml of bovine 
BLG. Proliferation of cells was measured using 31-1-tritium incorporation 
and is given as mean counts per minute. 
E] CBA/Ca males (n=2) 
BLG Fl Males (n=6) 
BLG Fl Females (n=5) 





10  CD 5.OX1O 
0 
Fig. 5.4b. In vitro T cell responses to Con A stimulation 
following immunisation with ovine BLG with either FCA 
or Alum. 
FCA 	 ALUM 
Mice were immunised with ovine BLG + FCA or Alum and 7 days later 
the popliteal lymph nodes were removed and a 2.5x106 cell suspension 
was made. Cells were stimulated with 4pg/ml of Con A for 3 days. 
Proliferation was measured using 31-1-tritium incorporation. 
LI CBA/Ca males 
LI CBA/Ca females 
BLG 	Fl males 
H BLG El females 
(nos)= number of mice tested 
133c 
The mean stimulation indices of lymph node cells stimulated 
with either 10, 50, 1 Oopgs of ovine BLG or 1 Oopgs of bovine 
BLG from female BLG-transgenic and CBA/Ca mice immunised 
with ovine BLG plus Alum, were compared using a 2 sample T-
test. BLG-transgenic mice made equivalent in vitro T cell 
responses to both 10 and 1 Oopgs of ovine BLG to those of 
CBA/Ca mice. Similarly ovine BLG primed lymph node cells 
from both CBA/Ca and BLG-transgenic female mice made 
equivalent responses to bovine BLG. Stimulation in vitro with 
Sopgs of ovine BLG resulted in transgenic cells making a 
significantly greater response to this antigen concentrations 
than lymph node cells from CBA/Ca mice, (p<0.01). 
Ovine BLG primed lymph node cells from male BLG-transgenic 
mice also responded to the three concentrations of ovine BLG 
to the same extent as CBA/Ca mouse cells. Differences 
between these two groups of mice were only seen after 
stimulation with bovine BLG, El BLG-transgenic mice made 
significantly reduced response to this protein (p<0.05) 
compared to CBA/Ca mice. 
Lymph node cells from ovine BLG and FCA primed BLG-
transgenic and CBA/Ca male mice were stimulated in vitro 
with ovine and bovine BLG. The mean stimulation indices for 
these groups are shown in Fi95.4 . Lymph node cells from 
BLG primed Fl BLG-transgenic and CBA/Ca mice proliferated 
to each ovine BLG concentration and bovine BLG similarly. 
Although no in vitro T cell data to ovine BLG were available for 
CBA/Ca female mice the mean stimulation indices of female 
Fl BLG-transgenic mice lymph node cells stimulated in vitro 
with ovine BLG were compared with the male transgenic 
response. Comparing the stimulation indices of female with 
male transgenic mice suggested that both sexes made 
equivalent responses, although female lymph node cells 
responded better to a bugs stimulation of ovine BLG (p<0.01). 
Taken together with the in vivo data, it would appear that 
no T cell tolerance following injection of either ovine and 
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Fig 5.5. T cell responses to bovine BLG 
EXPERIMENTAL GROUPS 	 SALINE CONTROLS 
BLG-transgenic (T) and non-transgenic (NT) mice were 
immunised with bovine BLG + FCA and 7 days later mice 
were challenged with 2% Hag bovine BLG (EXPT) or PBS 
(CO NT). 
(nos)= number of mice tested 
Male mice suckled on BLG-containing milk (S) 
Female mice suckled on BLG-containing milk(S) 
Male mice suckled on"normal" mouse milk (NS)  
El Female mice suckled on "normal" mouse milk (NS) 
Error bars are + iSO 
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5.2) T cell responses in BLG-suckled and non-suckled 
transgenic littermates. 
BLG-transgenic and non-transgenic mice derived from mating 
Fl heterozygous BLG-transgenic mice with CBA/Ca partners 
(see Fig. 4.7, Chapter 4) in such a way that offspring were 
either exposed to BLG via milk produced from lactating 
transgenic mother's or suckled on "normal" CBA/Ca mouse 
milk were tested for T cell responses in vivo. These crosses 
were set up to investigate whether suckling BLG-containing 
milk would influence the development of T cell responses to 
BLG and to compare the T cell responses of BLG-transgenic 
mice with those of their non-transgenic littermates. 
In the sections below the T cell data are pooled from more 
than one experiment 
i) In vivo T cell responses to bovine BLG. 
3 month old mice were identified as BLG-transgenic or non-
transgenic mice and were immunised for T cell analysis as 
described (see Chapter 2). The results of two such experiments 
are described in Fig. 5.5. All groups of mice challenged with 2% 
Hag bovine BLG made significantly greater responses than 
control mice challenged with saline (p<O.00l for all groups). 
No significant differences were observed between 
experimental groups; BLG-transgenic and non-transgenic mice 
made equivalent T cell responses to bovine BLG. 
The T cell responses of mice suckled on BLG-containing milk 
were equivalent to those of mice suckled on "normal" mouse 
milk with one exception. Non-transgenic female suckled on 
BLG-containing milk made significantly greater T cell 
responses than non-transgenic mice suckled on "normal" mouse 
milk (p<0.05). The former observation was not found in either 
of the individual experiments. 
In conclusion, BLG-transgenic mice were not tolerant to bovine 
BLG at the T cell level in vivo and suckling on BLG-containing 
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Fig 5.6. T cell responses to ovine BLG. 
EXPERIMENTAL GROUPS 	 SALINE CONTROLS 
BLG-transgenic (T) and non-transgenic (NT) mice were 
immunised with ovine BLG+FCA and 7 days later 
challenged with 2% Hag ovine BLG (EXPT) or PBS (CONT). 
(nos)= number of mice tested 
Ej Male mice suckled on BLG-containing milk (S) 
Fq Female mice suckled on BLG-containing milk (S) 
E Male mice suckled on "normal" mouse milk (NS) 
J Female mice suckled on "normal" mouse milk (NS) 
Error bars are + 1SD 
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EXPERIMENTAL 	GROUPS 
BLG-Transgenic (T) and non-transgenic (NT) mice, 
maintained on a diet lacking whey protein, were 
immunised with ovine BLG+FCA and 7 days later 
challenged with 2% Hag ovine BLG. 
(nos)= number of mice tested. 
Male mice suckled on BLG-containing milk (S) 
Female mice suckled on BLG-containing milk (5) 
El Male mice suckled on "normal" mouse milk (NS) 
: Female mice suckled on "normal" mouse milk (NS) 
Error bars are +1SD 
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ii) In vivo T cell responses to ovine BLG. 
Groups of BLG-transgenic and non-transgenic littermate mice 
either suckled on BLG-containing or "normal" mouse milk were 
tested for T cell responses to ovine BLG. Two experiments 
were performed see Fig. 5.6 Although the overall T cell 
responses to ovine BLG were 	than for bovine BLG the 
results were similar. There were significant increases in all 
experimental groups challenged with 2% Hag ovine BLG 
compared to controls (p<0.01). Like the bovine BLG data, male 
transgenic mice suckled on BLG-containing milk as well as 
female transgenic mice suckled on "normal" mouse milk made 
equivalent T cell responses to 2% Hag BLG as compared to their 
non-transgenic equivalents. In contrast, female transgenic 
mice suckled on BLG-containing milk made significantly lower 
T cell responses to ovine BLG (P<0.01) than equivalent non-
transgenic littermates. The same was observed for male 
transgenic mice suckled on "normal" mouse milk (P<0.05). 
However when the individual experiments were analysed 
separately, the above differences between transgenic and non-
transgenic mice were only found in one experiment. 
Suckling BLG-containing milk did not result in reduced T cell 
responses. 
This experiment was repeated on mice from the above crosses 
who following suckling were placed on a diet lacking whey 
protein. At three months of age these mice were immunised 
and challenged with ovine BLG. No saline controls were 
included. This experiment was performed twice, the pooled T 
cell responses are shown in Fig. 5.7. No difference was found 
between transgenic and non-transgenic mice with one 
exception; male transgenic mice suckled on "normal" mouse 
milk made significantly reduced T cell responses compared to 
their non-transgenic littermates (p<0.05). It should be noted 
that the T cell responses of male BLG-non-suckled mice were 
from one experiment. 
Suckling BLG-containing milk did not result in reduced T cell 
responses to ovine BLG with one exception; transgenic females 
suckled on BLG-containing milk had significantly reduced 
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Fig 5.8. 1 cell responses to ovine BLG 
EXPERIMENTAL GROUPS 
G7 backcrossed BLG-transgenic (T) and non-transgenic (NT) 
mice were immunised with ovine BLG+FCA and 7 days later 
challenged with 2% Hag ovine BLG. 
(nos) = number of mice tested. 
Male mice suckled on BLG-containing milk (S) 
Female mice suckled on BLG-containing milk (S) 
D Male mice suckled on "normal" mouse milk (NS) 
Female mice suckled on "normal" mouse milk (NS) 
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Fig. 5.9. 1 cell responses to saline 
SALINE CONTROLS 
G7 backcrossed BLG-transgenic (T) and non-transgenic (NT) 
mice were immunised with ovine BLG+FCA and 7 days later 
challenged with PBS. 
(nos)= number of mice tested. 
Male mice suckled on BLG-containing milk (S) 
Female mice suckled on BLG-containing milk (S) 
LI Male mice suckled on "normal" mouse milk(NS) 
LIII Female mice suckled on "normal" mouse milk (NS) 
Error bars are + 1 SD 
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responses (p<0.01) as compared to transgenic females suckled 
on "normal" mouse milk. When experiments were analysed 
separately this observation was found in only one experiment. 
It was also observed in this experiment that non-transgenic 
females suckled on BLG-containing milk made significantly 
reduced T cell responses (p<O.Ol) to ovine BLG as compared to 
non-transgenic females suckled on "normal" mouse milk. Only 
two mice were assayed in this group. 
5.3) T cell responses in BLG-suckled and non-suckled 
G7 transgenic littermates. 
The data indicate that in most cases BLG-transgenic and non-
transgenic mice make comparable T cell responses following 
either a ovine or bovine BLG challenge suggesting that no T 
cell tolerance to BLG had occurred in BLG-transgenic mice. One 
hypothesis to explain this result was that any differences at 
the T cell level were difficult to detect due to the 
heterogeneous MHC composition of the offspring from the 
original crosses. The effects of this segregating background 
were reduced by backcrossing onto a CBA/Ca background. 
Heterozygous transgenic and non-transgenic backcrossed 
generation 6 (G6) mice were mated as described in Fig.4.7 (see 
Chapter 4). At three months of age G7 BLG-transgenic or non-
transgenic animals were immunised and challenged with 2% 
Hag ovine BLG as previously described. This experiment was 
repeated twice and Fig. 5.8 shows the T cell responses from 
the pool of these experiments and Fig. 5.9 the T cell responses 
of G7 mice challenged with saline. 
i) In vivo responses to ovine BLG. 
Backcrossing onto a CBA/Ca background resulted in both 
transgenic and non-transgenic mice making significant T cell 
responses (p<O.Ol) to a 2% Hag ovine BLG challenge as 
compared to saline challenged control mice. The T cell 
responses of the former experimental groups were equivalent. 
Suckling BLG-containing milk did not reduce the T cell 
response to this protein. In one experiment however (data not 
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shown) female non-transgenic mice suckled on BLG-containing 
milk made significantly lower T cell responses to ovine BLG 
than non-transgenic mice not exposed to this protein 
(p<0.001). This effect disappeared after data were pooled. 
5.4) T cell summary 
In some in vivo experiments BLG-transgenic mice had reduced 
T cell responses to ovine BLG as compared to their non-
transgenic littermates, however this was not the case in the 
majority of experiments. Even when mice were primed with 
ovine BLG and challenged with bovine BLG, which elicits better 
secondary footpad thickening, evidence for reduced T cell 
responses in BLG-transgenic mice was not found (data not 
shown, see Appendix 15). In vitro assays also indicated that no 
difference in the ability to respond at the T cell level was 
evident between BLG-transgenic and CBAICa mice. Taken 
together with the above information and the fact that 
transgenic and non-transgenic mice produce equivalent T cell 
responses to bovine BLG it can be concluded that use of the 
footpad thickening in vivo assay and in vitro lymph node 
proliferation assays provided little evidence for 
hyporesponsiveness at the T cell level in BLG-transgenic mice. 
137 
CHAPTER 6 
BONE MARROW STUDIES 
Bone marrow chimaeras have been used extensively to dissect 
B and T cell tolerance mechanisms and are used in this chapter 
to determine whether hyporesponsiveness is an intrinsic 
property of transgenic lymphoid cells or due to expression of 
the transgene in bone marrow, thymus or other sites in the 
periphery. Goodnow et al (1 988) have shown that both the HEL 
transgenic mice and double transgenic (Dbl-tg) mice 
expressing both HEL and anti-HEL antibody transgenes are 
tolerant at the antibody level to HEL. Using bone marrow 
chimaeras Adams et al (1990) demonstrated in this case that 
hyporesponsiveness was an intrinsic property of the lymphoid 
cells themselves. Tolerance to HEL was induced in non-
transgenic mice reconstituted with bone marrow from a Dbl-tg 
mouse even when primed T cells were also transferred. In 
contrast, bone marrow experiments performed by Nemazee et 
al (1 989) in another transgenic system showed that tolerance 
was not an intrinsic property of the transgenic bone marrow 
derived B cells. Bone marrow, depleted of T cells, from 
transgenic mice with B cells specific for H2Kk when 
transferred into an H20  mouse resulted in immunological 
tolerance to H21(k.  This was not the case when transgenic 
bone marrow was transferred into H.2Dd mice. 
Bone marrow chimaeras have also been used to investigate T 
cell tolerance within the thymus. These experiments 
highlighted the importance of bone marrow derived cells, 
located within the thymus, in the removal of self-reactive T 
cells and also provided evidence that thymic epithelial cells 
possessing self antigens can be responsible for T cell 
tolerance although through a process of anergy rather than 
deletion. All these experiments are described in detail in the 
introduction (see Chapter 1). 
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As described in Chapter 4, BLG-transgenic male and female 
mice are immunologically hyporesponsive to both ovine and 
bovine BLG at the antibody level. To assess whether this is an 
intrinsic property of the immune cells themselves, in that 
they are unable to respond due to the effects of the transgene 
on T and B cells development, or due to an environmental 
effect, expression of the transgene within the animal 
resulting in silencing of self-reactive T or B cell clones, bone 
marrow chimaeras were established (see Materials and 
Methods, Chapter 2). T cells were not removed from the bone 
marrow preparations. 
6.1) Male bone marrow chimaeras 
In the first set of these experiments offspring from Fl BLG-
transgenic X CBA/Ca, and the reciprocal crosses were used as 
both bone marrow donors and recipients, transgenic and non-
transgenic mice having been identified by PCR. 
Two experiments of this kind were set up. In the first the mice 
were 9 months of age; in the second the mice were younger, 
3-4 months old. Following 1 O.5Gy of gamma irradiation, 
recipient mice were given either 107  BLG-transgenic or non-
transgenic littermate bone marrow intravenously (see 
Materials and Methods, Chapter 2). 3 months later they were 
immunised and antibody titres analysed as shown in Figs 6.1 
and 6.2. 
In experiment one (Fig. 6.1), 6 groups of mice were set up 
including 4 control groups. Two of the control groups of mice 
received autologous bone marrow and were designated T+T 
(transgenic recipients given transgenic bone marrow) and 
NT+NT (non-transgenic mice given non-transgenic bone 
marrow). The other control groups (CBA/Ca and Fl BLG-
transgenic mice) did not receive any bone marrow and no 
irradiation. Experimental groups received heterologous bone 
marrow and were designated T+NT (transgenic mice 
reconstituted with non-transgenic bone marrow) and NT+T 
(non-transgenic mice reconstituted with transgenic bone 
marrow). 
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Three months following bone marrow reconstitution mice were 
immunised with ovine BLG and antibody responses analysed as 
described. T+T control mice made low primary anti-ovine BLG 
IgG antibody titres following the first immunisation (ranging 
from no detectable antibody to 0) whilst NT+NT control mice 
made detectable levels of antibody (one mouse had no 
detectable antibodies; in the other mice titres ranged from 2 
to greater than 5). Following a secondary immunisation there 
was a slight but significant increase in the secondary titres 
for the T+T (range 2 to 4, p<0.05) group and a much larger 
increase for the NT+NT group (range 9 to 11, p<0.01). A further 
increase in anti-ovine BLG IgG titres occurred following a 
third immunisation for the NT+NT group (titres were >11, 
p<0.01). Comparing these two groups indicated a significantly 
reduced antibody response at both the primary and secondary 
antibody level for the T+T groups, hence confirming that these 
mice are hyporesponsive to BLG. This was further confirmed by 
the controls in this experiment; unirradiated Fl BLG-
transgenic control mice were hyporesponsive compared to 
unirradiated CBA/Ca following each immunistion with ovine 
BLG. 
Reconstituting ovine BLG-hyporesponsive BLG-transgenic mice 
with bone marrow from mice already shown to be responsive 
to this antigen (T+NT group) did not result in mice capable of 
producing high primary and secondary IgG titres to ovine BLG. 
Comparing the primary and secondary anti-ovine BLG IgG titres 
of T+T and T+NT groups of mice revealed that each group of 
mice made equivalent responses after each immunisation. The 
responses of T+NT mice and Fl BLG-transgenic mice were also 
comparable. 
In contrast the injection of bone marrow from mice shown to 
be tolerent to BLG into mice that were capable of responding 
(NT+T group) demonstrated that in a non-transgenic 
environment bone marrow cells from BLG-transgenic mice 
developed normal antibody responses to ovine BLG following 
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primary and secondary anti-BLG IgG titres to those of NT+NT 
and CBA/Ca mice. 
The second experiment confirmed the observations above (Fig. 
6.2). In this experiment only comparisons of the primary (1st 
bleed) and the tertiary responses (3rd bleed) were made. No 
significant increase in anti-ovine BLG IgG titres occurred in 
the T+T and T+NT groups. However NT+NT and NT+T mice made 
significant secondary antibody response to ovine BLG (p<O.Ol). 
Since the original transgene founders were on a C57BL/6 X 
CBA/Ca heterozygous background it was possible that some 
histocompatibility differences between donor marrow and 
recipient occurred. Although at the gross level there was no 
evidence for graft vs host disease, the experiment above was 
repeated after the transgene had been backcrossed onto a 
CBA/Ca background. Bone marrow transplantation experiments 
were performed on backcross generations 5 and 6 (G5 and G6 
respectively) mice. 
In the first experiment (Fig. 6.3), irradiated 3 month old 
CBA/Ca mice were reconstituted with G5 transgenic (C+T) or 
non-transgenic (C+NT) bone marrow. Contol mice were given 
CBA/Ca bone marrow (C+C). Mice were immunised for 
responses to ovine BLG as described in the Materials and 
Methods, (see Chapter 2) and the titres following primary and 
secondary immunisation are shown in Fig. 6.3. 
A first immunisation with ovine BLG resulted in low levels of 
anti-ovine IgG titres (range for C+T was from no detectable 
antibody to 2, for C+NT the titre range was from no detectable 
antibody to 3 and from no detectable antibody to 4 for C+C). A 
secondary immunisation induced a significant increase in anti-
IgG titres for each group (C+T p<0.01, C+NT p<O.Ol and C+C 
p<O.Ol). This also occurred following a third challenge (C+T 
p<O.Ol, C+NT p<O.Ol and C+C p<O.Ol). 
Comparisons of the antibody responses of each group indicated 
that the three groups of mice made similar primary and 
secondary responses. Thus reconstituting mice capable of 
producing antibodies to BLG (CBA/Ca) with bone marrow from 
ifil 
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transgenic mice did not induce hyporesponsiveness to BLG; 
anti-ovine BLG lgG responses of C+T groups were equivalent to 
those of CBA/Ca mice reconstituted with CBA/Ca or non-
transgenic bone marrow. 
This experiment was repeated and the same observations were 
noted, see Fig. 6.4. In this experiment however transgenic and 
non-transgenic G6 mice were reconstituted with CBA/Ca bone 
marrow (T+C and NT+C, respectively). The T+C mice did not 
make significant secondary antibody response to ovine BLG 
whereas the opposite was seen for non-transgenic G6 
littermates reconstituted with CBA/Ca (NT+C, p<0.05). Non-
transgenic mice receiving CBA/Ca bone marrow thus made a 
greater secondary response to BLG than transgenic mice 
receiving CBA/Ca bone marrow (p<0.05). T+C mice also made a 
significantly reduced secondary antibody response in 
comparison to C+T mice (p<O.Ol). 
In conclusion, male BLG-transgenic mice remain 
hyporesponsive to ovine BLG despite being reconstituted with 
bone marrow from an animal already shown to be capable of 
mounting an immune response. However when bone marrow 
from animals (BLG-transgenic mice) shown to be non-
responsive to BLG was used to reconstitute mice not 
possessing the gene the hyporesponsiveness was abrogated. 
Hence, bone marrow derived cells from a transgenic mouse 
have the capability to respond to ovine BLG. Environmental 
effects such as the expression of the transgene either in bone 
marrow stroma or in the periphery lead to the silencing or 
deletion of cells capable of responding to this protein. 
6.2) Female bone marrow chimaeras 
Bone marrow transfer experiments were also carried out using 
female donor and recipient mice. In these experiments 
recipient and donor mice were from a G5 backcrossed 
population. Again control mice were given autologous bone 
marrow and these included C+C, NT+NT and T+T groups, whilst 
experimental mice were given allogeneic bone marrow. The 
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experimental groups were T+C and NT+C (transgenic and non-
transgenic mice reconstituted with CBA/Ca bone marrow), C+T 
and C+NT (CBA/Ca mice reconstituted with either transgenic 
and non-transgenic bone marrow respectively) see Fig. 6.5. 
The results are essentially similar to those described for male 
animals and confirm the necessity for non-lymphoid 
expression of the transgene to induce hyporesponsiveness. 
6.3) 	Conclusion 
The genotype of the recipient dictated the immune status of 
the animal for both male and female mice; transgenic mice 
given CBA/Ca or NT bone marrow 	remained 	significantly 
hyporesponsive to ovine BLG. In contrast CBA/Ca or NT mice 
given transgenic bone marrow remained as responsive to BLG 
immunisation 	as 	the non-irradiated 	controls. 
Hyporesponsiveness to BLG is 	thus 	not 	transferable 	with 
transgenic 	bone 	marrow. 	However in transgenic 	recipients 
BLG-reactive cells 	were "silenced" 	presumably 	by 
microenvironmental expression of the BLG protein. These data 
are discussed in Chapter 8. 
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CHAPTER 7 
ORAL TOLERANCE TO BOVINE BLG ADMINISTERED 
VIA VOLUNTARY INGESTION 
Milk proteins are capable of inducing systemic tolerance when 
they are ingested as part of an animal's daily diet [330-334] or 
when they are present in drinking water or given by 
intragastric intubation [334]. Mice feeding on a solid diet in 
which either casein or whey proteins were the only protein 
source developed oral tolerance to these milk proteins. The 
onset of tolerance to dietary antigens is rapid since a 3 day 
exposure to casein and whey containing solid food diets 
resulted in 80-90% suppression of both antibody and T cell 
responses [331, 332]. T cell unresponsiveness to casein 
induced by oral tolerance was directed to the immunodominant 
and not cryptic components of this protein [332]. Oral 
tolerance was also observed to trypsin digested casein [330]. 
Despite the tolerability of milk proteins given orally, no 
tolerance to ovine BLG occurred in mice suckled on ovine BLG-
containing milk at either the antibody (Chapter 4) or T cell 
level (Chapter 5). This suggested that a continuous oral 
challenge with ovine BLG postnatally was not sufficient to 
induce oral tolerance. 
It was not possible to test the ability of BLG to induce oral 
tolerance in adult CBA/Ca mice due to a limited supply of 
purified ovine BLG. Instead CBA/Ca mice were given 
commercially prepared bovine BLG dissolved in their drinking 
water for both short and long periods of time to test the 
tolerogenic nature of this protein when administered in this 
fashion. Tolerance was investigated at both the antibody level, 
by ELISA, and the T cell level, by DTH assays. 
7.1) Antibody Studies. 
Groups of mice were given either 25mgs or 50mgs/day of 
bovine BLG dissolved in sterile water. Mice were either 
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25 24(W+) 2 2 2 2 
50 24(W+) 2 2 2 2 
25 21(W+) 2 2 2 2 
50 21(W+) 3 3 2 2 
25 24(W-) 2 2 2 2 
50 24(W-) 2 2 2 2 
25 21(W-) 1 1 1 1 
50 21(W-) 2 2 1 1 
* Mice were provided with BLG in their drinking water at a 
concentration of 5mgs!mI and 1 Omgs/mI. The intake is 
calculated in the assumption that mice will drink approximately 
5mls of water per day. 
++= number of experiments, and the number of mice per group 
was usually about 5. 
TABLE 7.2. % survival of CBA/Ca control mice after a 
second immunisation 
MALE/FEMALE W+/W- % 
SURVIVAL 
M W+ 64.3 
F W+ 55 
M W- 30 
F W- 47.8 
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exposed for 24 hours or 21 days to this antigen. One half of the 
groups tested were on a diet known to contain bovine BLG 
(whey protein positive, W+) whilst the other groups were on a 
diet lacking this protein (whey protein negative, W-). The 
experimental regimens are summarised in Table 7.1. 
Each group of mice were immunised 3 weeks following the end 
of exposure to bovine BLG with 50pgs of BLG plus FCA and bled 
2 weeks later. Mice were immunised at this time with 2% heat 
aggregated BLG and bled a second time 7 days later. The 
antibody titres were measured by [LISA as described before 
and the titres for the primary and secondary immune responses 
of each mouse were plotted (see Figs 7.1, 7.2, 7.3 and 7.4). 
Control CBA/Ca mice, used in the bovine BLG feeding 
experiments, were given sterile water to drink and were 
either on a (W+) or (W-) solid food diet. Regardless of food, 
more control CBA/Ca mice suffered anaphylaxis and died 
following a second immunisation with bovine BLG (2% Hag 
bovine BLG) than those mice given BLG in their drinking water. 
The number of control mice that died differed from experiment 
to experiment but was of the order of 50%. The percentage 
survival data are shown in Table 7.2. This made statistical 
comparisons between control groups and experimental BLG-fed 
groups in individual experiments sometimes difficult. To 
overcome this problem the combined anti-BLG antibody 
response of each bovine fed group were compared with the 
pooled anti-BLG titres for all control CBA/Ca mice tested, 
using a Mann Whitney test. 
i) Female mice fed Bovine BLG. 
Experiments were set up in which female CBA/Ca mice (on 
either the W+ or W- diet) were fed either 25 or 50mgs of 
bovine BLG for 24 hours or 21 days. The antibody responses of 
these mice following each immunisation with bovine BLG are 
shown in Figs 7.1 and 7.2, respectively. 
The anti-BLG responses of BLG fed mice were compared with 
the anti-BLG responses of control mice to analyses the effect 
of feeding bovine BLG. The anti-BLG responses of mice fed for 
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24 hours or 21 days were also compared to analyse whether 
feeding this protein for a long period of time induced a greater 
degree of hyporesponsiveness. 
a) Comparison of the antibody responses in mice fed 25mgs of 
bovine BLG for 24 hours (25/24) or 21 days (25/21) (Fig. 7.1). 
W+ mice 
Both the primary and secondary anti-BLG responses of the 
25/24 group were equivalent to saline fed control mice. In 
contrast the anti-BLG responses of the 25/21 group were 
significantly lower than control mice (p<O.00l). Comparing the 
responses of 25/24 and 25/21 groups indicated that a longer 
exposure time to bovine BLG resulted in a greater degree of 
hyporesponsiveness following a primary (p<0.05) and 
secondary (p<0.01) immunisation. 
W- mice 
Comparing the primary anti-BLG responses of BLG fed mice and 
control mice indicated that the 25/24 group made a 
significantly lower response to this protein. This was not seen 
for the 25/21 group (p<001). 
Regardless of the exposure period to BLG, the combined 
secondary anti-BLG lgG response of W- mice were lower than 
the equivalent responses of control mice (p<0.001). 
Unlike the W+ mice a longer exposure time to bovine BLG did 
not result in a greater degree of hyporesponsiveness. 
b) Comparison of the antibody responses of mice fed 50mgs of 
bovine BLG for 24 hours (50/24) or 21 days (50/21) (Fig. 7.2). 
1) W+ 
Following a primary immunisation with bovine BLG, saline fed 
control and 50/24 mice made equivalent anti-BLG lgG 
responses. In contrast the primary responses of the 50/21 
mice were significantly lower than control mice (p<0.001). 
Following a second immunisation both these BLG fed groups 
made significantly lower anti-BLG responses (50/24 p<0.01 
and 50/21 p<0.001) than control mice. No difference was found 
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As above, the 50/24 group made equivalent anti-BLG lgG 
following a primary immunisation with bovine BLG to control 
mice. In contrast the primary responses of the 50/21 mice 
were significantly lower than control mice (p<0.01). Following 
a second immunisation both these BLG fed groups made 
significantly lower anti-BLG responses (50/24 p<0.001 and 
50/21 p<0.001) compared to controls. 
Mice fed 50mgs of bovine BLG for 21 days made significantly 
lower primary and secondary anti-BLG titres than those mice 
fed for 24 hours (p<0.01 and p<0.01, respectively). 
ii) Male mice fed bovine BLG 
Male CBA/Ca mice were also tested and data analysed as 
described above. 
a) Comparison of the antibody responses of mice 25mgs of 
bovine BLG for 24 hours (25/24 ) and 21 days (25/21) (Fig. 
7.3). 
1) W+ 
Following a primary immunisation only the 25/21 fed mice 
made significantly lower anti-BLG responses as compared to 
control mice (p<0.05). However following a second challenge 
both groups had reduced secondary anti-BLG responses as 
compared to control mice (25/24 p<0.01 and 25/21 p<0.01). 
As with the female antibody data, giving bovine BLG for 21 
days significantly reduced the primary (p<0.05) and secondary 
(p<0.01) anti-bovine BLG response as compared to feeding BLG 
for 24 hours. 
2)W- 
Following a primary immunisation only the 25/21 fed mice 
made significantly lower anti-BLG responses as compared to 
control mice (p<0.01) however following a second 
immunisation BLG fed and control mice made equivalent 
secondary anti-BLG responses. 
ii) Comparison of the antibody responses of mice fed 50mgs of 
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Giving mice 50mgs of bovine BLG for 21 days significantly 
reduced the primary anti-BLG responses in these mice 
(p<0.001). This did not occur in the 50/24 fed mice. Following 
a secondary immunisation with bovine BLG both the 50/24 and 
50/21 fed mice made significantly lower anti-BLG responses 
than control mice (p<0.001 in both cases). The 50/21 fed mice 
made significantly lower responses than the 24 hour fed mice 
(p<0.001 and p<0.01 for primary and secondary antibody 
responses, respectively). 
2)W- 
Male mice were fed bovine BLG for 24 hours. After a second 
immunisation the anti-BLG responses of these mice were 
significantly lower than control mice (p<0.05). 
7.2) Summary of antibody data 
Control mice that were not exposed to bovine BLG in their 
drinking water, respond to a second immunisation with this 
protein by producing antibody titres greater than the primary 
response (p<0.001). Although in some of the groups of mice 
given BLG orally (50/24 W- female, 25/24 and 50/21 W+ 
males) a significant (p<0.05, p<0,05 and p<0.01, respectively) 
increase in antibody titre followed a second immunisation, the 
titres of antibody never reached that of control mice. Thus 
introducing bovine BLG into the drinking water of CBA/Ca mice 
induced hyporesponsiveness to this protein, with the exception 
of the 25/24 W+ fed female mice. It was also noted that 
although a 24 hours exposure to BLG did induce 
hyporesponsiveness, a better suppression of the antibody 
response was seen after 21 days of oral administration. Both 
doses induced a similar level of suppression. 
Although hyporesponsiveness at the antibody level to BLG 
could be detected after oral administration the degree of 
antibody reduction was small compared to that induced by the 
presence of the BLG transgene (see Chapter 4). In the light of 
these observations it is perhaps not surprising that 
differences between suckling or not suckling of BLG-
containing milk were difficult to detect. 
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Fig. 7.5 T cell responses to bovine BLG of female 
CBA/Ca mice following voluntary ingestion 
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Fig. 7.6 T cell responses to bovine BLG of male 
CBA/Ca mice following voluntary ingestion of 
either 25 or 50mgs of bovine BLG. 
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7.3) T Cell Studies 
The presence or absence of T cell hyporesponsiveness 
following administration of bovine BLG to drinking water was 
tested using the footpad thickening assay, as previously 
described (see Chapter 2). Individual T cell responses are 
shown in Appendix 16. 
Comparison of the responses of female mice fed bovine BLG 
(Fig.7. 5) 
Although all W+ females fed bovine BLG mice had reduced T 
cell response to BLG only the 25/24, 50/24 and 50/21 groups 
were significantly hyporesponsive (p<0.05, p<0.05 and p<0.01, 
respectively) compared to control mice. The differences 
observed between these groups were however small and 
variable. 
In W- females mice differences between control and fed mice 
T cell responses were similarly small and variable. Feeding 
25mgs of BLG for 24 hours or 21 days resulted in a slight 
decrease in response but this was only significant following a 
21 day exposure (p<0.05). Significantly reduced T cell 
responses were also seen after feeding 50mgs for 21 days 
group (p<0.01). 
Comparison of the responses of male mice fed bovine BLG 
(Fig. 7.6) 
Although all W+ males fed bovine BLG had reduced T cell 
responses to BLG compared to controls a significant reduction 
in responsiveness was only observed following a 25mg/day 
bovine BLG fed over 21 days (p<0.05) and following a 50mg 
feed for 24 hours (p<0.05). 
Like the female data the differences between experimental 
animals and controls were small and variable. 
Unlike W+ fed mice, W- male mice exposed to BLG in drinking 
water made equivalent T cell responses to controls mice, the 
only exception being the 50/21 fed group. 
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7.4) Summary of T cell data 
Although following exposure to bovine BLG in drinking water 
induced reductions in T cell responses to bovine BLG, as 
compared to controls, the differences were very small. This 
indicates that BLG is probably not an ideal antigen for 




8.1) Immune responses to ovine BLG 
Antigens can be described as either immunogenic or antigenic, 
the latter describing the property of an antigen to combine 
with surface or secreted antibodies but not to elicit an 
immune response. BLG is in fact antigenic since in both ELISA 
and Western blotting experiments, antibodies to BLG recognise 
this protein following purification. To be immunogenic an 
antigen must elicit either an antibody and/or a T cell response 
[335]. In this study purified ovine BLG induced both antibody 
and T cell responses (Chapter 3) after priming with an 
adjuvant, confirming its immunogenicity. BLG did not induce an 
immune response without an adjuvant (data not shown). 
i) Antibody responses to BLG 
Antibody responses to bovine BLG have previously been 
documented [336]. In these studies four antigenic regions on 
the molecule were described. 3 out of 4 of these regions were 
contained in the structure of a turn or random coil between 3-
sheets and all 4 epitopes were present on the outside of the 
three dimensional structure. Unfolding the BLG molecule did 
not reveal other B cell epitopes. The B cell epitopes described 
were 21Ser-40Arg, 1 49Leu-1 62l1e, 1  °2Tyr-1 24Arg and 
41Val-601-ys [336]. 
In this study the antibody responses to ovine and bovine BLG 
were measured using an ELISA technique. CBA/Ca, BALB/c, 
CBA/Ca x C57BJ/6 Fl and C57BJ/6 mice were shown to 
develop secondary antibody responses to ovine BLG. The level 
of secondary antibody responses to ovine BLG was similar to 
the antibody titres following an OVA challenge. 
The immune response to bovine BLG was studied in CBA/Ca 
mice only. Good anti-BLG lgG antibody titres were observed 
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following secondary challenge with bovine BLG, confirming its 
immunogenicity (see above). 
In conclusion, the protein BLG derived from either sheep or 
cows' milk can induce antibody responses comparable to those 
seen for OVA following a secondary challenge. 
ii) T cell responses to BLG 
T cell responses to BLG were analysed using a footpad 
thickening, DTH, assay. The response was quantitated by 
subtracting the footpad thickness (of BLG primed mice) before 
secondary challenge with the footpad thickness 24 hours 
following BLG challenge. Control mice (also primed with BLG) 
were challenged with PBS. 
Development of a DTH response requires an initial 
sensitisation period of between 7 and 14 days. In this study 
the sensitisation period was either 7 days (Chapter 3 and 5) or 
14 days (Chapter 7). Increasing the sensitisation period in 
Chapter 7 did not result in greater T cell responses. 
Compared to control mice, good DTH responses were found to 
both ovine and bovine BLG in CBA/Ca mice and to ovine BLG in 
BALB/c, C5713J/6 and Fl mice. It was also noted that the T cell 
response to ovine BLG was significantly lower than the 
response to bovine BLG. Why should there be such a large 
difference when both ovine and bovine BLG are cross-reactive 
proteins as shown at the antibody level (see Chapter 4). 
Takahashi et al (1 988) [337] have investigated the 
proliferative responses of BLG primed lymph node cells from 
BALB/c mice to tryptic and chymotryptic fragments of bovine 
BLG. Bovine BLG T cell epitopes were located on the surface of 
the 3D molecule mainly in the p turn. These were 21Ser-40Arg, 
41Val-60Lys and 102Tyr-124Arg from tryptic digests whilst 
21Ser-31 Leu, 59Gln-82Phe and 123VaI-140Leu for 
chymotryptic fragments. T cell epitopes were similar to B cell 
epitopes [337]. 
4 bovine BLG specific T cell clones, with a CD4+ve phenotype, 
were isolated from BALB/c mice immunised with this protein. 
Two of these clones recognised a peptide containing residues 
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42-56 of bovine BLG. These residues along with residues 62-
76 and 1 39-1 53 are the major T cell determinants of bovine 
BLG in BALB!c mice [338]. 
The nucleotide sequence of bovine BLG gene has recently been 
described [339]. The complete gene is 4724 base pair long and 
is 89% homologous to the ovine BLG gene sequence with 
complete conservation of gene organisation and splice sites 
[339]. In an earlier study Alexander et al (1991) [340] found 
that there was a 91% similarity between the cDNA sequences 
of ovine and bovine BLG [340]. In contrast it has been described 
that the primary structure of BLG from other species shows 
large diversity with an overall homology of only 13% of amino 
acids [341]. If these differences in ovine BLG lie within any of 
the above bovine BLG T cell epitopes this could explain the 
difference in responsiveness between bovine and ovine BLG. 
Titus and Chiller (1981) [329] described footpad DTH 
responses to OVA, BSA and HGG. In these experiments BDF1 
mice were primed with 501igs of antigen subcutaneously at the 
base of the tail and challenged, 7 days later, with PBS in one 
foot and 2% heat aggregated antigen in the other footpad. The 
DTH response was measured by subtracting the footpad 
thickness following a PBS challenge from that following a 
heat aggregated challenge. This resulted in a 1.42, 2.15 and 
1.82 millimetre increase following OVA, BSA or HGG 
challenges respectively. As discussed above increased footpad 
thickening occurred following an ovine or bovine challenge 
however responses were not as impressive as the T cell 
responses to the forementioned proteins. Why should this be? 
Perhaps priming T cells with BLG protein is not as efficient as 
priming with OVA, BSA or HGG proteins. Also in the 
aforementioned experiments the level of response was a 
measure of the difference between the thickness of the PBS 
injected versus the protein injected feet of the same mice. In 
the present study the response was a measure of the increase 
in the protein injected foot. 
In conclusion, mice primed with either bovine or ovine BLG 
produce a secondary T cell response, as shown by the 
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measurement of a DTH response, compared to controls. Bovine 
BLG, however, appeared to induce a better T cell response than 
ovine BLG. 
iii) MHC haplotype influence on the immune response to BLG 
It has been shown that genes within the MHC can affect the 
response to a particular protein, see Chapter 3. Mice with 
different MHC backgrounds, H2k, H2b, H2d and H2kXb, were 
tested for both antibody and T cell responses to ovine BLG. All 
groups of mice, regardless of MHC background, made similar 
immune responses to ovine BLG (at the antibody and T cell 
level) and bovine BLG (at the T cell level). 
These data suggest that segregation of MHC genes during 
backcrossing of transgenic animals was unlikely to have had 
an effect on the development of immunity to BLG. 
8.2) The immune responses to BLG in BLG-transgenic 
mice. 
i) Antibody responses 
Both ovine and bovine BLG induce antibody responses in 
"normal" mice. This was not the case for mice carrying the BLG 
transgene. At the antibody level BLG-transgenic mice were 
hyporesponsive to both these proteins as compared to "normal" 
CBA/Ca mice and non-transgenic littermates. This immune 
hyporesponsiveness was not global since the responses of 
BLG-transgenic mice to a third party antigen, OVA, was 
similar to "normal" mice. Hyporesponsiveness could not be 
attributed to BLG gene expression during lactation since virgin 
male and female BLG-transgenic mice were tolerant to both 
bovine and ovine BLG. Subsequent pregnancy and lactation did 
not affect this tolerance since virgin and exbreeder BLG-
transgenic female mice made comparably low antibody 
responses to ovine BLG. 
Suckling on BLG-containing milk was also not the mechanism 
for this tolerance since BLG-transgenic male and female 
offspring suckled on "normal" mouse milk were as 
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hyporesponsive as those offspring suckled on BLG-containing 
milk. 
It was concluded that tolerance was due to the possession 
and/or expression of the BLG transgene. This was confirmed by 
bone marrow chimaera experiments. Transferring bone marrow 
from CBA/Ca or non-transgenic mice into lethal irradiated 
transgenic mice did not abrogate antibody tolerance in the 
recipient mice. In contrast, transfering bone marrow from 
BLG-transgenic mice into lethally irradiated CBA/Ca or non-
transgenic mice did not abrogate the responsive status of the 
recipient mice. 
Although antibody hyporesponsiveness was observed in BLG-
transgenic mice a 100% antibody suppression level was never 
achieved. Recent findings indicate that tolerance to 
immunodominant epitopes of HEL but not to the subdominant 
epitopes of this molecule can occur [342]. Low levels of 
antibody in the BLG-transgenic mice might be to the 
subdominant epitopes. It is also possible that the antibody 
responses were to other milk proteins contaminating purified 
BLG samples (see Chapter 2). 
ii) T cell responses 
Unlike the antibody data, T cell hyporesponsiveness to either 
bovine or ovine BLG was not evident. BLG-transgenic mice 
made comparable T cell responses in vivo and in vitro to both 
these proteins as compared to CBA/Ca mice and non-
transgenic littermates, although the attempts to detect T cell 
tolerance to this protein were against a background of 
intrinsically low normal responses. 
The role of T cells in the hyporesponsiveness at the antibody 
level will be discussed below. 
8.3) Peripheral expression of milk proteins. 
If T cell tolerance is responsible for the observed antibody 
hyporesponsiveness in the BLG-transgenic mice then the 
question arises as to where the BLG-transgene was expressed. 
Transgene expression in either the thymus or in peripheral 
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tissues, such as the liver or kidneys, has been shown to induce 
tolerance in transgene specific T cells (see Chapter 1). 
Various groups have created transgenic mice expressing milk 
proteins (rat and goat p casein, cow and guinea pig a 
lactalbumin, and mouse and rat WAP) under the control of their 
own 5' promoter and 3' flanking regions, or non-milk proteins; 
al antitrypsin, human a) tissue plasminogen activator, b) HG, 
c) oncogene products, d) serum albumin, e) IFNy and 
chioroamphenicol acetyl transferase (CAT)) under the control 
of 5' promoter regions of various milk protein genes. Although 
expression of these proteins should have been tissue specific, 
i.e. restricted to mammary gland tissue expression in other 
tissues was observed (see Table 8.1). 
Analysis of the peripheral expression of BLG in various BLG-
transgenic lines [293], carrying the native BLG gene and 4.3kb 
5' promoter and 7.3kb 3' flanking regions, has shown that BLG 
mRNA was present only in the mammary glands of BLG-
transgenic mice, at low levels in virgin mice [310] and not in 
the kidneys, spleen, liver and lachrymal glands of lactating 
mice. In my study no BLG mRNA expression was evident in the 
lymph nodes of virgin BLG-transgenic mice. Barashi et al 
(1 994) [343] also created ovine BLG transgenic mice. These 
mice expressed the native ovine BLG gene under the control of 
either a 3 or 5.5kb BLG promoter along with 3' flanking 
regions. They also found that BLG mRNA expression was 
limited to the mammary gland tissue and that brain, kidney, 
skeletal muscle, skin and salivary gland tissue of virgin and 
lactating transgenic female mice were negative for the 
transgene expression. 
Therefore in contrast to transgenic mice expressing 'foreign' 
WAP, casein and a lactalbumin, the BLG transgene, under the 
control of its own 5' promoter and 3' flanking regions, is 
tissue specific, i.e. restricted to the mammary secretory 
epithelial cells [310]. These data suggest that the BLG gene 
construct used to generate the mice in my study appears to 




MILK THYMUS NON- METHOD 	OF REF 
TRANSGENE EXPRESSION MAMMARY TRANSGENE 
PROMOTER TESTED TRANSGENE DETECTION 
EXPRESSION  
Rat WAP + Kidney RNAase Bayna 	and 
protection Rosen 
(1 990)[368] 
B o v i n e 	a - Testis (male) Northern Vilotte 




gland (female)  
Rat pcasein + Brain RNAase Lee 
protection (1 988)[370] 
Guinea 	pig a + Skin , 	salivary Northern Maschio 
lactalbumin gland, 	heart, Blotting (1 99 1 )[37 1] 
I u ng( lactating 
female)  
Ovine BLG - NONE Northern Barashi 
Blotting (1 994)[343] 
Ovine BLG - NONE Northern Simons 
Blotting (1 987)[293] 
Ovine BLG - NONE Northern Harris 
Blotting (1 99O)[31 1] 
Goatpcasein + Skeletal Northern Roberts 




Goatf3casein + skin (lactatingNorthern Persy 
female) Blotting (1992)[373] 
Murine WAP + Salivary gland Northern Wall 
Blotting (1991 ){3741 
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However in contrast to the "native" BLG-transgenic mice, 
ectopic expression of the human serum albumin (HSA) gene 
under the control of either 3, 5.5, 1 0.8kb of 5' BLG promoter 
regions has been shown [343]. Lactating BLG/HSA transgenic 
females express HSA in their milk. In these mice the BLG/HSA 
construct was not exclusively expressed in the mammary gland 
secreting epithelial cells but was also present in skeletal 
muscle, kidney, brain, spleen, salivary gland and skin of 
lactating transgenic female mice. Mice that did not produce 
HSA in their milk did not have ectopic expression. Unlike 
female mice, HSA transcripts were found in the kidney or the 
salivary gland of 2 lines of transgenic male mice suggesting 
that this ectopic expression was hormonally regulated. 
Ectopic expression of proteins under the control of milk 
protein 5' promoter regions is not unique to the BLG/HSA 
transgenic mice, see Table 8.1. Ectopic expression of supposed 
tissue specific proteins has been explained as being due to the 
interaction of the elements of the BLG (or other milk protein) 
5' flanking promoter region and the HSA (or other proteins) 
sequences, resulting in a unique pattern of expression that 
differed from the original genes. It also suggests that the 3' 
flanking region and the BLG gene itself were important for 
mammary specific expression. 
8.4) Thymic expression of milk proteins 
Some authors (Table 8.1) analysed transgene expression in the 
thymus of their transgenic animals via Northern blotting and 
RNAase protection assays. Thymic expression was only found 
in two cases. Lee et al (1 989) [354] found thymic expression of 
CAT in the thymus of mice expressing CAT under the control of 
the rat 3 casein regulatory elements, whilst Husbands et al 
(1992) [196] and Sponaas et al (1994) [176] found thymic 
expression of H2Kb under the control of the 5' flanking 
regions of guinea pig a lactalbumin. Thymic expression of a 
transgene under the control of non-milk promoters, for 
example, liver [358] or pancreas [359] specific promoters, has 
also been shown via Northern blotting. These models suggest 
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TABLE 8.1 CONT 
MILK THYMUS NOW METHOD 	OF REF 
TRANSGENE EXPRESSION MAMMARY TRANSGENE 
PROMOTER TESTED TRANSGENE DETECTION 
EXPRESSION  
BLG/cil - Salivary gland Northern Archibald 
antitrypsin  Blotting (1 990)[375] 
BLG/HIFNy + NONE Northern Dobrovolsky 
Blotting (199 3)[347] 
BLG/HSA - Skeletal Northern Shani 
muscle 	and Blotting (199 2)[376] 
kidney  
BLG/HSA - Brain, 	spleen, Northern Barashi 
salivary gland, Blotting (1 994)[343] 
skeletal 
muscle, 
kidney, skin of 
lactating 
females 
Guinea 	pig a + Skin 	and RNAase Husband 
lactalbumin thymus protection (199 2)[196] 
/ H -2 Kb  
R a t 	13 + Thymus 	of CAT assays Lee 
casein/CAT virgin 	and (1 989)[344] 
lactating 
females 
Murine - Brain RNAase Andres 
WAP/HaRas protection (1987)[377] 
oncogene  
Murine - Bergman cells Northern Grunzburg[37 
WAP/HHG in the brains of Blotting 8] (1991) 
lactating 
females 
Murine + Tongue, RNAase Pittius 
WAP/Human kidney, protection (1 988)[379] 
tissue subingual gland 
plasminogen in 	lactating 
activator females 	and 
virgin 	male 
and females  
that the tissue-specificity of a transgene is sufficiently 
'leaky' to allow thymic expression. 
Other authors did not investigate whether transgene 
expression was evident in the thymus of their transgenic 
animals (see Table 8.1 cont). For example Barashi et al (1994) 
[343] did not investigate thymic expression of BLG, or 
BLG/HSA in "native" BLG and BLG/HSA transgenic mice and 
thymic expression was also not originally analysed in the 
ovine BLG-transgenic mice, carrying the native BLG gene (4.3kb 
5' promoter and 7.3kb 3' flanking regions) used in my study 
[293]. Although no thymic expression of BLG/HIFNy was found 
[352] it is possible that thymic expression of BLG might occur 
since mammary-specific transgene expression is leaky, as 
described above, and since thymic expression of the VSV 
glycoprotein (VSV-GP) was found in BLG/VZV-GP transgenic 
mice (Steinhoff et al, unpublished data) 
In the present study, thymus tissue from virgin male and 
virgin and lactating female BLG-transgenic mice was analysed 
for BLG mRNA expression. Total RNA was extracted from these 
tissues and, following gel electrophoresis and Northern 
blotting, probed with 32P labelled BLG cDNA [293]. No thymic 
expression of BLG mRNA was observed in any of these tissues, 
even after long autoradiograph exposure. Thymic expression of 
BLG protein was also not found (data not shown) and taken 
together these data indicate that BLG is not expressed 
intrathymically. It is however possible that these assays are 
not sensitive enough to detect very low levels of the BLG-
transgene expression in the thymus. Low levels of the T 
antigen (Tag) mRNA, under the control of the rat insulin 
promoter, were found in the thymus of Tag transgenic mice 
even though expression was directed to the pancreas [360]. 
Low levels of the transgene expression, 3000-10,000  times 
lower than that of pancreatic B cells, were revealed using RT-
PCR, a more sensitive technique than other RNA detection 
systems. Future experiments should include RT-PCR assays of 
thymic RNA isolated from the" both BLG-transgenic and CBA/Ca 
control mice. 
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Husbands et al (1992) [196] were able to confirm thymic 
expression of H21(b in mice transgenic for this protein 
through the use of thymic chimaeras. Thymectomised H2Kk 
mice were given T cell depleted H2Kk bone marrow and either 
an H2Kk or an H21(b, non-transgenic or transgenic adult 
thymus, respectively, under the kidney capsule. 90 days later 
mice were given a H21(b skin graft. Only those mice given the 
H2Kb transgenic thymus accept the graft. A similar 
experiment could be set up using the backcrossed BLG-
transgenic and non-transgenic mice except the test for 
tolerance would be the absence of BLG-specific antibody 
following immunisation. This experiment could be simplified 
by using CBAICa nude mice given 2' deoxyguanosine treated 
transgenic and non-transgenic thymi under the kidney capsule 
such that host derived T cells developed in the donor thymus. 
Again the test of tolerance would be the absence of BLG-
specific antibody following immunisation. 
Is tolerance to BLG due to peripheral expression of this 
transgene? Soluble peripheral antigens can reach the thymus 
[162, 342, 361] and either induce tolerance [162, 342] or have 
no effect [361]. Low doses of HEL (blood levels >lOng/ml) 
induced T cell tolerance to HEL and the immunodominant HEL 
peptide whilst 200ngs/ml of soluble H2Kk did not. Tolerance 
therefore not only depends on the amount of protein in the 
serum but on the nature of the protein. The experiments in my 
study do not rule out the possibility that small amounts of 
soluble BLG reach the thymus where they may or may not have 
an effect. The RNA data however indicate that circulating 
protein concentrations would be extremely low. 
8.5) T cell tolerance hypothesis 
IL]IH1 vs  TH2 
BLG was described earlier as a T dependent antigen, implying 
that B cells required T cell help before they could produce 
antibody to this protein. The lack of antibody but not T cell 
responses to both ovine and bovine BLG in the BLG-transgenic 
mice suggests that no T cell tolerance had occurred. However 
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it is possible that differences in tolerogenic susceptibility 
occurred at the level of CD4+ve T helper cell subsets in these 
mice. For example, TH2 cells but not TH1  cells may have been 
tolerised in these transgenic mice. 
TH1 cells have been described as the T helper cell subset 
responsible for in vivo DTH responses [362] and in vitro lymph 
node proliferation following a subcutaneous challenge with 
FCA plus antigen [363]. Since T cell responses in my study 
were measured using in vivo DTH responses and in vitro lymph 
node proliferation assays, following subcutaneous priming 
with BLG plus FCA, it is possible that the T cell responses 
noted in BLG-transgenic, CBA/Ca and non-transgenic mice 
were due to TH1 priming. It is also possible that in the 
transgenic mice this helper T cell subset was refractory to 
tolerance induction. 
Priming of TH2  cells, on the other hand, occurs following 
immunisation with an antigen in Alum. For example, CBA/H 
mice given primary and secondary immunisations with 501jgs 
of BSA in Alum produced IgGi antibodies [364] characteristic 
of a TH2 response. Since immunisation with BLG plus Alum 
resulted in the absence of a T cell dependent antibody response 
in BLG-transgenic mice this T helper cell subset maybe 
susceptible to tolerance. 
Differences in the susceptibility of CD4 subsets to tolerance 
induction have been published [365-367]. The experiments in 
these papers suggest that it is the TH1  and not the TH2  cells 
that are susceptible to tolerance: however this conclusion is 
derived from experiments in which tolerance was induced 
peripherally. In my experiments any possible TH2 tolerance 
would have to be either due to thymic or unspecified 
expression of the transgene. 
Immunisation (ip) or (iv) with either deaggregated soluble 
human gamma globulin, dHGG, [367] or UV-inactivated Theilers 
murine encephalomyelitis virus [365, 366], respectively, 
resulted in antigen-specific unresponsiveness of the TH1  cells 
as shown at the cytokine level. In contrast priming of TH2 
cells was observed [366]. Differences in tolerance 
160 
susceptibility at the TH subset level were also described by 
Gilbert et al (1 990) [368]. Following in vitro stimulation with 
fixed APCs, that had been preincubated with HGG (to allow 
processing and presentation of HGG peptides) TH2 cells but not 
TH1 cells made proliferative responses to HGG presented by 
freshly isolated APCs. Although the response of TH2  cells was 
not affected, their ability to support B cell antibody 
production was tolerised. This may explain why T cell 
responses following an BLG/Alum subcutaneous injection were 
found despite the lack of antibody production. Although Gilbert 
et al (1 990) [368] ruled out the possiblity that TH1  and  TH2 
cells recognised different HGG epitopes, since Vp expression 
on HGG specific TH clones were markedly heterogeneous, the 
possibility that TH1 and  TH2  cells recognise different 
epitopes of bovine and ovine BLG can not be ruled out. 
Although TH1  and  TH2  cells participate in antibody production, 
it is possible that the response to BLG is predominantly a TH2 
phenonomen. Cher and Mossman (1 987) [362] have suggested 
that some antigens appear to preferentially induce one or 
other or both TH1  and  TH2  cells. In the present study the 
antibody isotype profile was not analysed so it is not known 
which T cell subset(s) were induced following BLG 
immunisation. Future experiments investigating the isotype 
profile, particularly concentrating on the IgGi, TH2  antibody 
responses verses lgG2a, TH1  antibody responses, of the 
immune response to BLG in CBA/Ca, non-transgenic and BLG-
transgenic mice would help to clarify this point. If the above 
hypothesis was correct the predominant class of antibody 
produced following a secondary challenge in CBA!Ca and non-
transgenic mice would be IgGi, while the antibody profile for 
BLG-transgenic mice would lack this isotype, regardless of the 
adjuvant used during challenging. 
Hyporesponsiveness at the antibody level was not 100% in the 
BLG-transgenic mice. It is possible that this is due to the 
priming of non-tolerant TH1  cells following an Alum challenge. 
Bomford (1980) [364] found that the secondary response of 
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BSA plus Alum resulted in both lgGl and IgG2a responses. 
Again, future experiments would investigate this point. 
Although the above are attractive theories preliminary 
experiments have shown that BLG-transgenic mice immunised 
with ovine BLG plus FCA, intraperitoneally, remained 
hyporesponsive at the antibody level as compared to non-
transgenic mice (data not shown). Although this supports the 
hypothesis that T cells are not rendered hyporesponsive in the 
BLG-transgenic mice it also supports the hypothesis that T 
cell tolerance in these mice may be at the TH2  subset level 
since immunisation with FCA may not stimulate TH2 cells 
involved in the response. 
ii) Possible mechanisms of T cell tolerance. 
Thymic involvement in the antibody hyporesponsiveness to BLG 
in BLG-transgenic mice cannot be ruled out. If tolerance was 
achieved at the level of the thymus what mechanism(s) would 
be involved? Tolerance in the thymus has been attributed to 
deletion of self-reactive cells through expression of a self 
antigen on thymic stromal cells. Anergy can also occur when 
antigen is encountered on these cells. Thymic epithelial and 
bone marrow-derived cells have also been shown to induce 
tolerance via deletion [191-193], anergy [177, 189] and down 
regulation of TCR and CD8 molecules [196, 197]. Recent work 
suggests that thymic epithelial cells can also induce tolerance 
to Class 2 presented antigens. 
Husbands et al (1992) [196] created transgenic mice 
expressing H21(b under the control of the guinea pig a 
lactalbumin promoter elements. These mice were tolerant to 
this alloantigen, tolerance being attributed to thymic 
expression of the H21(b transgene. Sponaas et al (1994) [176], 
through the use of bone marrow chimaeras, indicated that 
unlike bone marrow-derived cells, radioresistant cells 
(presumably epithelial cells) in the thymus of these mice were 
responsible for this tolerance. Crossing these mice with H21(b 
specific TCR transgenic mice indicated that tolerance 
occurred late in development through deletion of self-reactive 
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cells since large numbers of DP cells expressing the anti-H-
21(b transgenic receptors were present whilst CD8+4- TCR 
transgenic cells were absent. Deletion of these cells was 
attributed to transgene expression in the medullary epithelial 
cells [176]. 
Bone marrow chimaera experiments in this thesis also agree 
with the above bone marrow chimaera findings; that 
transgenic radioresistant cells rather than bone marrow-
derived cells are responsible for tolerance since transfer of 
BLG-transgenic bone marrow into either lethally irradiated 
non-transgenic littermates or CBA/Ca mice resulted in no 
antibody tolerance. Transferring non-transgenic or CBA/Ca 
bone marrow into lethally irradiated BLG-transgenic mice 
resulted in tolerance. It is possible that developing non- 
transgenic T cells are rendered tolerant to BLG expressed on 
thymic epithelial cells. Deletion of BLG-reactive T cells could 
not be analysed in the present study. CD4+ve T cell clones that 
recognise bovine BLG have been isolated from immunised 
BALB/c mice [338]. Sequencing TCR genes of these clones may 
facilitate the production of anti-BLG TCR transgenic mice 
which would allow the derivation of double transgenic animals 
with which to analyse thymic tolerance to BLG. 
The expression of a self protein on thymic epithelial cells has 
also been shown to induce a state of 'split-tolerance' [194, 
195]. Split-tolerance results in unresponsiveness in vivo but 
not in vitro. If thymic epithelial cells are responsible for the 
BLG-transgenic T cell tolerance, 'split-tolerance' may also 
occur in these mice. Split-tolerance might result in the 
deletion of high affinity TH2  cells, which might explain the 
reduced anti-BLG responses in these mice, whilst low affinity 
TH1 cells escape tolerance, which might explain the T cell In 
vitro activation following BLG stimulation. 
Tolerance to transgenes outwith the thymus has been 
documented and is known as peripheral tolerance. Can 
systemic tolerance occur as a result of specific expression of 
the BLG transgene in the mammary gland secretory cells? To 
date tolerance induced by exclusive transgene expression in 
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the mammary gland has not been documented. Peripheral 
tolerance, even after in vivo priming, to MHC class 1 and 2 as 
well as viral protein transgenes expressed in liver, pancreas, 
erthyroid, neuroectodermal or epithelial cells (see Chapter 1) 
however has been established. These data suggest that 
peripherally expressed transgenes were both accessible to the 
immune system and tolerogenic. Virgin and pregnant BLG-
transgenic mice express BLG mRNA at either very low or high 
levels in the mammary gland respectively. Although sections 
of mammary tissue from both virgin and lactating BLG-
transgenic mice were not tested for T cell infiltrates, the lack 
of tissue damage and the absence of mammary tumors 
suggests that at both low and high levels of expression, the 
BLG-transgene did not induce any autoimmune infiltration. The 
absence of an autoimmune response in the mammary tissue is 
not due to this organ being an immunologically privileged site 
since; 1) following infusion of sheep mammary glands with 
killed Staphylococcus aureus or OVA Class 2 +ve B cells, CD4 
+ve and CD8+ve cells were found [369, 370] and 2) lymphocytes 
from the Peyers' patch have been shown to migrate to the 
mammary gland with an influx of IgA-producing cells during 
late pregnancy and early lactation [371]. 
If tolerance to BLG is a peripheral phenonomen the mechanism 
of tolerance is unknown. It is possible that BLG produced in the 
virgin mammary gland is taken up by non-professional antigen 
presenting cells (APCs) surrounding the mammary tissue 
which home to the local lymph node. Presentation of antigen by 
non-professional APCs may induce tolerance via anergy. The 
absence of any detectable protein and extremely low or absent 
levels of mRNA in virgin female and male transgenic animals 
make this explanation unlikely. 
8.6) B cell tolerance hypothesis 
An alternative explanation for the described antibody 
hyporesponsiveness is that tolerance is at the level of the B 
cell. B cell tolerance to proteins has been documented (see 
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Table 8.2 B cell tolerance 
ANTIGEN FORM 	OF B 	CELLS T 	CELLS 
ANTIGEN PRESENT! HELP 
(promoter) RESPONSIVE  
VSV-G Membrane  
(SV40)  
VSV-G Membrane (H-  
2Kb)  
H2Kk Membrane -I- - 
HEL 	 1 Soluble  
HEL I Membrane -I- - 
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Chapter 1) although this tolerance has been found to co-exist 
with T cell tolerance (see Table 8.2). One example of this is 
described in experiments with soluble HEL transgenic mice. 
Immunising these mice with HEL coupled to SRBC resulted in 
reduced (by 50 fold) anti-HEL responses whilst anti-SRBC 
responses were similar to that of controls. Since T cells in 
these mice were tolerant to HEL coupling HEL to SRBC provided 
alternative T cell help to HEL-specific B cells. 
Recently B cell tolerance in the absence of T cell tolerance has 
been documented [372]. Ryelandt et al (1 995) [372] noted that 
offspring suckled on dHGG-containing mother's milk did not 
produce anti-HGG-specific antibodies when challenged with 
the immunogenic forms of HGG plus FCA in adulthood. In 
contrast anti-HGG-specific T cells responses occurred 
following immunisation with either the immunogenic forms of 
HGG or with haptenated HGG. Non-tolerant HGG specific T cells 
produced a cytokine profile characteristic of both a TH1  and 
TH2 response. B cell tolerance in the absence of T cell 
tolerance was confirmed by experiments where T cells had 
been depleted via anti-CD3 treatment. B cell tolerance to dHGG 
occurred in the absence of T cells. 
B cell tolerance occurs through either deletion or anergy, the 
general consensus being that clonal deletion occurs when B 
cells encounter membrane bound (multivalent) antigen whilst 
functional silencing or anergy, occurs when B cells encounter 
soluble (monovalent) antigen. If B cell tolerance does exists in 
BLG-transgenic mice which of these mechanisms results in 
tolerance? Anergy has been shown to occur when self-reactive 
B cells encounter large concentrations of soluble self antigen, 
for example HEL (see Chapter 1). No evidence for soluble BLG 
was found in these mice (data not shown) making the observed 
tolerance unlikely to be via anergy. However anergy can occur 
following interaction with membrane proteins which are at 
low density, for example VSV-GP (see Chapter 1). Mice 
transgenic for VSV-GP are tolerant at the antibody level 
perhaps due to transgene expresson in the kidney, heart, 
thymus, brain, liver and CNS. As mentioned earlier no 
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expression of BLG on various tissues was evident although it 
is possible that these tests were not sensitive enough to 
detect very small amounts of protein. It has also been 
demonstrated via irradiation chimaera studies that anergy is 
an intrinsic property of the tolerant B cells such that 
tolerance is transferable. In my study tolerance was not 
transferable, although bone marrow rather than spleen cells 
were being transferred. 
B cell tolerance in the BLG-transgenic mice maybe attributed 
to deletion of BLG-specific B cells. Clonal deletion of B cells 
occurs when immature B cells encounter antigen in the bone 
marrow; for example, membrane bound H2Kk and membrane 
HEL induce the deletion of antiH2Kkspecific B cells and 
anti-HEL -specific B cells respectively (see Chapter 1). If B 
cells are being deleted in BLG-transgenic mice it is possible 
that this is a result of BLG transgene protein expression 
within the marrow stroma. However no data on BLG mRNA 
expression in the bone marrow is available to date. Deletion 
has also been shown using bone marrow chimaera experiments. 
For example, transferring bone marrow from mice expressing 
transgenic antiH21(k lg into H2Kk mice resulted in deletion 
of antiH2Kk specific B cells. Transferring bone marrow from 
anti-HEL mice into HEL expressing mice resulted similarly in 
deletion of HEL-specific B cells. In my bone marrow chimaeras 
B cell tolerance occurred if haematopoietic cells were placed 
in a BLG-transgenic host. This result is similar to those 
described above suggesting that the absence of a BLG-specific 
antibody response maybe due to deletion of B cells within the 
bone marrow. 
Published data on B cell tolerance has relied on transgenic 
mice in which all B cells expressed a particular antigen 
specific idiotype (see Chapter 1). Unlike the B cells in these 
mice, B cells in the BLG-transgenic mice are not a monoclonal 
population making investigation of the tolerogenic mechanism 
difficult. 
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8.7) Is BLG an oral tolerogen? 
Experiments in which newborn mice were exposed to antigens 
orally during the neonatal period have suggested that priming 
rather than tolerance occurs following exposure to an antigen 
in the first few days of life [262, 373-375]. Adult mice fed 
OVA (1 mg/g of body weight) on the first day of life made 
enhanced antibody responses to OVA following parenteral 
immunisation compared to saline fed controls [262, 374]. 
Tolerance was established if mice were fed OVA from day 7 
onwards [374] or after day 10 of life [2621. Continuous 
exposure however from days 1-4 or 1-14 [262] resulted in 
suppression of both antibody and T cell responses; continuous 
exposure affecting the T cell more than the antibody response. 
HGG has also been shown to induce effective oral tolerance 
[374, 3761. In contrast to OVA no priming occurred when 
similar doses of HGG (lmg/g of body weight) were fed to 1 day 
old mice: a reduction in the dose to lpg/g was necessary to 
produce this effect [374]. 
In the above experiments antigen was administered through an 
intragastric tube. Oral tolerance in neonatal mice has also 
been shown through a more "natural" system' i.e. suckling 
antigen contained in their mother's milk [374, 376, 377]. 
Deaggregated HGG [374, 376] and deaggregated OVA [374] were 
injected into female mice 24 hours [374, 376] or 3 days 
postnatally [374]. Tolerance to both proteins, as seen by the 
lack of antibody responses in suckled mice following 
parenteral immunisation, was observed [374, 376]. Tolerance 
in these cases was due to the absorption of antigenically 
intact protein after suckling, since 0.3-0.6mgs/ml of HGG was 
found in neonatal circulation. Tolerance was also specific 
since HGG-suckled mice responded to a non-specific antigen 
(bromine treated RBC) to the same extent as non-suckled mice. 
Tolerance to sheep RBCs has also been shown in mice suckled 
on RBC containing mother's milk [374]. 
Taken together these data suggest that oral tolerance can 
occur in neonatal mice either fed antigen intragastically or 
through suckling. 
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Oral administration of protein to adult mice also results in 
systemic tolerance. For example, 25mgs of OVA dissolved in 
saline, administered intragastrically resulted in up to 93% lgG 
suppression [266, 288] and 97% T cell suppression [266, 288] 
The dose of antigen given has been shown to be important 
[290]: a 5-25mgs OVA feed induced both DTH and anti-OVA 
hyporesponsiveness whereas a 1-2mg OVA feed resulted in 
significant antibody but not DTH suppression in BALB/c mice. 
A low dose of OVA, 100 or 500pgs, suppressed neither the 
antibody nor the T cell responses, whilst 1 Opgs resulted in 
priming of the DTH, but not antibody responses. 
OVA administered orally is taken up rapidly by the gut [261, 
266, 287]. Sera taken 5 and 60 minutes from mice fed 25mgs 
of OVA, contained 44ngs/ml and 74ngs/ml of OVA respectively 
[287]. Injecting sera taken 5 minutes following an OVA feed 
into naive recipient mice did not affect the antibody or DTH 
responses to injected OVA in these mice. On the other hand 
sera taken after 60 minutes suppressed DTH responses to OVA 
[287]. These data suggested that processing of an antigen is 
important for tolerance induction. 
Ovine BLG-transgenic mice producing a foreign protein in high 
concentrations in milk, allowed the effect of administering 
protein through a "natural" oral route to be analysed. Crosses 
of BLG-transgenic X CBA/Ca mice were set up such that both 
transgenic and non-transgenic offspring were suckled on 
either BLG-containing milk or "normal" mouse milk from 
lactating BLG-transgenic or CBA/Ca mothers respectively. 
Offspring were suckled on their mothers milk for 21 days 
before being weaned onto a diet containing or lacking bovine 
BLG. As mentioned above continuous feeding of OVA from day 
1-14  of life and suckling on HGG containing milk resulted in 
antibody and T cell tolerance. It was thus hypothesised that 
continuous exposure to BLG, for 21 days, would have the same 
effect. Mice were challenged at 3 months of age with ovine 
BLG 	plus Alum intra peritonea lly for antibody responses or 
with ovine BLG plus FCA subcutanously for T cell responses. 
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Although significant systemic hyporesponsiveness, at both the 
antibody and T cell level, occurred following oral 
administration of bovine BLG to adult CBA/Ca mice (see 
below), no evidence for oral tolerance to ovine BLG was 
observed in mice suckling on ovine BLG-containing milk. The 
antibody responses in both non-transgenic mice suckled on 
either BLG-containing or "normal" milk made equivalent 
responses with the exception of non-transgenic females in one 
experiment only (Chapters 4 and 5). Suckling BLG-containing 
milk did not affect the hyporesponsive seen for BLG-
transgenic mice. At the T cell level, as measured by DTH 
responses, no tolerance was found; non-transgenic mice 
suckled on either BLG-containing or "normal" milk made 
equivalent DTH responses to BLG. 
Although mice were exposed to ovine BLG within the first 24 
hours of life no priming of either the antibody or T cell 
responses was evident. This was further shown via cross-
fostering experiments. Neonatal mice were suckled on BLG- 
containing milk or "normal" mouse milk for the first 4-6 days 
of life before being cross-fostered on to lactating mother 
producing "normal" mouse milk or BLG-containing milk 
respectively. In this experiment (data not shown) exposure to 
BLG early in life did not result in either priming or tolerance. 
Why did the exposure of neonatal mice to ovine BLG for the 
first 21 days of life not induce oral tolerance at both the 
antibody and T cell level? Oral tolerance in adult animals, to 
whey proteins, present as the major protein component of a 
solid food diet, has previously been reported [331] in BALB/c 
mice and this finding was confirmed for CBA/Ca mice in 
Chapter 7. Mice fed bovine BLG at concentrations in the range 
of 25-86mgs/ml (Chapter 7) or 290mg per day had a 5-7 fold 
reduction in anti-BLG lgG responses and a 35-45% reduction in 
anti-BLG T cell responses or a 98% suppression of both 
antibody and T cell responses respectively. Taken together 
these data suggest that BLG is tolerogenic. However its 
tolerogenic properties may only be revealed following feeding 
with a large quantity. Perhaps then the amount of BLG ingested 
169 
by neonatal animals was not sufficient to induce tolerance. 
Although the amount of ovine BLG ingested by neonatal mice 
was not calculated, BLG was shown to be present in the 
stomachs of pups suckling on BLG-containing milk. 
Electrophoresis of the gut contents of mice suckled on BLG-
containing milk showed a strongly staining band after 
Coomassie blue staining and Western blotting of an intensity 
that suggested BLG was the major protein component in this 
milk. This finding is in agreement with Simons et al (1 987) 
[293] who found that BLG was the major protein in the milk of 
lactating BLG-transgenic mice. These authors calculated that 
the concentration of ovine BLG in the milk of line 45 mice was 
between 1 4-22mgsIml. 
Melamed and Friedman (1 993) [269] found that tolerance to 
20mgs of OVA occurred quickly in adult mice following a 
single intragastric feed. However tolerance was short lived 
(21 days) in the absence of additional antigen. "BLG-suckled" 
mice were exposed continuously to antigen until immunisation 
since they were weaned onto a diet containing 1.25% bovine 
BLG after suckling (resulting in ingestion of an estimated 
36.25mgs of BLG/day). Following immunisation these mice 
were as responsive to ovine BLG as a control group fed on a 
BLG free diet. Continuous BLG exposure following weaning is 
therefore unlikely to be the cause of responsiveness observed 
in this study. 
Hanson (1981) [374] suggested that the effects of oral 
tolerance were best seen if mice were immunised 2 rather 
than 6 weeks following feeding of antigen, thus suggesting 
that the tolerogenic effect of feeding diminished with time. 
Mice in my study were immunised 9 weeks after the last oral 
administration of antigen and it remains a possibility that 
hyporesponsiveness to ovine BLG had declined over this period 
inspite of the presence of BLG in the diet. 
In summary, although no oral tolerance towards ovine BLG was 
evident in adult non-transgenic and BLG-transgenic mice 
suckled on BLG-containing milk, (during the first 21 days of 
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life) oral tolerance to bovine BLG could be achieved in adult 
CBA/Ca mice. It is possible that oral tolerance may have 
occurred following suckling on BLG-containing milk for a short 
period but had waned over the length of time between weaning 
and challenge. The question of whether oral tolerance to 
maternal milk proteins normally occurs in the suckling 
offspring was not analysed in this study. 
Oral tolerance to bovine BLG did occur in adult CBA/Ca mice 
fed this protein in their drinking water. However the level of 
suppression of both the antibody and T cell response in this 
study was not as impressive as those described by Enomoto et 
al (1993) [331]. Various differences including experimental 
procedure, the strain of mouse used and the amount of bovine 
BLG fed could explain the differences seen between these 
experiments. Of these three differences the first two may be 
of most importance. 
Oral tolerance to OVA has been shown to be affected by mouse 
genetic backgrounds [266, 267]. For example BALB/c (H-2d) 
mice fed OVA had a 85-90% suppressed OVA specific DTH 
response whilst BALB/b (H-2b) mice also fed this protein were 
responsive to OVA at a DTH level. In contrast (BALB/c X 
BALBIb) El mice fed OVA had a 63% suppressed OVA specific 
DTH response. The relatively low levels of oral tolerance to 
bovine BLG that occurred in the CBA/Ca mouse (H-2k), used in 
my study, may be a consequence of MHC genotype: the BALB/c 
mice used in Enomotots study were (H-2d). Although the 
susceptibility of other mouse strains to oral tolerance to BLG 
was not carried out in my study, Enomoto et al (1993) [331] 
found that both C3H/He (H-2k) and C57BL/6 (H-2b) mice were 
susceptible to oral tolerance to whey proteins and that the 
levels of suppression in these mice was similar to that of 
BALB/c mice. Although CBA/Ca and C3H/He mice both express 
H2k it was also shown by Lamont et al (1988) [267] that H2k 
mice show marked variation in the induction of oral tolerance 
to OVA suggesting an additional role of genetic factors 
outwith the MHC in oral tolerance. 
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Enomoto et al (1993) [331] calculated that mice received 
0.29gs of bovine BLG per day in their study. In contrast, mice 
in my study received 25-86mgs of bovine BLG depending on the 
presence or absence of whey protein in the solid food diet. For 
example a diet containing 1.25% of BLG resulted in the 
ingestion of 36.25mgs of BLG (based on an average daily intake 
of 2.9gs). The difference between Enomoto's results and my 
result's could be affected by the amount of BLG ingested, the 
greater the amount the more tolerance. 
Ingestion of a small amount of BLG may result in no, or very 
little, protein reaching the systemic system due to 
denaturation in the stomach, whilst ingestion of large amounts 
of undigested BLG may result in large amounts of protein 
reaching the systemic blood supply. This hypothesis is 
however unlikely to be relevant since, 1) BLG is stable at pH 
3.5, the pH of the stomach, [303] thus allowing undigested BLG, 
regardless of amount ingested to reach the systemic blood 
supply, 2) denatured whey protein can induce oral tolerance to 
BLG [331], although in this study large quantities of denatured 
whey protein (560mgs/day) were given which may have 
allowed a large quantity of protein to reach the systemic 
circulation and c) the amount of BLG fed in my study was the 
same or greater than the amount of OVA ingested in some 
experiments [261, 266, 267, 288, 378, 3791. Hence there 
should have been sufficient antigen to induce tolerance. 
Oral tolerance, at both the T cell and antibody level, to another 
milk protein has been documented [330, 332-334]. Both anti- 
casein antibody and T cell responses were suppressed (87.8%) 
in mice fed a solid food diet in which casein was the only 
protein. Although these mice were tolerant a weak but 
significant responses was observed and it was found that 
tolerance in this case was to the immunodominant peptides of 
casein not to the cryptic epitopes. It is unlikely that the 
relatively limited tolerance to bovine BLG in my study was an 
immunodominance phenomenon since suppression of B and T 
cell responses to bovine BLG was almost 100% in the Enomoto 
study. 
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As described in Chapter 1 oral tolerance occurs either via 
suppression or anergy. In this study the mechanism of oral 
tolerance was not analysed. Anergy is thought to occur when 
soluble antigen, in the systemic system, is presented to T 
cells in the absence of a co-stimulatory signal. Soluble bovine 
BLG has been found in the systemic blood supply of mice fed a 
whey protein containing solid food diet [331] suggesting that 
oral tolerance to this protein maybe via anergy. 
8.8) Summary of future work 
T cell tolerance. 
T cell tolerance should be further investigated using 
haptenated BLG compounds. If T cell tolerance exists in BLG-
transgenic mice then no anti-hapten responses would occur 
and this would facilitate investigations into the T cell 
subset(s) affected. As suggested earlier TH2  cells rather than 
TH1 cells maybe tolerant and this hypothesis should be further 
investigated by the analysis of both cytokine and antibody 
profiles of BLG-transgenics versus non-transgenic mice 
following immunisation with BLG plus Alum or FCA. 
The mechanism of T cell tolerance could also be analysed. 
Although no BLG mRNA expression was found in various 
tissues, including the thymus following Northern blotting, 
future work should re-investigate expression using a 
technique known to be sensitive for small amounts of RNA, RT-
PCR. 
In conjunction with the forementioned experiments thymic 
involvement should also be analysed using thymic chimaeras, 
for example, 	grafting BLG-transgenic and non-transgenic 
thymi under the kidney capsule of CBA/Ca nude mice such that 
host derived T cells develop in donor thymi. BLG expression in 
the transgenic thymi would be expected to induce tolerance in 
these mice. 
OVA trans-genic mice 
It would be interesting to repeat the experiments detailed in 
this thesis using 	an OVA transgenic system. This would 
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involve the production of transgenic mice with OVA under the 
control of BLG promoter elements. Much is known about the 
immune response to OVA making it the ideal antigen for such a 
study. 
B cell tolerance 
B cell tolerance should be analysed further through the use of 
hapten-carrier experiments, for example coupling BLG (hapten) 
to SRBC (carrier). Since B cell tolerance can co-exist with T 
cell tolerance the above situation bypasses T cell tolerance by 
providing an alternative T cell help (SRBC specific cells) to 
hapten specific B cells. If BLG specific B cells are tolerant in 
BLG-transgenic mice it could be predicted that no anti-BLG 
antibody response would be detected even in the presence of T 
cell help. 
If B cell tolerance is evident the mechanism involved could be 
investigated. At present the favoured mechanism is deletion of 
BLG specific B cells within the bone marrow although the 
presence of BLG in this tissue has not been evaluated. Future 
experiments should therefore investigate whether BLG mRNA 
or protein is present in the marrow stroma. Although B cell 
anergy has been ruled out in this model since soluble BLG is 
not found in these mice, anergy could be further investigated 
via the transfer of transgenic B cells into a non-transgenic 
host. If tolerance was found to be transferable anergy may 
also be involved. 
BLG as an oral toleroqen 
Oral tolerance to BLG did not occur in mice suckled on BLG-
containing milk as compared to mice suckled on "normal" 
mouse milk. The lack of tolerance was attributed firstly to the 
lack of a continuous source of tolerogen and secondly to the 
fact that the mice were challenged 3 months from birth by 
which time oral tolerance may have subsided. Future 
experiments should therefore investigate whether tolerance to 
BLG did occur but had waned through time. These experiments 
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would involve challenging BLG-suckled mice at various time 
points after weaning and before mice reach 3 months of age. 
It would also be of interest to test whether tolerance to other 
murine milk proteins occurred in suckling offspring. 
Adult mice given bovine BLG in their drinking water were 
tolerant to this protein although the level of tolerance was not 
comparable to that found in other laboratories [331]. One 
reason for this was that CBA/Ca mice were tested in my study 
whilst BALB/c mice were tested in Enomoto's study. It would 
be interesting to test the susceptibiliy of BALB/c mice to oral 
tolerance induction with bovine BLG. 
It is possible that BLG is not a good protein to study with 
respect to oral tolerance. The production of transgenic mice 
producing OVA in milk, during lactation, would provide a better 
model for the study of induction of oral tolerance via suckling, 
since much data is available on the mechanisms of oral 
tolerance to this protein. 
In future experiments the mechanism of BLG oral tolerance 
should be analysed. In vitro anergy should be investigated by 
analysis of cytokine production. In vivo the mechanism could 
be investigated by dissection of the IgG subclass response 
since oral tolerance induced through anergy results in the 
selective tolerisation of TH1  cells (resulting in decreased 
lgG2a antibody levels) but not TH2  cell [270, 273, 280]. In the 
present study only the total lgG response was analysed. 
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APPENDIX 1 	Raw data for the Lowry test 
a) OD values (600nm) for BSA controls obtained in the Lowry 
tests performed for the BLG purifications 2-6. 
RRA rnncpntrtinn (ma/ml 
Purificat 
-ion 50 100 
(nos)  
200 300 400 
2 0.343 0.697 1.200 1.464 1.710 
3 0.325 0.585 0.976 1.334 1.606 
4 0.353 0.600 0.945 1.296 1.600 
5 0.332 0.583 1.014 1.394 1.624 
6 0.395 0.610 0.993 1.300 1 	1.498 
b) OD values for BSA controls obtained in the Lowry test 
performed for the first BLG purification. 
RcA rnnentritinn (ma/ml) 
Purificat 
-ion 80 160 240 320 400 
(nos) _______  
1 0.498 0.829 1 	1.154 1.406 1.718 
c) OD values for BLG samples obtained in the Lowry test 
performed for BLG purification 1-6 
RI r. rnnrantrtinn (ma/ml) 
Purificat 
-ion 62.5 125 
(nos)  
250 500 1000 
1 0.354 0.582 0.916 1.508 >2 
2 0.226 0.432 0.744 1.256 1.750 
3 0.278 0.523 0.874 1.420 1.606 
4 0.270 0.521 0.873 1.384 1.918 
5 0.274 0.513 0.879 1.3281 1.692 
6 0.202 0.376 0.741 1.166 1.466 
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APPENDIX 2 	Solutions for SDS gels and Western 
blotting 
(All reagents and chemicals in the following sections were 
purchased from SIGMA unless stated) 
15 % Polyacrlyamide gels 
Solution makes enough for 2 gels. 
699mls 30% Acrylamide 




* Resolving gel buffer= 1 9.2gs of Tris (pH8.8) and 0.4g of SIDS 
made up to 1 00mls with dHO. 
Stacking gel solution 
Solution makes enough for 2 gels. 
0.5mls 	30% Acrylamide solution 
1 .25m1s Stacking gel buffer * 
5Opls 	APS 
7pls Temed 
* Stacking gel buffer = 6.06gs of Tris (pH6.8) and 0.4gs of SIDS 
made up in 1 OOmls of dH20. 
Sample buffer 
1 OOmls of sample buffer was made up in dH20. 
25m1s 	Stacking gel buffer 
20gs Glycerol 
lOgs 	SIDS 
5mls 20mM (pH7.5) EDTA 
1 OmIs 	Mercaptoethanol 
D) SIDS page gels electrolysis 
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E) Destaining solution 
2 litres of destaining buffer was made up in dH20. 
10% Methanol (BDH) 
10% Acetic Acid (BDH) 
F) Transfering! Blotting Buffer 
5 litres of blotting buffer was made up with 4 litres of dH20. 
15.1 5gs Tris base 
72.05gs Glycine 
5gs 	SDS 
1 litre Methanol (BDH) 
G) Blocking buffer 
200mls PBS 
lOOpls Tween 20 
lOgs 	BSA 
H) PBS-Tween 
2 litres of PBS plus 0.05% Tween 20 
I) Tris saline solution 
1 00mls of Tris saline solution was made up in dH20. 
0.12g 	Trizma 
0.9g NaCl (pH7.4) 
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APPENDIX 3 	ELISA solutions 
Coating Buffer (pH9.6); 
1 litre of coating buffer made up in dH20 
	
1.5g 	Na2CO3(BDH) 
2.93g NaHCO3 (BDH) 
0.2g 	NaN3 
Washing buffer (pH7.2): 
1 litre of washing buffer made up in dH20 
1.07g 	Na2HPO (anhyd) (BDH) 
0.39g NaH2PO4.21-120 (BDH) 
8.5g 	NaCl 	 (BDH) 
0.05% Tween 20 
c) Diluting Buffer (pH7.2); 
1 litre of diluting buffer made up in dH20 
1.07g 	Na2HPO (anhyd) (BDH) 
0.39g NaH2PO4.21-120 (BDH) 
8.5g 	NaCl 	 (BDH) 




APPENDIX 4 	Solutions for PCR. 
Tail Buffer: 
1 litre of Tail buffer made up in dH20 
0.3M 	NaAcetate 
10mM TrisHCL (pH7.9) 
1mM EDTA (pH8.0) 
1% 	SIDS 
Tail buffer solution was autoclaved before SDS was added. 
Al 0% SIDS stock solution was filter sterilised using a 
0.22pmillipore filter. 
Stock Proteinase K 
A stock solution of proteinase K of 20mg/mi was made up in 
sterile dH20 and stored at 200C until use. 5pls of this stock 
solution was added to 0.5mls of tail buffer for tail digestion. 
Red cell lysate 
1 litre of Red cell lysate was made up in dH20 and autoclaved 
155mM NH4CI 
10mM 	KHCO3 
OA MM EDTA-Na2 (pH7.4) 
1 5mls of red cell lysate was used per mouse. 
lox PCR mix. 
1 litre of 1 OX PCR buffer was made up in dH20. 
500mM 	KCI 
100mM Tris-CI (pH8.3) 
1 5mM 	MgCl2 
0.1% Gelating (BDH) 
Solution was autoclaved and stored at 200C until use. 
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E) Triphosihate mixture (Boehringer) 
2501ils of 100mM dATP 
2501i1s of 100mM dTTP 
250pls of 100mM dCTP 
250p1s of 100mM dGTP 
250jiIs of distilled 	H20. 
This solution was mixed and aliquoted. Stored at 200C until 
used. 
5X loading buffer; 
1 litre of loading buffer was made up in dH20. 
15% 	Ficoll 400 
0.05% SIDS 
20mM EDTA (pH8.0) 
0.125% Orange  
TAE running buffer; 
1 litre of TAE running buffer was made up in dHO to give a 
50X stock solution. 
242g 	Tris Base 
37.2g Na2EDTA.2H20 (pH8.5) 
57.1 ml Glacial Acetic Acid (BDH) 
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APPENDIX 5 	RNA analysis. 
Distilled water used had been autoclaved and DEPC treated. 
I% Fomaldehyde gels 
For each gel 
0.5g Agarose 
5mls lox MEN* 
36mls distilled H20 
1 8mls Formaldehyde (BDH) 
Ethidium Bromide 
Agarose, 1 OX MEN and dH20 were melted via microwaving 
before being cooled to 650C at which time formaldehyde was 
added. A 2-3mm gel was then poured. 
lOX MEN* (pH7.2) 




Gels were run in 1 OX MEN buffer, 
900mls of dH20. 
lOOmIs of 1 OX MEN plus 
Sample Buffer 
per lOOpls 
5Ojils 	100% stock solution of Formamide 
1 7.2pls 35-75% stock solution of Formaldehyde 
lOpls 	1 O MEN 
22.8jils dH20. 
Northern blotting 20X SSC Buffer (pH7) 
1 litre of ZOX SSC was made up with dH20 
175.3g NaCI 
88.2g 	Sodium citrate 
TE buffer 
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I litre of TE buffer was made up in dH20. 
10mM Tris HCI (pH 7.4) 
1 mM EDTA (pH8) 
F) Denhart solution 




5gs Bovine serum albumin 
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APPENDIX 6 	SDS mouse diets. 
Rat and mouse Nol Maintenance diet and rat and mouse No 3 
Breeding diet. 
INGREDIENTS % COMPOSITION for % COMPOSITION for 
MAINTENANCE DIET BREEDING 	DIET 




VEGETABLE 6.0% 16.5% 
PROTEINS (Ext. 
Soya Bean Meal)  
ANIMAL PROTEINS 2.5% 15.0% 
(Whey 	protein) 
(* Fish Meal *)  
ENERGY SOURCES 0.5% 2.0% 







* Fish meal = Breeding diet only 
Whey protein, 50% of the whey protein is p- Lactoglobulin 
with approximate concentration of 3.Ogs whilst 12% is c-
Lactalbumin with approximate concentration of 0.7gs. 5% is 
Bovine serum albumin, 0.23% is casein and minor proteins and 
30% is Immunoglobulins 
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APPENDIX 7 HARLAN TEKLAD 9608 TRM (Auto) mouse 
diet 
In this diet dried whey protein has been substituted with 









dried brewers yeast, 
and minerals and vitamins. 
Calculated oil concentration is 5% 
Calaulated protein concentration is 18.4%. 
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APPENDIX 8 	Individual T cell responses of CBA/Ca 
female mice immunised and challenged with different 















0.02 0.07 0.10 0.12 0.38 0.16 
0.01 0.07 0.10 0.02 0.44 0.35 
0.05 10.01 1 0.01 10.07 10.38 0.28 
0.03 10.09 10.03 10.09 10.49 10.47 
0.02 10.11 10.07 10.04 10.29 0.32 
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0.10 0.04 0.10 0.04 
öJi -  0.03 	10.17 0.01 
0.21 0.02 10.13 0.00 
2 0.00 	10.11 0.09 
0.21 0.03 10.07 0.01 
0.18 0.00 10.13 0.03 
2 0.15 0.02 10.1 0.03 
0.18 0.01 10.11 0.03 
0.30 0.02 10.09 0.08 
0.41 0.03 10.13 0.02 
o:oo 1_0.03 























1 0.49 1 0.2 0.02 
0.47  0.01 0.22 0.01 
0.55  0.05 0.2 0.02 
0.17 0.01 0.2 0.09 
0.39  0.05 0.21 0.03 
0.1 2 0.01 0.18 0.01 
2 0.11  0.02 0.22 0.01 
0.12  0.02 0.18 0.04 
0.12  0.03 0.11 1 0.02 
3) C57Rl/ X CBA/Ca El 
EXPT El male El male EXPT Fl El 




0.19 0.08 1 0.07 
0.16 10.05 1 10.31 10.12 
APPENDIX 9 	Individual T cell responses (mm) for 


















1 0.22 0.10 0.22 0.07 
0.34 0.06 0.19 0.07 
0.34 0.07 0.18 0.07 
0.24 0.10 0.11 0.04 
0.36 0.02 10.18 0.04 
2 0.11 0.08 10.17 0.01 
0.21 0.08 0.21 0.03 
0.05 0.23 0.01 
_ _____ 0.21 0.07 
 0.24 0.01 
EXPT = mice challenged with 2% Hag BLG 
CONT = mice challenged with saline 
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APPENDIX 10 	Antibody responses of mice either 
suckled on BLG-containing or "normal" mouse milk. 
Following weaning mice were maintained on a diet 
lacking whey protein (see Chapter 4). 
i) Non-transgenic mice suckled on BLG-containing milk 
M(1) M(2) M(3) F(1) F(2) F(3) 
2 >11 >11 2 >11 >11 
3 >11 >11 2 >11 >11 
4 >11 >11 2 >11 >11 
5 >11 >11 4 >11 	1>11 
5 >11 >11 5 >11 1>11 
>5 >11_ >11_ 5 >11 1>11_ 
>5 >11 >11 5 >11 1>11 
>5 9 >11 >5 >11_ >1 - 
>5 2 11 >5 >11_ >1 - 
>5 9 >11 
>5 8 11 
7 1 3 1 9 
ii) Transgenic mice suckled on BLG-containing milk 
minoi 
iii) Non-transgenic mice suckled on "normal" mouse milk 
M(1) M(2)IM(3)IF(l) F(2) F(3) 
7 >11 
1>11 
>11 18 1>11 1>11 
5 1>11 18 1>11 1>11 
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>5 >11 >11 4 >11 1>11 
>5 >11 >11 2 6 1>11 
>5 10 >11  
4 10 >11  
2 110 1>11 I 
0 13 1>11 I 
iv) Transgenic mice suckled on "normal" mouse milk 
M= male mice 
F= female mice 
(nos)= bleed number 
ND= no detectable antibody. 
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APPENDIX 11 	Individual T cell responses (mm) for 
Fl BLG-transgenic and CBA/Ca immunised with bovine 
or ovine BLG (see Chapter 5). 




























1 0.48 0.05 0.34 0.03 0.56 0.00 0.29 0.01 
0.55 024 0.02 10.65 0.02 0.19 10.04 
0.37 10.03 0.59 0.03 0.25 0.44 10.04 
0.48 0.02 0.39  0.27  0.36 10.01 
0.37 0.03 0.03  0.33  
2 0.05 0.02 0.27 0.08 - 
0.13 0.01 0.18 0.02  
0.18 10.01 0.28  
0.11 10.01  











1 0.07 0.01 0.13 0.01 
0.15 0.04 0.10 0.04 
0.21 0.07 0.05 0.04 
0.21  0.05 0.01 






EXPT = mice challenged with 2% BLG 
CONT = mice challenged with saline 
M = male mice 
F 	female mice 
APPENDIX 12 	Individual T cell responses (mm) for 
mice suckled on BLG-containinci or "normal" mouse 
milk immunised with bovine or ovine BLG (see Chapter 
I) bovine BLG- 























1 0.65 0.28 10.33 0.34 0.66 0.40 0.27 0.22 
0.26 0.41 	10.33 0.38 0.47 0.35 0.35 0.28 
0.23 0.48 10.46 0.42 10.30 0.30 0.29 10.20 
0.28 0.4 10.29 0.45 10.34 0.22 0.25 10.38 
0.40 0.59 10.36 0.31 10.38 0.50 0.37 10.12 
2 0.37 0.84 10.39 0.28 10.56 0.35 0.51 0.22 
0.47 0.59 10.39 0.31 10.40 0.37 0.21 0.26 
0.34 0.46 
10.76 
0.43 45 0.42 0.13 0.23 
0.46 0.48 
0.6t
40. 0.231 0.49 0.39 0.28 
0.56 040 0.34 0.2__ 0.69 0.41 0.40 











1 0.03 0.03 0.09 0.07 
0.05 0.10 0.09 0.02 
0.02 10.05 10.13 0.04 
0.03 10.15 0.11 0.07 
0.04 1 0.04 0.01 
ii) ovine BLG-

























1 0.13 0.27 0.14 0.22 0.19 0.22 0.18 0.08 
0.21 0.18 0.11 0.19 0.14 0.17 0.20 0.10 
0. LL 0.26 0.10 0.25 0.13 0.21 0.23 0.2 
0.18 0.24 0.05 
10.13 
0.16 0.12 0.33  10.231  
0.19 0.26 0.27 
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2 0.25 0.47 0.18 0.21 0.15 0.12 0.11 0.22 
0.23 0.23 0.04 0.16 0.13 0.19 0.15 0.11 
0.38 0.14 0.24 0.13 0.22 0.29 0.19 0.17 
0.32 0.17 0.06 0.14 0.13 0.16 0.04 0.13 ____ 
0.05 10.23 1 0.22 0.05 0.03 






T= BLG-transgenic mice 
NT= non-transgenic mice 
S= mice suckled on BLG-containing milk 
NS= mice suckled on "normal" mouse milk 
M = male mice 
F = female mice 
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APPENDIX 13 	Individual T cell responses (mm) for 
mice suckled on either BLG-containinci or "normal" 
mouse milk. Following weaning mice were placed on a 
diet lacking whey protein (see Chapter 5). 











T= transgenic mice 
NT= non-transgenic mice 
S = mice suckled on BLG-containing milk 
NS= mice suckled on "normal" mouse milk 
M= male mice 
F= female mice 
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APPENDIX 14 	Individual T cell responses (mm) for 
G7 mice suckled on either BLG-containing or "normal" 
mouse milk (see Chapter 5). 
i) ovine BLG-

























1 0.12 0.09 023 0.13 0.22 0.30 0.22 0.21 
0.15 0.24 0.12 0.14 0.22 0.19 0.30 0.38 
0.17 0.20 10.09 0.25 	10.10 0.23 0.15 0.25 
0.10 0.16 	10.14 0.16 10.16 0.17 0.22 
0.25 0.20 10.06 0.10 10.05 0.12 0.28 
0.20 0.24 10.19 0.18  0.16  0.25 
0.13 0.13 	10.11 0.15 10.19 10.23 
0.20 1 0.15  0.20  0.29 
0.21  0.16  0.14  0.27 
0.13  0.15 
0.23  
2 0.20 0.41 0.15 0.06 10.30 0.03 0.08 0.07 
0.32 0.01 0.19 0.20 0.07 0.24 0.07 
0.10 0.15 0.21  0.9 0.19 10.09 
0.22 0.15 0.01  0.19 0.06 10.05 
0.22 0.09 0.17  0.12  0.23 
0.17  0.15  0.15 
0.05  ____ 0.12 
0.02 







T= BLG-transgenic mice 
NT = non-transgeniC mice 
S = mice suckled on BLG-containing milk 
NS = mice suckled on "normal" mouse milk 
M= male mice 
F = female mice 
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APPENDIX 15 	Individual T cell responses (mm) for 
mice immunised with ovine BLG and challenged with 
2% Hag bovine BLG (see Chapter 5). 


























1 0.35 0.34 0.19 0.22 0.13 0.27 0.20 0.36 
0.16 0.47 0.14 0.25 0.11 0.24 0.12 0.17 
0.18 0.22 10.17 0.30 10.17 0.26 0.22 10.26 
0.20 0.31 10.17 0.20 10.15 0.12 0.21 
0.30 022  0.08 0.29 0.27 
0.27 0.12  0.22  0.22 
0.43 0.29  0.17  
0.16 0.16  0.30  
0.37 1  0.17  
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APPENDIX 16 	Individual T cell responses (mm) for 
mice fed bovine BLG (see Chapter 7) 
























































1 0.17 0.24 









































2  0.38 














W+ = whey containing diet 
W- = whey deficient diet 
50/21 = 50mgs of bovine BLG for 21 days 
25/21 = 25mgs of bovine BLG for 21 days 
50/24 = 50mgs of bovine BLG for 24 hour 
25/24 = 25mgs of bovine BLG for 24 hours 
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APPENDIX 16 cont 	Individual T cell responses (mm) 
for control mice fed saline in the BLG feeding 
experiments (see Chapter 7). 













0.25 0.32 0.07 0.35 
0.28 0.27 0.13 0.36 
0.12 10.32 0.44 0.35 
0.24 10.20 0.23 0.38 
0.15 10.27 0.33 0.26 
0.32 10.38 0.29 0.26 
0.44 0.23 0.07 0.30 
0.26  0.16  
0.12 ______ 0.07  
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